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Alternative splicing is a key process that enables the expression of a large number of proteins from a 
limited number of genes. Regulation of alternative splicing has been directly linked with the 
hallmarks of cancer. Human Transformer 2-α and -β are two homologous RNA binding proteins 
involved in the regulation of alternative splicing that are overexpressed in many different cancers. 
Previous work suggests Tra2β interacts closely with RBMX, encoded by the gene RBMX, to regulate 
the splicing of key pathologically related genes such as SMN2. The objective of this study is to 
investigate the role of alternative splicing regulators in breast cancer in order to further understand 
their biological function. Firstly, I utilise previously obtained RNAseq data from the double 
knockdown of Tra2α and Tra2β in the MDA-MB-231 breast cancer cell line to identify an extended 
number of genes regulated by Tra2 proteins using recently developed bioinformatics pipelines. The 
analysis revealed a range of alternative events including intron retentions, alternative 3’ and 5’ splice 
sites and exon repression events, suggesting different mechanisms of splice site regulation by Tra2 
proteins. I experimentally validated the results of the RNAseq analysis by PCR. Subsequent Gene 
Ontology enrichment analysis of Tra2-regulated targets reveals several genes involved in the cellular 
response to DNA damage. I employed western immunoblotting to investigate the protein expression 
changes in these genes and was able to detect short protein isoforms expressed for MBD4 and XPA. 
Subsequently, nuclear fractionation and immunofluorescence microscopy of Tra2 depleted cells 
showed cytoplasmic localisation of the short isoforms for both MBD4 and XPA. In order to determine 
the role of the alternative isoforms regulated by Tra2 proteins, antisense oligonucleotide targeting 
exon 5 of BRIP1, exon 3 of CHEK1, and exon 5 of XPA  were transfected into MDA-MB-231 cells. 
Expression of the short XPA isoform using antisense oligonucleotides results in an increase of γH2AX 
and reduced cell viability. This data suggests Tra2 proteins sustain the DNA integrity and protect the 
cells from death by ensuring the expression of correctly spliced DNA repair genes. In order to 
compare the role of Tra2 proteins with the commonly associated splicing regulator RBMX, I knocked 
down the expression of RBMX in MDA-MB-231 cells and obtained RNAseq data. Bioinformatics 
analysis was able to identify many commonly regulated alternative events, but also some novel 
isoforms regulated by RBMX alone. RNAseq data also unveiled an interesting autoregulatory 
mechanism for the RBMX gene, whereby the expression of RBMX is regulated by alternative splicing 
of the 3’ UTR. Subsequent examination of Upf1 knockdown cells showed stabilisation of the 
alternating isoform of RBMX indicating it is targeted by nonsense mediated decay. Future work into 
the role of RBMX regulated targets similar to the work done for Tra2-regulated genes could reveal a 




Chapter 1: Introduction 
1.1 The central dogma 
The human genome sequencing project completed 16 years ago was a monumental achievement in 
human genetics that allowed scientists for the first time to navigate through the blueprint of life - 
the human genome. The central dogma of molecular biology states that information flows from DNA 
to RNA and finally to protein. However, this principle oversimplifies the true nature of biological 
processes that occur in order to carry out the instructions of the genome. In prokaryotes the flow of 
information from DNA to protein is somewhat linear. DNA is transcribed into RNA and almost 
simultaneously translated into protein. However, in eukaryotes transcription and translation occur 
separately. The precursor messenger RNA (pre-mRNA) transcribed from the DNA is a complementary 
molecule that must undergo a series of post-transcriptional modifications prior to translation. Pre-
mRNA processing begins with 5' capping and is closely followed by splicing and polyadenylation. The 
pre-mRNA contains protein coding sequences known as exons separated by non-coding sequences 
known as introns. One of the first steps of pre-mRNA modifications that occurs simultaneously with 
transcription is pre-mRNA splicing, whereby the non-coding introns are spliced out, leaving behind a 
coding sequence that can be translated into protein. 
An apparent consequence of post-transcriptional editing of RNA is the increased repertoire of 
proteins from a limited number of genes. The human genome contains approximately 21,000 
protein coding genes (Pertea et al., 2018). However, the number of detectable unique proteins 
expressed in human cells surpasses 90,000 (Harrison, Kumar, Lang, Snyder, & Gerstein, 2002). This 
proteomic diversity is a characteristic that becomes more apparent in species of the animal 
kingdom, especially those further out in the evolutionary tree. Such diversity is a consequence of 
post-transcriptional modifications such as alternative splicing, alternative polyadenylation and RNA 
editing (Lander, 2011). More than 95% of the human protein coding genes are alternatively spliced 
(Q. Pan, Shai, Lee, Frey, & Blencowe, 2008). As a result, a single pre-mRNA can be spliced differently 
resulting in multiple ‘mature’ mRNA species that code for different protein isoforms. Furthermore, 
alternative splicing can affect the reading frame of the mRNA creating non-coding mRNA sequences, 
therefore playing a role in post-transcriptional regulation of gene expression. 
Post-transcriptional modifications such as alternative splicing produce protein isoforms that can be 
structurally and functionally distinct from one another. Post-transcriptional modifications of the RNA 




ubiquitylation, dramatically increase the complexity of the proteome from a limited number of 
genes (Wilhelm et al., 2014). Understanding the mechanism and role of post-transcriptional (and 
post-translational) modifications is essential to understanding the full potential of the genome. 
Evidently the central dogma model of information flow is oversimplified and does not represent the 
complexity of regulatory pathways involved in genome transcription and translation in human cells. 
1.2 RNA transcription and post-transcriptional modifications 
RNA transcription is a complex reaction which creates RNA molecules complementary to the 
antisense DNA strand. There are three steps to RNA transcription: initiation, elongation and 
termination. The most important multiprotein complex involved in these steps is RNA Pol-II which 
interacts with a number of processing factors that coordinate transcription (Glover-Cutter, Kim, 
Espinosa, & Bentley, 2008). RNA Pol-II first recognises and binds to the promoter region of a gene 
causing the DNA to unwind hence initiation transcription (Mischo & Proudfoot, 2013). During 
elongation RNA Pol-II sequentially reads the antisense strand of the DNA and adds complementary 
nucleotides to the nascent RNA being transcribed. The final step of transcription relies on RNA Pol-II 
recognising the transcription termination signal. RNA Pol-II then recruits the polyadenylation 
complex via the C-Terminal Domain (CTD), detaches from the DNA and releases the RNA transcript. 
1.2.1 5’ capping and 3’ polyadenylation of the mRNA 
A general misconception regarding post-transcriptional modifications is the idea that they occur 
after transcription is complete - probably due to the misleading prefix “post”. However, many 
studies have shown that most post-transcriptional modifications occur simultaneously with 
transcription. One of the first mRNA modifications is the addition of a 5’ cap. In humans, this can be 
performed by two different enzymes: human capping enzyme (HCE) and RNA 7-methyltransferase 
(MT) (Furuichi & Shatkin, 2000). RNA Pol-II can recruit both HCE and MT via its’ CTD domain when 
phosphorylated (Shuman, 1997). The 5’ cap is a guanine nucleotide, methylated on the 7th carbon of 
the guanosine base (m7G), that binds to the 5’ carbon of the first nucleotide of the nascent RNA via 
its’ own 5’ carbon through a triphosphate bridge. The m7G cap is essential for mRNA stability, but it 
is the cap-binding complex (CBC), comprised of Cbp20 and Cbp80, which causes importance of the 
cap in various functional processes of mRNA modifications (Figure 1) (Gonatopoulos-Pournatzis & 
Cowling, 2014). The CBC can interact with and recruit components of the spliceosome thereby 
playing a role in pre-mRNA splicing (Konarska, Padgett, & Sharp, 1984; Pabis et al., 2013). 
Furthermore, the CBC guides the mature mRNA through the nuclear envelope during nuclear export 




initiation factors-4G (eIF4G) and eIF4A to the 5’ end of the mRNA. Depending on the success of the 
pioneer round of translation the CBC-bound mRNA is targeted by nonsense mediated decay (NMD) 
or the eIF4E replaces CBC and begins the steady-state round of translation (Maquat, Hwang, Sato, & 
Tang, 2010). Among other roles, the 5’ cap-bound CBC has also been shown to interact with 3’ 
processing factors bound to the polyadenylation sites of the mRNA (Ramanathan, Robb, & Chan, 
2016). Depletion of CBC in HeLa cells strongly reduced endonucleolytic cleavage and polyadenylation 
(Flaherty, Fortes, Izaurralde, Mattaj, & Gilmartin, 1997).  
 
Figure 1 Cap Binding Complex (CBC) role in RNA processing. CBC composed of Cbp80 and Cbp20 subunits binds to m7G cap 
and facilitates interactions with key components of RNA processing highlighting the importance of the 5’ cap. CycT1, cyclin 
T1; Cdk9, Cyclin dependent kinase 9; Upf1, RNA helicase and ATPase; U4, U5 and U6, Spliceosome snRNPs; Dcp, decapping 
mRNA; DXO decapping exoribonuclease. Image adapted from (Gonatopoulos-Pournatzis & Cowling, 2014) 
Polyadenylation is in itself another important post-transcriptional modification step that plays a role 
in mRNA stability and nuclear export. Upon transcription termination several factors are recruited to 
the 3’ end of the mRNA in order to add the poly(A) tail. A poly(A) tail is a nearly universal feature of 
mRNAs in eukaryotes. The cleavage and polyadenylation specificity factor (CPSF) is one of the main 
interacting proteins that recognises the strongly conserved polyadenylation signal AAUAAA and 
cleaves the mRNA approximately 20 nucleotides downstream (N. J. Proudfoot & Brownlee, 1976). 
The addition and elongation of the poly(A) chain is then performed by the poly(A) polymerase with 
the help of the poly(A)-binding protein II (PABII) (Bienroth, Keller, & Wahle, 1993). Interestingly, 
studies suggest that binding of PABII, even in the absence of a poly(A) tail, is sufficient for mRNA 
stabilisation (Coller, Gray, & Wickens, 1998), and it is PABII that regulates the length of the poly(A) 




facilitates the transport of the mRNA through the nuclear envelope and recruits translation initiation 
factors in the cytoplasm (N. K. Gray, Coller, Dickson, & Wickens, 2000; Vinciguerra & Stutz, 2004).  
Although well conserved, the polyadenylation signal sequence is relatively short and may occur 
multiple times within the mRNA. Therefore, it is possible for an mRNA to be polyadenylated at 
different sites producing multiple isoforms - alternative polyadenylation. An important determinant 
for polyadenylation site selection is the strength of the signal, which is determined by the distance 
between the hexanucleotide AAUAAA and the GU-rich element, an auxiliary sequence usually 
positioned 20-40 nucleotides downstream of the cleavage site (N. Proudfoot, 1991). Another aspect 
that influences alternative polyadenylation is the concentration of the regulatory factors. As an 
example, the low concentration of the cleavage stimulation factor (CstF) in B lymphocytes causes the 
expression of the membrane (μm) bound isoform of the IgM heavy chain (Figure 2) (Colgan & 
Manley, 1997). While in plasma cells the abundance of CstF means it no longer acts as a limiting 
factor, therefore allowing for the selection of the weaker μs polyadenylation signal. Additionally, 
recent studies suggest that splicing of the last intron of an mRNA can be functionally linked with 
polyadenylation, indicating splicing factors can act as auxiliary elements in poly(A) site selection 
(Niwa, Rose, & Berget, 1990; Wassarman & Steitz, 1993). The sequence elements and regulatory 
factors can be classified as cis- and trans-acting elements, respectively, and the same principle will 
be discussed again in relation to alternative splicing. 
 
Figure 2 The concentration of Cleavage stimulation factor (CstF) and strength of polyadenylation site are two determining 
factors in alternative polyadenylation site selection as demonstrated by the example of IgM heavy chain isoforms present 




1.2.2 Pre-mRNA splicing and alternative splicing in eukaryotes 
Pre-mRNA splicing is an important RNA modification that removes non-coding introns and 
sequentially joins exons together to form a continuous protein coding sequence known as the open 
reading frame (ORF) ready for translation (Matlin, Clark, & Smith, 2005). However, splicing plays a 
crucial role in determining the final coding sequence of the mRNA, hence having an impact in both 
the transcriptome and proteome of the cell. Splicing occurs simultaneously with transcription and 
begins shortly after transcription initiation and 5’ capping. The recognition and splicing of introns is 
performed by the splicing machinery and is influenced by a range of auxiliary RNA-binding proteins 
(RBPs) and heterogeneous nuclear ribonucleoproteins (hnRNPs) (Cramer et al., 2001). While some 
exons are constitutively spliced, meaning they are present in every mRNA isoform produced from a 
given gene, many are alternatively spliced resulting in alternative splice patterns, a process known as 
alternative splicing. Previous studies have shown that RNA Pol II can play a role in the determination 
of splice patterns. Slowing down transcription elongation rate in human and yeast cells through 
mutations of the RNA Pol II can decrease exon skipping (de la Mata et al., 2003; Ip et al., 2011). 
Furthermore, the RNA binding protein SRSF2, an important pre-mRNA splicing factor, can bind 
paused RNA Pol II and activate transcription elongation, indicating that components of the splicing 
machinery can also influence transcription (Ji et al., 2013). 
Alternatively spliced transcripts often differ in their coding capacity, stability, or translational 
efficiency (Figure 3) (Kelemen et al., 2013). Human protein coding genes produce on average three 
different mRNA transcripts (Djebali et al., 2012). While the majority of alternatively spliced 
transcripts introduce diversity to the proteome by affecting the protein coding sequence, an 
estimated one third of alternatively spliced mRNAs contain alterations to the ORF (Lewis, Green, & 
Brenner, 2003). A shift in the ORF can potentially introduce premature termination codons (PTCs) 
causing the mRNA to be targeted by nonsense-mediated decay (NMD), a surveillance mechanism 
that actively degrades nonsense mRNAs. The close connection between alternative splicing and 
NMD suggests that alternative splicing can regulate gene expression. Furthermore, alternative 
splicing of the untranslated regions (UTRs) can also influence gene expression by affecting mRNA 
stability (Hughes, 2006). The 5’ UTR is the region between the 5’ cap and the ORF, and is estimated 
to contain upstream ORFs in 10% of human mRNAs, suggesting alternative splicing can influence 
gene expression via alternative 5’ UTR splicing (Pesole et al., 2001). Furthermore, regulatory 
elements within the 5’ UTR involved in the recruitment of translation initiation factors and ribosomal 
binding can differ across alternative isoforms of the same gene and therefore influence translation 




average five times longer than the 5’ UTR in humans (Pesole et al., 2001). Alternative 
polyadenylation and alternative splicing can both affect the 3’ UTR sequence. Splice junctions within 
the 3’ UTR located further than 55 nucleotides downstream of the stop codon can flag the mRNA for 
degradation via NMD (Nagy & Maquat, 1998; J. Zhang, Sun, Qian, & Maquat, 1998). The importance 
of accurate splicing is further highlighted by the fact that more than 15,000 variants affect splice 
sites or regulatory sequences that lead to wide range of cancers (He, Zhou, Zuo, Cheng, & Zhou, 
2009). Moreover, there is increasing evidence associating atypically long and complex UTRs 
containing regulatory elements with oncogenes, tumour suppressors and other genes associated 
with cell proliferation (Kozak, 1991; Singh, Wolfe, Zhong, Rätsch, & Wendel, 2015; Venkat et al., 
2020), 
 
Figure 3 (A) The different modes of alternative splicing, including (B) alternative promoter usage. Image adapted from 




1.2.2.1 Spliceosome machinery and the splicing reaction 
The recognition and excision of non-coding intronic sequences from transcribed pre-mRNAs is 
performed by a multi-megadalton ribonucleoprotein (RNP) complex known as the spliceosome 
(Papasaikas & Valcárcel, 2016). In humans two spliceosomes exist, the major and the minor 
spliceosome. They are comprised of over 150 proteins and a set of small nuclear RNPs (snRNPs) 
(Rappsilber, Ryder, Lamond, & Mann, 2002). The major spliceosome consists of five snRNPs known 
as U1, U2, U4/U6 and U5 which are involved in the recognition and removal of U2-type introns. 
Whereas, the minor spliceosome catalyses the removal of the less abundant U12-type introns, 
utilising the analogous snRNP group of U11/U12 and U4atac/U6atac snRNPs, with the U5 snRNP 
shared between the machineries (Patel & Steitz, 2003). There is some evidence suggesting the 
spliceosome is pre-assembled into a megastructure containing four active spliceosomes termed as 
the supraspliceosome (Azubel, Habib, Sperling, & Sperling, 2006; Patel & Steitz, 2003), however the 
majority of scientific reports indicate that the spliceosome is assembled anew at each splicing event 
(Wahl, Will, & Luhrmann, 2009; Will & Lührmann, 2011). 
Mechanistically, the spliceosome directs two sequential SN2-type transesterification reactions 
(Figure 4) (Wahl et al., 2009). The first step involves the nucleophilic attack on the phosphodiester 
bond of the 5’ splice site (ss) by the branchpoint adenosine nucleotide resulting in cleavage of the 5’ 
exon and generation of the lariat intron. The second transesterification reaction occurs when the 
3’OH group of the cleaved 5’ exon attacks the 3’ splice site (3’ss). Consequently, the exons are 
ligated together, and the intron is released as a lariat. 
 
Figure 4 The splicing reaction as represented by the two SN2-type transesterification reactions. These are the two key 
reactions facilitated by over 200 proteins and RNAs that assemble to form the spliceosome. BPS, Branch point sequence. 




Throughout the process of splicing, the spliceosomal components assemble on the RNA in a defined 
series of complexes known as the H, A, B and C splicing complexes (Wahl et al., 2009). Complex H is 
effectively pre-spliceosome assembly and is an essential step that involves the association of several 
RBPs with the pre-mRNA guiding the spliceosome to the right splice sites. The initiating step of U1 
snRNP interaction with the 5’ splice site (5’ss) is stabilised by other auxiliary RBPs. The U2 auxiliary 
factor (U2AF) interacts with the splicing factor 1/branch point bound protein (SF1/BBP) to recognise 
the branch site upstream the 3’ splice site (3’ss) (also known as the E complex). Subsequently, U2 
snRNP binds to the branch site in an ATP-dependent manner replacing SF1/BBP, forming complex A. 
Complex B formation involves the association of a tri-snRNP complex composed of U4/U6 and U5 
with the spliceosome which is guided by a large complex of protein known as NineTeen Complex 
(NTC) (Figure 5) (Hogg, McGrail, & O'Keefe, 2010). During the first transesterification reaction 
catalysed by the RNA-dependent ATPase Prp2 the spliceosome undergoes remodelling, leading to 
the dissociation of U1 and U4 forming complex C. In the second transesterification reaction the NTC 
guides the removal of the intron lariat and subsequent ligation of the upstream 5’ss exon to the 3’ss 
exon. Upon completion of the splicing reaction, the removed intron lariat is degraded and the 
snRNPs are recycled in subsequent splicing reactions. Spliceosome formation is reviewed in further 
detail by (Wahl et al., 2009). 
 
Figure 5 Major spliceosome assembly and the respective complexes formed during intron removal from the pre-mRNA. 




1.2.2.2 Splice site recognition and cis-acting elements 
Exons are often classified as constitutive or alternative exons. This classification reflects the strength 
of the splice site signal recognised by the spliceosome during complexes H and A. The recognition of 
splice sites by the spliceosome machinery is essential for correct splicing and is dependent on the 
complementarity between splice site sequences and the snRNPs. Constitutively spliced exons are 
often flanked by strong splice sites relative to alternative exons. Splice site strength can be predicted 
using online tools such as Splicing RegulatiOn Online Graphical Engine (SROOGLE) (Schwartz, Hall, & 
Ast, 2009).  
Splice site recognition can be influenced by cis-acting elements. These are sequences on the pre-
mRNA that enhance (exonic splicing enhancers (ESE) and intronic splicing enhancers (ISE)) or 
inhibit/silence (exonic splicing silencers (ESS) and intronic splicing silencers (ISS)) splice site selection. 
Recognition of both constitutive and alternative exons is largely influenced by splicing enhancer and 
silencer sequences (Matlin et al., 2005). Cis-regulatory elements are highly enriched within the 
regulated exons or close proximity to the splice sites (Sorek & Ast, 2003), but distal regulatory 
sequences have also been reported (Ule et al., 2006). 
1.2.2.3 Trans-acting factors: SR-proteins and hnRNPs 
For cis-regulatory elements to exhibit their effect on splice site recognition they must be bound by 
RNA binding proteins. These are trans-regulatory proteins which include members of the SR-protein 
family and the heterogenous nuclear ribonucleoproteins (hnRNPs). Generally, SR-proteins act to 
enhance splice site recognition by binding to ESEs or proximal ISEs and by recruiting U1 snRNP to the 
5’ss during complex A formation (Zhou & Fu, 2013). SR-proteins contain an arginine/serine-rich 
domain (RS-domain) and one or more RNA recognition motifs (RRMs). The RS-domain plays an 
important role for protein-protein interactions with other SR-proteins and components of the 
spliceosome (J. Y. Wu & Maniatis, 1993), whereas the RRM facilitates direct interaction with the RNA 
through cis-elements. Classical SR-proteins (SRSF1 – SRSF6) are defined based on recognition by the 
mAb104 monoclonal antibody, structural similarities, purification using magnesium chloride and 
function in both alternative and constitutive splicing (Long & Caceres, 2009). However, structurally 
similar proteins known as SR-like proteins are also involved in splicing regulation. SR-like proteins 
contain at least one RS-domain and an RRM allowing them to interact with the cis-regulatory 
elements, other SR-proteins and recruit spliceosomal snRNPs. Examples of SR-like proteins include 
both subunits of the U2AF heterodimer (U2AF65 and U2AF35), as well as the homologous pair Tra2α 




concentration and phosphorylation state. SR-protein kinases such as SRPK1 phosphorylate serine 
residues on the RS-domains of SR-proteins (Zhong, Ding, Adams, Ghosh, & Fu, 2009). Several models 
have been previously proposed for the mechanisms of splicing regulation by SR-proteins (Figure 6). 
The classical model of U2AF recruitment to ESE sequences and stabilisation of the interaction 
between the spliceosome and the splice sites is the most widely accepted model (Graveley, Hertel, & 
Maniatis, 2001). SR-proteins may also act by inhibiting the antagonistic function of hnRNPs, which 
are thought to silence splice sites when bound to exonic cis-regulatory elements. This model is 
concentration dependent as it suggests SR-proteins compete with hnRNPs to bind exonic sequences 
(Zhu, Mayeda, & Krainer, 2001). Another commonly accepted mechanism of action suggests SR-
proteins bind to intronic elements near the splice site and inhibit U2AF recruitment. This model 
suggests an inhibitory role for SR-proteins that is dependent on the mRNA location of their binding 
(Erkelenz et al., 2013). Finally, SR-proteins have been suggested to affect the splicing of a target pre-
mRNA without directly binding to it, but instead interacting via the RS-domain with the U4/U6 and 





Figure 6 Splicing regulatory models for SR-proteins. A) The classical model of SR-proteins binding to ESEs and stabilising the 
interaction between U2AF and the 3’ss. B) ‘Competitive’ model where SR-proteins prevent the antagonistic action of 
hnRNPs. C) By binding onto intronic sequences SR-proteins can repress splice site recognition. D) SR-proteins may recruit 
spliceosomal components independently of RNA-binding. Image adapted from Dr Andrew Best thesis, 2014. 
Unlike SR-proteins, hnRNPs inhibit splicing when binding to exonic splicing silencer sequences 




intronic sites. The activating or repressive activity of hnRNPs is largely dependent on their binding 
location, relative concentration and affinity to cis-elements (Fu & Ares, 2014). hnRNPs can also 
interact with other RBPs in a cooperative fashion but can also compete for the same binding sites. 
This was evidenced in the case of polypyrimidine tract-binding protein (PTB, also known as hnRNP I) 
and Quaking (QK) which were shown to regulate an overlapping network of 172 alternatively spliced 
cassette exons (Hall et al., 2013). However, some exons were repressed or activated by both (80) 
and some showed antagonistic regulation by PTB and QK (92).   
1.3 The role of Tra2 proteins in the regulation of alternative splicing 
Transformer-2 (Tra2) is an SR-like protein involved in alternative splicing originally identified in 
Drosophila melanogaster where it plays a key role in sex differentiation and spermatogenesis (Elliott, 
Best, Dalgliesh, Ehrmann, & Grellscheid, 2012). In humans, there are two distinct Tra2 genes, TRA2A 
and TRA2B, coding for Tra2α and Tra2β respectively (referred to as Tra2 proteins throughout this 
thesis). In fact, two copies of Tra2 are found in all vertebrates and the sequence is evolutionarily well 
conserved across species (S. Grellscheid et al., 2011). Tra2α and Tra2β share 63% amino acid 
sequence homology and have similar structural features (Elliott et al., 2012). They have particularly 
high sequence conservation across the RRM which accounts for the fact that their target sequences 
are similar, however most SR-proteins tend to bind GAA-rich targets (Long & Caceres, 2009). High 
throughput sequencing cross linking immunoprecipitation (HITS-CLIP) and RIP-seq have been used to 
show Tra2β commonly binds to the AGAAGA hexamer (S. Grellscheid et al., 2011; Uren et al., 2012). 
An interesting feature of the Tra2 proteins is the interaction between the two. Initially Tra2β was 
identified to autoregulate its own protein expression by promoting the inclusion of its own 
alternative exon 2. TRA2B exon 2 is a poison exon containing several in-frame stop codons. Inclusion 
of this exon in the mRNA of TRA2B leads to its degradation via nonsense mediated decay (NMD). 
Grellscheid et al. (2011) discovered that mouse Tra2a also contains a poison exon 2. This exon shows 
high sequence conservation across vertebrates and most interestingly is regulated by Sfrs10 (TRA2B 
in mice).  Remarkably, the inclusion of Tra2a exon 2 in the mRNA was testis specific which correlates 
with an increased expression of Sfrs10. Subsequently, human TRA2A poison exon 2 was found to be 
regulated by Tra2β in a human breast cancer cell line (Figure 7)(Andrew Best et al., 2014). The 
interesting dynamic between the two proteins shows that Tra2β may have a master regulator role 





Figure 7 RNAseq and iCLIP data showing TRA2A and TRA2B poison exons. Vertical arrows indicate Tra2β iCLIP tags present 
on the poison exons for both TRA2A and TRA2B. However, RNAseq reads (green peaks) mapped on the human genome 
from the UCSC genome browser do not detect these poison exons due to nonsense mediated decay. RNAseq and iCLIP 
data derived from MDA-MB-231 cells. Image adapted from Best et al. (2014) 
The TRA2B gene produces five mRNA isoforms including the isoform containing the poison exon 
described above. Only two of the other mRNAs produce protein isoforms: the full-length isoform 
and Tra2β-3 which misses RS-domain 1 (Tra2βΔRS1) (Figure 8) (Nayler, Cap, & Stamm, 1998). 
Although Tra2β may regulate its own expression levels via inclusion of the poison exon, it has not 
been observed to influence the expression of the Tra2β-3 isoform. The role of Tra2β-3 is not known 
but the expression of this isoform is conserved in vertebrates and is tissue specific, so it is likely to 
carry out some function (Cléry et al., 2011). The full-length isoform has also been described to 





Figure 8 Alternative splicing events with the TRA2B gene. Highlighted in blue are open reading frames which produce two 
protein isoforms (A) and (B). The poison exon highlighted in red expresses an mRNA isoform targeted by NMD. Image 
adapted from Soilov et al., 2004. 
Tra2β has been shown to directly interact with RBMX (also known as hnRNP G), coded by the gene 
RBMX, to promote the inclusion of exon 7 in the SMN2 gene (Hofmann & Wirth, 2002). This gene is 
particularly important for patients with spinal muscular atrophy who have non-functional SMN1 
alleles because normally SMN2 expression can rescue neuronal function. However, exon 7 of SMN2 
is normally skipped and cannot produce a functional SMN protein. Tra2β can act to promote exon 7 
inclusion and potentially restore in vivo function (Hofmann, Lorson, Stamm, Androphy, & Wirth, 
2000). Alternative splicing of Homeodomain interacting protein kinase 3 (HIPK3) is also regulated by 
Tra2β (Julian P. Venables et al., 2005). The HIPK3 exon T is a poison exon and is exclusively spliced in 
the testes suggesting that Tra2β is directly regulating HIPK3 expression in the testis via alternative 
splicing of exon T (S. N. Grellscheid et al., 2011). Another testis specific exon regulated by Tra2β is 
the Nasp-T exon. Unlike HIPK3-T, Nasp-T is a coding exon that contains 975 nucleotides with 
approximately 37 Tra2β-binding sites (Elliott et al., 2012). The Nasp gene is essential for mouse 
development (Richardson et al., 2006), and the isoform including exon-T is associated with meiotic 
chromosomes and monitors double-strand break repair (Richardson et al., 2000). There is an overall 
tendency for Tra2β to regulate exon inclusion in a tissue-specific manner, particularly in the testis. 
An interesting find is the discovery that Tra2β, an alternative splicing regulator, is vital to the 
development of embryos in mice. Mende et al. (2010) found that double-Tra2β deletion is 
embryonic lethal (Mende et al., 2010). The exact mechanism behind this fundamental role in 




development. Interestingly, development of male germ cells continues into the adult which suggests 
that the reason Tra2β is important in development might be associated with regulation of the testis 
specific exons. The fact that Tra2β strictly controls alternative splicing in the testis and is essential in 
embryo development may suggest a role in cells undergoing rapid cell division. 
1.4 Role of Tra2α/β and RBMX in cancer 
Rapid cellular division is a hallmark of cancer. Previous reports have identified many mutations 
disrupting normal alternative splicing in cancer (H.-X. Liu, Cartegni, Zhang, & Krainer, 2001; Lukas et 
al., 2001). Likewise, recent investigations into the mechanisms that drive tumorigenesis have 
suggested that RNA binding proteins play a significant role in cancer by regulating post-
transcriptional mRNA expression (Galante et al., 2009; M.-Y. Kim, Hur, & Jeong, 2009). Since 
alternative splicing applies to more than 95% of protein coding genes it is possible that disruptions of 
this mechanism can lead to the generation of an array of protein isoforms, some of which may 
contribute to tumorigenesis (Pajares et al., 2007). Involvement of Tra2β in lung squamous cell 
carcinoma (LUSC) and adenocarcinoma (LUAD), among other regulators of alternative splicing 
(Coomer, Black, Greystoke, Munkley, & Elliott, 2019), highlights the importance of alternative 
splicing in aggressive cancers. There are already several reports suggesting that Tra2 proteins are 
overexpressed in cancers (Fischer et al., 2004a; Gabriel et al., 2009; Watermann et al., 2006). Tra2β 
overexpression has been associated with poor prognosis in cervical cancer and LUSC patients 
(Sebestyén et al., 2016). A study of invasive breast cancer patients showed significant 
overexpression of Tra2β proteins compared to other SR-proteins (Figure 9). This suggests that Tra2β 
may play a significant role in breast cancer development through alternative splicing regulation.  
Similarly, overexpression of RBMX has been correlated with expression of the pro-apoptotic Bax 
gene in breast cancer (Martínez-Arribas et al., 2006). Identification of lung cancer patients with 
truncating mutations in the RBMX gene suggests RBMX may act as a tumour suppressor (D. Zhang, 
Qu, Zhou, Wang, & Zhou, 2018). However, the general consensus is that RBMX, a hnRNP, functions 
as an RNA binding protein to regulate splicing. This has been previously demonstrated in conjunction 
with Tra2β in the co-regulation of SMN2 exon 7 (discussed previously) and antagonistic regulation of 
TPM3 (Nasim, Chernova, Chowdhury, Yue, & Eperon, 2003). The role of RBMX in disease is reviewed 





Figure 9 Expression of TRA2A and TRA2B in breast cancer. Both mRNA and protein expression of the SR-like proteins are 
significantly increased in breast cancer tissue. Image adapted from Watermann et al. (2006) 
 
1.5 Background to this thesis 
The work on this thesis in relation to Tra2 proteins is a continuation of a project initially undertaken 
by Dr Andrew Best. Dr Best’s work was mainly focused on investigating Tra2β regulated exons in the 
MDA-MB-231 cell line, a model of invasive breast cancer. To identify such targets, he performed 
iCLIP (individual-nucleotide resolution Cross-Linking and ImmunoPrecipitation) analysis to identify 
RNA targets bound by Tra2β in MDA-MB-231 cells. Subsequently, Dr Best performed RNA 
sequencing of the MDA-MB-231 cells treated with negative control siRNA and siRNA targeting TRA2A 
and TRA2B. As shown on his Nature Communications publication, in order to observe a significant 
effect on the expression of different isoforms regulated by Tra2β, a knockdown of both Tra2 
proteins was required (Andrew Best et al., 2014). The double knockdown was necessary as the 
absence of one homologue could be overshadowed by the overexpression of the other as a 
consequence of the negative feedback pathway between the two genes. Due to the similarities in 
the structure and amino acid homology of the two Tra2 genes, targets regulated by Tra2β could also 
be regulated by Tra2α. The RNAseq reads from control and Tra2 double knockdown samples were 
mapped to the human reference genome hg19 using Tophat 2. The results of the investigation 
revealed a set of 54 potential Tra2 targets, one of which was the CHEK1 gene. This gene was shown 
to be directly regulated by Tra2β, which promotes exon 3 inclusion and leads to the production of 
full-length functioning CHEK1 in cancer cells. The CHK1 protein is known to be an important 
checkpoint regulator that can control cell cycle progression and the Tra2 overexpression in breast 
cancer is pushing the cell through the cell cycle checkpoints by increasing CHK1 protein levels. The 




Tra2 in breast cancer. However, the full profile of alternatively spliced targets regulated by Tra2 is 
potentially much larger. Depletion of Tra2 proteins in MDA-MB-231 cells lead to reduced cell 
viability (Andrew Best, James, Hysenaj, Tyson-Capper, & Elliott, 2016). Nuclear morphology of cells 
treated with siRNAs targeting both TRA2A and TRA2B showed distinct features of abnormal of 
chromosomal organisation. This indicates the role of Tra2 proteins extends well beyond the 
regulation of alternative splicing of CHEK1. In this project I utilise the data from the RNAseq and 
iCLIP experiments to investigate more potential targets of Tra2α/β in the MDA-MB-231 breast 





1.6 Research aims and objectives  
The key objective of this thesis is to investigate the role of the RNA-binding proteins Tra2α, Tra2β 
and RBMX in the regulation of alternative splicing of essential genes. 
The aim of this project was to more efficiently analyse the RNAseq data obtained from triple 
negative breast cancer MDA-MB-231 cells by a previous PhD student, Dr Andrew Best. In his work, 
Dr Best identified several important genes under the regulation of Tra2 proteins, particularly CHEK1. 
However, CHEK1 overexpression did not rescue cells from death after Tra2α/β double knockdown 
(Andrew Best et al., 2014). In this project, I was prompted to robustly analyse the RNAseq data using 
multiple improved bioinformatics pipelines in order to identify novel alternatively spliced events 
regulated by Tra2α/β. I also investigated enriched Gene Ontology pathways that elude to the 
potential functional role of Tra2 proteins in the breast cancer cells. 
Alternative splice changes regulated by Tra2 proteins induce the expression of alternative isoforms 
that can potentially alter protein structure and function. Therefore, we hypothesised that protein 
changes corresponding to these splice changes must be detected in order to confidently determine if 
these isoform influence breast cancer cell function and survivability. Following identification of 
alternative events that affect protein isoform expression of Tra2-regulated genes, I used modified 
antisense oligonucleotides to imitate the individual splice changes. Subsequently, I assessed the 
functional impact of the induced isoforms in breast cancer cell function and survival. 
Regulation of alternative splicing is a complex process that involves the interactions of many RNA 
binding proteins. Tra2β has been known to interact with RBMX in the regulation of SMN2 splicing, a 
clinically relevant gene (Cléry et al., 2011; Moursy, Allain, & Cléry, 2014). Therefore, I aimed to 
investigate the regulatory overlap between Tra2 proteins and RBMX using transcriptome-wide 
analysis of RNAseq data obtained from RBMX knockdown MDA-MB-231 cells. In this thesis, I analyse 
the first global analysis of RBMX-regulated alternative events with the aim of identifying mechanistic 
patterns or splice regulation by RBMX and affected genes potentially important to the biology of 





Chapter 2: System wide screening of alternative isoforms regulated by 
Tra2α and Tra2β in breast cancer 
2.1 Introduction 
Tra2 proteins are ubiquitously expressed in the human body. However, increased expression of both 
Tra2α and Tra2β observed in several cancers raises a question to the role of these genes in the 
development and maintenance of cancer cells. The knockdown of both Tra2 proteins in the MDA-
MB-231 breast cancer cell line had severe effects on the cell survivability and clearly affected the 
splicing of several key genes (Andrew Best et al., 2014). Particularly, the alternatively spliced exon 3 
of Checkpoint Kinase 1 (CHEK1) was shown to be directly bound and regulated by Tra2β. In turn, 
skipping of exon 3 led to loss of CHK1 protein, and a parallel increase in DNA damage monitored by 
γH2AX accumulation. Direct siRNA depletion of CHEK1 also caused an accumulation of γH2AX levels. 
However, cell rescue experiments using tetracycline induced CHEK1 overexpression did not restore 
the viability of cells treated with siRNA against TRA2A and TRA2B. This was a clear indication that 
Tra2α/β are likely to be regulating other genes essential for cell survival.  
The full scope of Tra2-regulated alternative events might not have been exposed by the original 
analysis of the RNAseq. A potential limiting factor could be the analysis power provided by the 
bioinformatics tool DexSeq. While DexSeq is a package specifically developed to detect alternative 
splicing events, there are many evident drawbacks. DexSeq is a bioinformatics package focused on 
finding differential exon usage by using RNA-seq exon counts. The ratio of the reads overlaying an 
exon and the reads mapped to the flanking exons of the same gene is considered when calculating 
exon usage. This difference is defined as differential exon usage (similar to Percentage Splicing 
Inclusion, PSI, which is often used to calculated splice site usage in RT-PCR experiments) and 
considers the total read counts over each exon in the calculations. While the method takes into 
consideration differences from biological replicates, there are several drawbacks that may have 
prevented our initial investigations from identifying the full range of target genes regulated by Tra2 
proteins. Firstly, the DexSeq algorithm relies on read counts mapped over predefined exons using a 
binning method. Reads that map onto intronic regions or cryptic exons that have not been defined in 
the reference genome will not be used in the analysis. This limits the potential of DexSeq to identify 
novel cryptic exons or intron retention changes. Secondly, the PSI calculations rely purely on the 
number of reads overlapping with an exon with respect to all reads falling on the whole gene. 




the exon-exon junction reads (reads that map on two exons while skipping the spliced sequence in 
between) are simply used to add to the total count of reads for each respective exon they map to. 
Such simplistic sorting of junction reads devalues the information they provide.  
Having such drawbacks in mind we thought to re-analyse our RNAseq data using other 
bioinformatics pipelines that have sought to tackle these issues. Mixture of ISOforms (MISO) and 
Modelling Alternative Junction Inclusion Quantification (MAJIQ) are two bioinformatics pipelines 
that implement exon-exon junctions in the analysis of each splice junction. Moreover, both MISO 
and MAJIQ will consider reads that map to non-exonic regions and so are able to identify splicing 
patterns involving cryptic exons or intron retentions (Figure 10). While the packages have similarities 
and are improvements on DexSeq, MAJIQ is much more recently developed pipeline. The 
developers, Prof Yoseph Barash’s bioinformatics group that collaborated on this project, are 
continuously improving the pipeline to increase sensitivity and reduce false positive calls. In 
addition, they have developed Voila, a visualisation package that creates interactive summary files 
with gene splice graphs, local splicing variations (LSV) and their quantification (Vaquero-Garcia, 
Barrera, Gazzara, González-Vallinas, et al., 2016). 
The benefit of analysing our data using multiple additional bioinformatics pipelines is two-fold. 
Firstly, we can comprehensively identify alternatively spliced essential genes regulated by Tra2 
proteins. This is would help identify other genes/isoforms responsible for the dramatic effect of Tra2 
double knockdown. Secondly, we can identify the full landscape of Tra2-regulated alternative 
isoforms. This is an important outcome of the analysis that can hint to the role of Tra2 proteins in 
the long term. While investigating the effects of strong changes in essential genes is important to 
evaluate the immediate effect of Tra2-protein knockdown in the cells, exploring the full range of 
target genes regulated by Tra2 can direct us to their normal role in the cell and potential function in 
both normal biology and carcinogenesis. 
Gene Ontology enrichment analysis will be a useful tool to highlight important biological and cellular 
pathways regulated by Tra2 proteins. In this chapter, we make use of GO terms associated with 
Tra2-regulated genes identified by all three bioinformatics pipelines. We also investigate the effect 
of some of the splice changes at the protein level to determine a role of Tra2 proteins in GO-





Figure 10 RNAseq reads overlaping the splice junctions are utilised by both MISO and MAJIQ in determining the isoform 






2.2 Chapter aims and objectives 
The main objective of this chapter is to understand the role of Tra2α/β proteins in the cell, and how 
they might contribute to the development of breast cancer. Here we aim to: 
Interrogate our previous RNAseq data using new bioinformatics programmes to determine if there 
are additional Tra2β-dependent target exons in the MDA-MB-231 cell line. 
Investigate the composition and predicted effects of alternative splicing events regulated by Tra2 
proteins in MDA-MB-231 cells. 
Investigate the Gene Ontology enrichment data to highlight cellular/biological pathways under the 
potential regulation of Tra2 proteins. 
Identify candidate genes and test their protein expression changes upon Tra2 double depletion. 






2.3 Materials and methods 
2.3.1 Bioinformatics analysis of RNAseq data 
The RNAseq data published originally in the nature communications paper by Best et al. 2014 was 
analysed using DexSeq and MISO (this analysis was kindly performed by Mr Yaobo Xu at the Institute 
of Genetic Medicine). In collaboration with the bioinformatics team based at the University of 
Pennsylvania lead by Prof. Yoseph Barash we reanalysed the data with a more comprehensive 
bioinformatics tool named MAJIQ, which utilises a similar approach to MISO to identify alternative 
events within the RNAseq data (Vaquero-Garcia, Barrera, Gazzara, González-Vallinas, et al., 2016). 
RNAseq data analysis using MAJIQ was performed by Matthew Gazzara at the University of 
Pennsylvania. MAJIQ provides in depth detail regarding each local splicing variation (LSV) and utilises 
improved algorithms to identify alternative events based on a larger database of predefined exons. 
Both MISO and MAJIQ analysis methods use a 20% change in percentage splicing inclusion (PSI) as a 
minimum cut-off. 
To identify biological pathways that are potentially regulated by the Tra2 proteins we used Gene 
Ontology (GO) analysis on the list of targets that showed to be alternatively spliced upon Tra2 
double depletion. The GO enrichment analysis was performed by Dr. Katherine James using all three 
datasets (DexSeq, MISO and MAJIQ) separately and combined.  
2.3.2 Cell culture 
The breast cancer cell line MDA-MB-231 was maintained in Dulbecco’s Modified Eagle Medium with 
10% fetal bovine serum and 1% Penicillin and Streptomycin antibiotics. The cells were incubated at 
37°C with 5% CO2 and stored in 75 cm2 tissue flasks. Cells were split regularly at 4-5 day intervals, at 
a 1 in 5 ratio. The cell line was provided to me by Dr Andrew Best but was originally purchased from 
the American Type Culture Collection.  
2.3.3 siRNA knockdown 
Tra2α and Tra2β transient double knockdown was established using siRNAs targeting TRA2A 
(Ambion IDs: s26664) and TRA2B (Ambion IDs: s12749) transfected with Lipofectamine RNAiMax 
transfection protocol (ThermoFisher). Negative control cells were transfected with scramble siRNA 
(Ambion Cat#: 4390843). Cells were transfected with siRNA transfection mixtures diluted in 150µl of 
Opti-MEM using 12µl of 10µM negative control siRNA or 6µl of 10µM siRNA targeting TRA2A and 6µl 
of 10µM siRNA targeting TRA2B simultaneously. Each transfection mixture was then combined with 
6µl of Lipofectamine RNAiMAX reagent (ThermoFisher) which was diluted in 150µl of Opti-MEM. The 




231 cells were seeded on 6-well plates 24 hours prior to transfection at a confluence of 
approximately 1x106, measured using a haemocytometer. Upon siRNA transfection cells were for the 
incubated for 72 hours at 37°C, after which they were harvested using trypsin. Samples were split to 
provide RNA (cells treated with Trizol) and protein (cells treated with 2x Protein Loading buffer). 
2.3.4 cDNA and PCR quantification 
The RNA from cells treated with siRNA against TRA2A and TRA2B was extracted using standard Trizol 
RNA extraction (Life Technologies) following manufacturer’s instructions. In each case cDNA was 
synthesized from 500ng total RNA in 10µl reactions using Superscript VILO cDNA synthesis kit 
(Invitrogen) following manufacturer’s instructions. To analyse the splicing profiles of the alternative 
events primers were designed using Primer 3 Plus and the predicted PCR products were confirmed 
using the UCSC In-Silico PCR tool. Primers were designed to have a melting temperature of 60°C (+/-
1°C) often including an internal screening primer (Full list of primers for all chapters in the 
Appendix). All PCR reactions were performed using GoTaq G2 DNA polymerase kit from Promega. All 
PCR products were examined using the Qiaxcel capillary electrophoresis system (Qiagen) and PSI was 
calculated using concentration from three biological replicates of control and Tra2 double 
knockdown cels. The following formula was used to derive PSI:  
Conc of ′exon included′ PCR band (ng/µl) 
Conc of ′exon included′+′exon exluded′ PCR bands (ng/µl)
𝑥100 = 𝑃𝑆𝐼 (%) 
 
End point PCR reaction mix  
5x Reaction buffer 4µl 
Forward Primer (10µM) 1µl 
Reverse Primer (10µM) 1µl 
dNTPs (10µM) 0.4µl 




Thermocycler programme   
1 Heat Activation  95°C 5 min 
2 Denaturation 95°C 20 sec 
3 Annealing 58°C 30 sec 
4 Extension 72°C 60 sec (Cycle to step 2 x29) 
5 Final Extension 72°C 10 min 





2.3.5 Western Immunoblotting 
Cells dissolved in 2x Protein Loading buffer (4% SDS, 20% glycerol, 200mM DTT, 0.01% bromphenol 
blue and 0.1 M Tris HCl, pH 6.8) were used to obtain protein samples from each siRNA knockdown 
case. Samples were briefly sonicated and then denatured at 100°C for 5 minutes. Protein was 
separated using 10% SDS-polyacrylamide gel and then transferred onto PVDF membrane (Hybond-P, 
GE Healthcare) using semi-dry transfer methods. Membranes were blocked for 1 hour with 5% non-
fat milk, and in some cases 1% horse serum, diluted in Tris-Buffered Saline with Tween 20 (TBS-T). 
Often the membrane was incubated overnight at 4°C (or at room temperature for 1 hour) with the 
primary antibody diluted in blocking solution at ratios suggested by the manufacturer. Membranes 
were then washed with TBST prior to the addition of the species-specific secondary antibody 
conjugated to horseradish peroxidise. Enhanced chemiluminescent (ECL) Prime Western 
Immunoblotting Detection kit (Amersham) was used to activate the horseradish peroxidise for film 
development. Quantification of western blot bands was done using ImageJ (Fiji software). A list of 
antibodies used is shown in the table below.  
Primary Antibodies Cat. number Dilution 
CENPQ Rockland, 200-401-B48S 1/1000 
SUV39H2 Proteintech, 11338-1-AP 1/2000 
ZCCHC11 Proteintech, 18980-1-AP 1/1000 
Sin1 (MAPKAP1) Cell Signalling, D7G1A 1/2000 
Tra2β Abcam, ab31353 1/2000 
β-Actin Sigma-Aldrich, A5441 1/2000 
α-Tubulin Sigma-Aldrich, T5168 1/2000 
H3K4me2 Millipore, 07-030 1/2000 
H3K4me3 Diaogenode, MAb-003-050 1/1000 
H3K27me3 Diagenode, pAb-069-050 1/1000 
 
2.3.6 Histone H3 methylation state 
Histone H3 methylation profiling was performed by Western blotting by Dr. Alejandro Villarreal at 
Freiburg University, Germany (Prof. Tanja Vogel laboratory). For this experiment MDA-MB-231 cells 
were treated with siRNA using same transfection protocol as above but were incubated for 72 hours 







2.4.1 MISO and MAJIQ identify over 500 additional changes upon Tra2 double depletion  
2.4.1.1 Mixture of ISOforms, MISO 
The computational analysis using MISO was performed by Yaobo Xu (Newcastle University) and 
predicted 84 alternative events that are potentially regulated by Tra2 proteins, 6 of which were 
previously identified by DexSeq. The analysis used a 20% dPSI minimum cutoff. 69 out of 84 (82%) 
alternative events identified by MISO were cassette exons (Figure 11, and Appendix Table 1). These 
include 10 cases of mutually exclusive exons. An example of the mutually exclusive exon splicing is in 
the COX10 gene. COX10 encodes an important protein member of the Cytochrome C Oxidase 
assembly. The mutually exclusive splice event regulated by the Tra2 proteins involves the exclusive 
use of exons 3 and 4 of COX10. The UCSC genome database predicts that each of these alternative 
isoforms can produce translatable mRNA that encode for proteins of 251 amino acids (exon 3 
included) and 226 amino acids (exon 4 included).  To determine if there are any evident changes in 
the structures of these two isoforms, I ran the amino acid sequences through the Pfam protein 
analysis online tool found at https://pfam.xfam.org/ (El-Gebali et al., 2019). Both sequences contain 
the UBiA prenyltransferase protein subunit which is predominantly unaffected in either isoform. 
Since there is little change in the predicted structure of the protein it is difficult to anticipate the 
effect of the isoform switch in the assembly of Cytochrome C Oxidase.  See Appendix, Table 2 for a 
list of MISO identified targets and the anticipated Pfam domains affected. 
 
Figure 11 Tra2-regulated alternatively spliced genes identified by MISO. Percentage Splicing Inclusion of alternative events 




The use of exon-exon junction reads enabled MISO to clearly identify alternative use of 5’ and 3’ 
splice sites in 15 different genes (4 and 11 respectively). The identification of alternatively selected 
splice sites was novel compared to the results from DexSeq. One example of the use of an 
alternative 3’ splice site is found in the Retinoblastoma binding protein 4 (RBBP4) gene (Figure 12). 
RBBP4 encodes a ubiquitously expressed nuclear protein that is involved in histone acetylation and 
chromatin assembly. The alternative 3’ splice site used in the Tra2 double knockdown cells is located 
in the 3’UTR region of the last exon. The iCLIP data shows a large cluster of Tra2β binding sites near 
the control-expressed 3’ splice site. This is strong evidence suggesting Tra2 proteins are directly 
regulating the use of this alternative splice site. The alternative last exon introduces a different 
amino acid sequence at the C-terminus of the protein that leads to a shorter protein. However, Pfam 
domain predictions show the shorter protein still contains all five WD40 domains, a domain often 
found in transcription factors and signal transduction proteins. 
 
Figure 12 Alternative splicing of RBBP4. RNAseq data from the Tra2 knockdown (top) and the control (bottom) samples, as 
viewed on the UCSC browser, show a clear switch in the 3' splice site usage (indicated by red arrow) corresponding to 
predicted isoforms by Ensembl 
To verify the results from MISO we compared the splicing profiles between MDA-MB-231 cells 
transfected with a negative control siRNA or TRA2A and TRA2B siRNAs. Total RNAs were extracted 
and analysed by reverse transcriptase polymerase chain reaction (rt-PCR) using primer pairs or other 
primer combinations able to detect the expected isoforms. In total, we designed primers for and 
tested 34 novel alternative events identified by MISO. In 31 (91%) of these we were able to confirm 
the alternative changes predicted by RNAseq (Appendix, Table 1). While validation by PCR is 
important, particularly in cases where there are no iCLIP tags in the vicinity of the alternative events, 
we are confident that the calls made by MISO are pointing to real changes in the RNA splice isoform 




2.4.1.2 Modelling Alternative Junction Inclusion Quantification, MAJIQ 
The bioinformatics team of Prof Yoseph Barash at the University of Pennsylvania analysed our 
RNAseq data using their analysis package, MAJIQ. A total of 679 local splicing variations (LSV) were 
found in 474 genes - note that one alternative event may have more than one LSV, each indicating 
exon splicing changes observed from the point of view of the flanking exons. 15 of these genes were 
found to have 2 alternative events being regulated by Tra2 proteins. Much like MISO, most targets 
identified by MAJIQ were alternative cassette exons (502 out of 679 LSV, 74%). MAJIQ was the only 
pipeline able to confidently identify 35 repressed exons (all previously identified splice changes have 
negative PSIs in response to Tra2α/β depletion, while these 35 exons had positive PSI changes) 
(Figure 13). MAJIQ was also capable of identifying changes in intron retention for 19 genes, a role 
that Tra2 proteins have not been previously known for. 
The extensive use of RNAseq reads overlapping exon junctions allowed MAJIQ to identify a range of 
complex alternatively spliced events. 334 out of 679 LSVs found by MAJIQ are considered as complex 
due to the involvement of three or more splice junctions. Complex LSV can pose a problem when 
trying to determine the correct splicing event. As an example, consider an alternatively spliced exon 
that also contains an alternative 3’ splice site within its coding sequence. In this example LSV a dPSI 
change of -60% could be calculated based on a -50% change due to the exon being fully skipped and 
-10% due to the use of the alternative 3’ splice site. Figure 14a shows the alternative splice change 
predictions by MAJIQ for the MBD4 gene. The multiple exon-exon junctions in play between exon 2, 
3 and 4 of the gene can create a range of possible alternative isoforms. Indeed, RT-PCR shows 
several faint bands in the Tra2α/β depleted cells (Figure 14b). An analysis of the cumulative 
distribution function (CDF) of the dPSIs for the third junction in the 334 complex LSVs shows that in 
approximately 10% of the cases the 3rd junction changes by 10% (the complex LSV analysis was 
performed by Matthew Gazzara, University of Pennsylvania). The visualisation programme Voila 
helps us understand better the complex splice events and directs us in designing the right primers to 
test such cases. Interestingly, some complex alternative events occur over multiple exons. We were 
able to identify and validate by PCR seven such events in the following genes: GINS1, INO80C, 
OARD1, SLC35A1, UBAC2, UIMC1 and XPA. We will investigate a few of these cases in more detail 





Figure 13 Alternative events identified by MAJIQ include a variety of complex events, however the majority of Tra2α/β 
targets are cassette exons 
As with MISO, we set out to validate a proportion of the alternative splicing events identified by 
MAJIQ using RT-PCR and capillary gel electrophoresis. In total we tested the splicing profiles of 94 
genes encompassing a range of alternative events. 83 (88%) of the events tested by PCR confirmed 
the results predicted by MAJIQ (Appendix table 2). However, the dPSI values obtained by our PCR 
results (both for MISO and MAJIQ) were not always the same, often smaller than those predicted by 
the pipelines. The discordance in the dPSI value measured could be due to a range of confounding 
variables and differences between processes used to obtain the results. One obvious reason is the 
different experimental methods; MISO/MAJIQ use data from RNAseq whereas our validation is 
based on the PCR band intensity measured by capillary gel electrophoresis. Primer affinity and 
amplification bias of shorter amplicons can heavily affect the dPSI results from PCR. Furthermore, 
the knockdown efficiency in the samples sent for sequencing may be slightly different from that 
obtained in the samples used to perform the validations. All things considered however we were 
able to validate approximately 90% of the MISO and MAJIQ targets tested, all showing changes in 
the expected direction which gives us confidence that the bioinformatics analysis of the RNAseq data 





Figure 14 Complex LSV example in the MBD4 gene. Two Local Splicing Variants (LSVs) identified by MAJIQ shown in part a) 
are in fact describing the same exon-exon junction reads but calculate the PSI values differently. In LSV2 of this example 
the proposed main isoform uses the downstream splice site of exon two which connects to exon 3 (green line, green bar). 
The green bar (next to yellow star) represents the use of this junction, which is then drastically reduced (-70%) in the 
knockdown cells where alternative splice junctions are used (bars next to red star). Part b) of the figure shows a capillary 
gel electrophoresis of the RT-PCR for MBD4. Several smaller bands are visible in the Tra2α/β knockdown cells suggesting a 
multitude of alternative isoforms may be present in these conditions. ** represents p<0.01, calculated by Student’s t-test 
from three biological replicates. 
2.4.1.3 Tra2 proteins are predominantly involved in the regulation of alternative splicing 
The Tra2 proteins are SR-like proteins and were classically known to be involved in alternative 
splicing alone (Tacke, Tohyama, Ogawa, & Manley, 1998). However, the cassette exons identified by 
DexSeq, and reported by Dr Best (Andrew Best et al., 2014), included a large number of constitutive 
exons being spliced out of the mRNA in the absence of Tra2 proteins - 26 out of 54 exons have a 
control PSI of 95% or higher. Among the target cassette exons identified by MISO only 19% are 
constitutive exons, less than half the rate of constitutive exons identified by DexSeq. SImilarly, the 
MAJIQ-identified differentially spliced constitutive cassette exons only comprise 17% of the total 




regulation of constitutive exons but confirms their role as being predominantly involved in regulating 
alternative splice. 
 
Figure 15 Data combined from all three bioinformatics pipelines confirm that Tra2 proteins predominantly regulate splicing 
of alternative cassette exons, but also highlight other mechanistically interesting events 
2.4.1.4 Combined data from all three bioinformatics analysis shows that only a small proportion of 
alternative events are commonly identified by all three pipelines 
Rerunning the RNAseq data through MISO and MAJIQ helped identify a total of 502 novel 
differentially spliced targets. Figure 16 shows the overlap of target genes identified by each 
bioinformatics tool. Only 49 novel alternative events were commonly identified by MISO and MAJIQ 
(Figure 16). Although this is only 10% of the total number of novel events, it accounts for 58% of all 
the exons identified by MISO. Despite the differences this overlap suggests that MAJIQ is capable of 
identifying the majority of MISO targets, but the opposite is less likely. To our surprise I found that 
only 5 events were identified by all three bioinformatics tools (CHEK1 ex3 included). This low level of 
concordance between the three packages is a clear indicator of the differences in the algorithms 
used to investigate differential splicing. However, MAJIQ is clearly a more powerful analysis tool over 
the others as it was able to detect almost 10 times more targets, with a high validation rate, 
including a wide range of complex alternative events that reveal new mechanisms by which Tra2 
proteins may be regulating splicing. Appendix, Table 4 shows all previously identified DexSeq 




Despite the clear computational advantages of MISO and MAJIQ in analysing the RNAseq data, 37 
out of the 54 exons identified by DexSeq were not detected. One reason for this could be the 
thorough use of the iCLIP data in conjunction with the results from DexSeq. This allowed the 
identification of several exons that were showing lower than 20% PSI changes, which is the minimum 
cutoff used by both MISO and MAJIQ. Although some targets identified by MISO and MAJIQ do not 
have iCLIP tags, the RNAseq data clearly shows they are alternatively spliced in Tra2 double 
knockdown cells. These changes in alternative splicing can still be attributed to the direct effect of 
Tra2 proteins (although with lower confidence) since the iCLIP tags are only showing binding sites for 
Tra2β.  
 
Figure 16 Tra2 regulated targets identified by bioinformatics. The total number of alternative events identified by all 3 
bioinformatics packages, indicating only 5 events were commonly detected. Percentages represent the portion of targets 
relative to the total number of alternative events identified by all 3 bioinformatics packages. 
2.4.2  MISO and MAJIQ reveal an array of mechanistically complex splicing events that 
include alternative 3’ and 5’ splice sites, intron retentions and multiple exon skipping events 
2.4.2.1 Tra2α and Tra2β repress the splicing of 35 cassette exons 
As SR-like proteins Tra2-α and Tra2-β can bind exonic sequences known as exonic splicing enhancer 




exons they bind to. We were able to identify target cassette exons that are being repressed by Tra2α 
and Tra2β. MISO identified a few targets showing positive dPSI but they were low confidence hits 
with dPSI changes below the 20% cutoff. MAJIQ identified 35 target exons that were being regulated 
by Tra2 proteins and showed increased PSI in the Tra2 knockdown cells.  
In order to understand the mechanism behind the regulation of these repressed exons the binding 
patterns of Tra2β were analysed based on the iCLIP data. We utilised the previously reported and 
validated non-changing control exons (Best et al. 2014) as our baseline control cassette exons, and 
compared the iCLIP patterns over constitutive, activated and repressed cassette exons identified by 
MAJIQ. Figure 17 shows the total iCLIP tags counted over the upstream, target and downstream 
exons for each of the categories. Notice that not all the exons identified in each category have iCLIP 
tags associated with them, hence the number of exons used for this analysis is different to the total 
number of exons identified in each group. In order to test the distribution of Tra2β binding sites we 
used chi-square test for each category under the null hypothesis of no correlation between iCLIP 
tags and target exons. The results show significant abundance of Tra2β binding sites within target 
exons of activated (p-value 0.009) and constitutive (p-value 0.007) exons. Moreover, repressed 
exons are shown to have significantly fewer iCLIP tags (p-value 0.03) in the target exons relative to 
the flanking upstream/downstream exons, whereas control non-changing target exons show no 
significant correlation between number of iCLIP tags and target exons. Our data suggests that Tra2β 
may be repressing these exons by binding onto downstream/upstream exons. A study by Ghigna et 
al. 2005, previously reported their findings on the regulation of exon 11 of Ron, an important 
tyrosine kinase receptor (Ghigna et al., 2005). Their data showed that the strength of the enhancer 
signal in the downstream exon 12 bound by the splicing factor SRSF1 (SF2/ASF) would parallel the 
skipping of exon 11. It is possible therefore that Tra2 proteins could repress upstream exons in a 





Figure 17 Bar chart indicating the relative presence of Tra2β iCLIP binding tags for constitutive, activated and repressed 
exons. Chi square test p-values *p<0.05 and **p<0.01 
2.4.2.2 Tra2 depleted cells show changes in the inclusion of several introns/bleeding exons 
Intron inclusion is not a common occurrence in the transcriptome, and alternative splicing of introns 
is often overlooked. In order to detect changes in intronic regions splicing analysis packages must 
consider reads that map onto intronic regions and junction reads that overlap junctions between 
exons and introns. In our data, MAJIQ was the only pipeline capable of detecting changes in intron 
retentions. The analysis identified 19 target genes with delta percentage intron retention (dPIR) over 
20%. Only 3 target genes, NT5C3A, KIAA0141 and PTPN2, were found to contain introns that are 
repressed by Tra2α and Tra2β (positive dPIR). 16 introns show negative dPIR including introns in 
CHEK1, AKT1S1 and BUB3, genes predicted to be regulated by Tra2 proteins in the MISO analysis too. 
Although the data from MAJIQ is very promising, it is important to bear in mind that these are only 
predictions and a manual inspection of each case is ultimately necessary to fully understand what is 
behind each event. Upon closer inspection there are a few intron retention cases that may need to 
be excluded. Interestingly, these are all the three cases also identified by MISO to be alternatively 
spliced. For instance, MISO classifies the AKT1S1 alternative event as an alternative 5’ splice site that 
matches with the 5’ splice site of the “intron” defined by MAJIQ. The decrease in read coverage in 




the coding areas in the reference genome MAJIQ uses, the Ensembl Gene Predictions database 
(2014). Similarly, the alternative events in BUB3 and CHEK1 involve alternative splice sites located in 
the final exons of the genes (Figure 18). Because of the predicted, but not validated, reading frames 
in the reference genome these alternative events are listed as intron retentions by MAJIQ. In order 
to confidently classify these events, we designed primers to test the splice junctions by RT-PCR. 
Primers were designed to bind the flanking exons and where necessary an internal primer was 
added. The PCR results show a clear change in the alternative splicing of these events but no 
evidence of intron inclusion. Although the classification of these events may be incorrect, MAJIQ was 
still able to flag up the splice changes. 
 
Figure 18 A second alternative event identified in CHEK1 shows an alternative poly(A) site selected further downstream 
from the normally expressed isoform. This event was incorrectly classified as an intron retention event by MAJIQ. UCSC 
genome browser view of RNAseq data, red arrows highlighting the changing RNAseq read coverage peaks accordingly. 
In order to confirm that Tra2 proteins are indeed causing changes in intron inclusion we also tested 
four other intron retention cases; NT5C3A, POLR3C, ANTXR2 and NCK1 (Figure 19). The dPIR changes 
measured by PCR were considerably lower than those calculated by MAJIQ for the remaining three 
targets. This could be due to PCR amplification bias or potential differences in the knockdown 
efficiency. However, the changes measured were in the expected direction indicating that Tra2 
proteins can regulate intron retention. Interestingly, the event identified in POLR3C resembles an 
exitron. The affected exon is 256 nucleotides long and the region being spliced out is only predicted 
to occur by the Ensembl Gene Prediction database. However, the prediction indicates this is a non-






Figure 19 Alternative splicing in POLR3C shows an exitron is spliced out in Tra2 double knockdown cells. UCSC view of 
RNAseq data. Red arrows highlight the boundaries of the exitron. 
2.4.3 Alternative events regulated by Tra2 proteins directly impact the open reading frame 
or crucial protein domains 
Alternative splicing can have a range of effects on the final product of a gene. In our approach of 
analysing the RNAseq data I set out to identify and rank the alternative splicing events based on 
their impact on the quantity of alternative isoforms expressed. While this was helpful to highlight 
the target genes whose splicing patterns are strongly dependent on the presence of Tra2 proteins, it 
does not readily bring any light to the effect on the proteins encoded by these genes. To gain an 
insight to the potential effect on the proteome caused by the changes in alternative splicing we 
manually inspected each novel alternative event identified by MISO and MAJIQ to assess the effects 
anticipated for the proteins expressed by each gene. All 556 alternatively spliced targets were 
analysed using the Pfam domain prediction tool, which identified a potential change in important 
protein domains in approximately 37% of the Tra2 targets (Figure 20). Although these predictions 
are simply based on the anticipated effect on the protein sequence, it is likely that the newly 
expressed protein isoforms upon Tra2 double depletion may not be the same as their control-
counterparts. In addition, we observed that approximately 12% of the total alternative events 
introduce a premature stop codon in the mRNA sequence. In this context a premature stop codon is 
not only a stop codon that is earlier in the sequence of the mRNA, but specifically it is located prior 
to at least one exon-exon junction. This way we are more confident to classify such alternative 
isoforms as targets of nonsense mediated decay. Hence, overall our results show that in the absence 
of Tra2 proteins a large proportion (49%) of the alternative isoforms are likely to produce a 
structurally different protein or no protein at all. A strong indicator supporting this scenario comes 
from the previously described conclusion that Tra2 proteins are necessary for the splicing of some 
constitutive exons. In principle, constitutive exons are often very well conserved exons and can 




that the involvement of Tra2 proteins in the regulation of constitutive exons and already established 
alternative isoforms has a strong impact on the proteome of the cell. 
 
Figure 20 Percentages of alternative events regulated by Tra2 proteins that affect reading frame or disrupt predicted 
protein domains. All 556 target genes identified by DexSeq, MISO and MAJIQ were analysed and are accounted for in this 
chart 
2.4.4 Tra2β binding is associated with alternatively spliced exons 
The Tra2β iCLIP data from the MDA-MB-231 cells has been essential to help create a full picture of 
the landscape of genes bound by Tra2β. Extensive analysis of the RNAseq data has been useful at 
identifying the full range of differential splicing events potentially regulated by Tra2 proteins. 
Although there is a clear overlap of Tra2β bound and differentially spliced exons, there are a 
significant number of differentially spliced exons with no Tra2β iCLIP tags nearby, and several exons 
bound by Tra2β that do not show differential splicing. Such occurrences can be due to several 
possibilities but importantly they challenge our hypothesis that ‘Tra2 protein binding is essential for 
alternative splicing’. To test this hypothesis, we sought to interrogate the RNAseq from MAJIQ and 
the Tra2β iCLIP data. Matthew Gazzara at the University of Pennsylvania compared the total number 
of differentially spliced targets that contain Tra2β iCLIP clusters in at least one exon of the regulated 
LSV to a set of high-confidence, non-changing LSVs. Figure 21 shows a cumulative fraction plot and a 
significant association of Tra2β iCLIP clusters and differentially spliced LSVs (p<6x10-10, two-tailed 
Fisher’s Exact test).  
In order to determine if Tra2β binding to the target changing exons is related to the delta PSI of the 
bound exon we extended the analysis to include all novel cassette exon skipping events found 




show that Tra2β-bound changing-exons (Bound A, Figure 21) are differentially spliced at a 
significantly higher rate (p<1.5x10-20, Kolmogornov-Smirnov test). This indicates that Tra2β binding 
can strongly influence the total change in splicing inclusion of the bound exon. 
 
 
Figure 21 Analysis of Tra2α/β bound exons. Left: Cumulative fraction analysis of Tra2β bound exons that show alternative 
splicing vs non-changing exons. Kolmogornov-Smirnov test, p-value: 0.00052. Right: Cumulative fraction analysis of Tra2β 
iCLIP tags shows stronger dPSI changes associated with target exons (Abound) relative to flanking exons (upstream 
“C1bound” and downstream “C2bound”). Note, C1bound and C2bound curve overlap.  
2.4.5 Tra2 proteins regulate the splice patterns of other splice factors 
While our results from the analysis of Tra2-bound changing vs non-changing exons show strong 
evidence that Tra2-binding can significantly increase the dPSI response, we also observe several 
alternatively spliced genes that have no Tra2β iCLIP tags in the nearby sequences. Such splice 
changes could be due to other RNA-binding proteins regulated by Tra2α/β that in turn are also 
regulators of alternative splicing. Two very good examples of other splicing regulators that could be 
controlled by Tra2α and Tra2β are the alternatively spliced genes Quaking (QKI) and DEAD-box 
Helicase 5 (DDX5), two RNA-binding proteins known to regulate pre-mRNA splicing (Galarneau & 
Richard, 2005; Kar et al., 2011). The changing exons in both examples are associated with large 
clusters of Tra2β iCLIP tags indicating direct binding of Tra2 proteins. Interestingly, the cassette 
exons affected in both genes are constitutive exons, but their lengths are multiples of 3 (3n 
nucleotides), hence the spliced isoforms should remain in-frame and express shorter proteins. Pfam 
domain prediction indicates that the changes in protein sequence would disrupt the KH-domain for 
QKI and the Helicase conserved C-terminal domain in the case of DDX5. We were able to confirm 




difficult to determine exactly which Tra2-unbound alternative events are due to the effects of QKI or 
DDX5 (or other genes) considering that the conditions here involve a multitude of other gene 
changes (Figure 22). However, the presence of these alternative splicing regulators being clearly 
affected by the Tra2-double knockdown may provide an explanation for the lack of Tra2β iCLIP tags 
over some strongly changing alternative events in our data. 
 
Figure 22 Alternatively spliced exon 31 of DDX5 is also associated with many Tra2β iCLIP binding tags. Figure shows the 
RNAseq read coverage over the target and flanking exons as viewed on the UCSC browser. 
2.4.6 Gene Ontology enrichment analysis identifies only one enriched term: “Chromatin 
Organisation” 
Gene Ontology (GO) enrichment analysis can be a useful tool to investigate enrichment of biological 
or cellular pathways in the list of target genes regulated by Tra2 proteins. In the course of my PhD 
we have performed this analysis several times using several lists of target genes and the results have 
varied significantly, especially due to the changes in the database of GO terms used. During the early 
stages of our work the GO enrichment analysis performed by Katherine James (Newcastle 
University) using the total target lists, including genes from DexSeq, MISO and MAJIQ, we identified 
7 enriched GO terms. However, recent changes in the Bioconductor database of Gene Ontology 
terms the results from the GO enrichment analysis show only 1 term to have statistically significant 
enrichment in our list of genes (chromatin organisation). Much of the analysis that directed our lab 
work was based on the original results of the GO enrichment analysis. 
2.4.6.1 Genes involved in chromosome biology show strong changes in RNA splicing 
Our initial Gene Ontology enrichment analysis identified 3 enriched terms strongly implicated in 
chromosome regulation (‘sister chromatid segregation’, ‘chromosome segregation’ and ‘chromatin 
remodelling’), and a further two terms that are associated with chromosome modification (‘histone 
H3-K9 modification’ and ‘regulation of gene expression, epigenetic’) (Figure 23). These results are 




al. 2014), indicating a clear importance of the Tra2 role in these pathways. The results from Dr. 
Best’s work indicated that the effect of Tra2 proteins on chromosome biology could be the cause of 
the abnormal nuclear morphology reported in Best et al. 2014. Identifying similar biological 
pathways enriched in a much larger dataset of Tra2-regulated genes is a strong indicator of the role 
of Tra2 proteins in chromosome regulation. In order to be confident however we must confirm that 
indeed the Tra2 knockdown cells are having an effect in the proteins expressed by the target genes 
involved in ‘chromosome biology’. We set out to test the expression of genes from each GO enriched 
term using western immunoblotting. Target genes were selected based on certain criteria. Firstly, it 
is important to carefully investigate each alternative event in order to determine if the splice switch 
is predicted to either produce a shorter/larger protein or none at all. Some alternative protein 
isoforms made by splice changes such as mutually exclusive exons (that are similar in length) or 
alternative 5’ and 3’ splice sites that differ by few amino acids may be impossible to test by western 
blotting. Secondly, we ranked the genes within the enriched groups by dPSI. We reasoned that lower 
dPSI events may not make much change to protein isoform levels. Finally, we selected targets based 
on the extent of available literature on their individual roles and function. Genes that are well known 
to have an effect in chromosome biology and are alternatively spliced upon Tra2 double knockdown 





Figure 23 Initial GO enrichment analysis highlighted several GO enriched terms associated with chromosome biology. Note 
that "DNA Damage" genes were manually highlighted, some of which are investigated further in the following chapter. 
#Number atop of each column represent the total number of genes in each GO term/group. Genes in highlighted in green 
boxes are DNA damage associated genes, and in yellow boxes are genes involved in chromosome biology. 
2.4.6.2 Tra2-regulated DNA binding proteins involved in chromosome biology do not show changes at 
the protein level 
The substantial number of Tra2α/β target associated with chromosome biology raises the question 
of the potential role alternative splicing can have in these genes. To investigate a potential role of 
the alternative changes in chromosome biology we must first determine these changes are affecting 
the protein expression pattern of the target genes. 
My attention was directed at the CENPQ gene (Figure 24). This gene encodes for the Centromere 
Protein Q and is a component of the CENPA-CAD complex that is recruited to the centromeres and is 
involved in mitotic progression and chromosome segregation. Interaction of CENPQ and PIBP1 was 
shown to be essential for their localisation to the centromere, and therefore the localisation of the 
CENPA-CAD (Kang et al. 2011). Our bioinformatics search has also identified alternative events 




CENPQ upon Tra2 double knockdown was significantly stronger (-54%) than those measured in 
CENPK (-34%) and CENPT (-20%). Moreover, the alternative event in CENPQ is anticipated to create a 
shorter isoform of the protein which should be detectable by western immunoblotting. However, 
the results were disappointing as no short CENPQ isoform was detected and the primary CENPQ 
protein isoform does not significantly change expression even when we tried testing the knockdown 
after 96 hours of transfection to account for protein turnover (Figure 25). 
 
Figure 24 Alternative splicing in CENPQ. UCSC genome browser view of the RNAseq tracks shows a reduction in read 
coverage of the first coding exon (red arrow) associated by a cluster of Tra2β iCLIP tags. 
Similar to the CENP-family of proteins regulated by Tra2α/β we also noticed that a group of zinc 
finger DNA-binding proteins undergo alternative splice changes at high dPSIs. Namely the CCHC-
domain containing genes ZCCHC7, ZCCHC9 and ZCCHC11 show dPSIs ranging from -46% to -72%. The 
ZCCHC11 gene, also known as TUT4, encodes for an RNA uridyltransferase that uses UTP to add 
uridines to the 3’ end of substrate RNA molecules. Although ZCCHC11 does not show the highest 
changing dPSI among the three candidate zinc finger proteins, the alternative event involves the 
skipping of exon 2 that in turn is predicted to encode a much shorter protein isoform (108kDa). The 
shorter isoform lacks 5 predicted domains present in the full-length protein (185kDa). We were able 
to validate the isoform switch consistently at the RNA level. However, the antibody used against 
ZCCHC11 was not able to detect the expression of the shorter isoform we predicted or any other 






Figure 25 Reverse transcription PCR validation of CENPQ, MAPKAP1 and SUV39H2 shows strong and statistically significant 
dPSI changes in Tra2α/β depleted cells. b) Western Immunoblotting of corresponding proteins does not show significant 
reductions (c) at the protein level relative to control samples. Quantification of protein expression was done using ImageJ 
for samples with three biological replicates. Significance measured using Student’s t-test. ** represents p<0.01 
The MAPKAP1 gene encodes a protein called SIN1 (Stress-activated map kinase interacting protein 1) 
which is a component of the mTOR complex 2. This complex is a key regulator of cell growth and 
survival in response to endogenous growth factors. There are six known protein coding isoforms for 
this gene listed on UniProt KB, also defined by the RefSeq genes on the UCSC genome database. The 
alternative event being affected by the Tra2 double knockdown indicates the use of an alternative 
cassette exon. The RNAseq changes over this exon are also associated with a cluster of Tra2β iCLIP 
tags. The estimate dPSI change by the bioinformatics tools is -36%. We were able to confirm this 
change by RT-PCR of the cDNA from control vs Tra2 double knockdown samples. Alternative splicing 




start codon in the downstream exon 5. The remainder of the protein sequence is in frame. The 
shorter isoform is predicted to express a 37kDa protein which is missing the SIN1 motif as illustrated 
by the Pfam protein domain prediction tool. The SIN1 motif has been shown to interact with Ras and 
act as a Ras-inhibitor (Schroder 2007). The results from our western immunoblotting however were 
unable to detect the shorter isoform at all (Figure 25). This could be due to the specificity of the 
antibody to the N-terminus. However, we did not see a change in the protein level of the full length 
SIN1 isoform even when we repeated the knockdown for 96 hours to allow for protein turnover. 
Although we only investigated a relatively small number of proteins from the group of genes 
involved in chromosome biology, our data from western immunoblotting have consistently failed to 
identify the predicted short protein isoforms or decreased expression of the control-expressed 
isoforms. Taken as a whole, analyses so far indicated that it was important to examine isoform 
switches at the protein level as well as the RNA level, in order to understand why depletion of Tra2α 
and Tra2β caused cell death. 
2.4.6.3 Tra2 deficient cells show a switch in the methylation pattern of histone 3 
The GO enrichment analysis pointed our attention towards the regulation of chromosomes. A 
noticeable number of target genes are directly involved in histone methylation/demethylation such 
as the KDM1A, KDM3A and SUV39H2. Therefore, we sought to investigate if Tra2 double knockdown 
has an effect on the methylation pattern of Histone 3 in collaboration with Prof. Tanja Vogel’s lab 
(Freiburg University). We knocked down the expression of Tra2α and Tra2β in MDA-MB-231 cells 
over 72 and 108 hours as previously described and collected the protein in RIPA buffer. The 
methylation of Histone 3 at lysine residue K4 and K27 was investigated with respect to the total 
presence of Histone 3 expression. Interestingly, levels of H3K4me2 were significantly reduced after 
the 72 hour knockdown but no significant change was measured after 108 hours. H3K4me2 has been 
previously reported to be positively associated with transcription factor binding regions (Ying Wang, 
Li, & Hu, 2014). H3K4me3 however remained unchanged across both experiments. The 
trimethylation of lysine 27 (H3K27me3) was observed to increase in the 72 hour and 108 hour Tra2 
siRNA transfected cells, however the change was only statistically significant in the 108 hour treated 
cells (Figure 26). H3K27 trimethylation plays a role in maintaining gene transcriptional repression 
and is deposited preferentially at CpG-dense promoters (Ferrari et al., 2014). Tra2 double 
knockdown cells clearly show alterations in the methylation patterns associated with transcriptional 
repression. Pasini et al. 2004 showed that SET-domain-containing methyltransferases are directly 
involved in the methylation of histone H3K9/27 (Pasini, Bracken, Jensen, Denchi, & Helin, 2004). A 





Figure 26 Western immunoblotting of different methylation conformations for Histone 3 show a significant switch from 
dimethylated of H3K4 to trimethylated H3K27. This work was done by Tanja Vogel’s laboratory, Frieburg University. 
*p<0.05 
The protein encoded by SUV39H2 is a histone methyltransferase that specifically trimethylates Lys-9 
of histone 3 near the centromeric region (Dillon 2005 and Schuhmacher 2015). MDA-MB-231 cells 
depleted of Tra2 proteins express a shorter mRNA isoform of SUV39H2 that makes use of an 
alternative 5’ splice site within exon 3. A cluster of Tra2β iCLIP tags over exon 3 suggests the 
involvement of Tra2 proteins in the regulation of this alternative event. The short alternative isoform 
is well defined by the UCSC genome database and is predicted to encode a 26kDa protein isoform. 
To evaluate the potential impact of the alternative splice switch we ran the sequences of the two 
isoforms through the Pfam protein domain prediction tool. The shorter isoform is clearly missing the 
“pre-SET” motif, a zinc binding protein motif functioning as a 3-dimensional scaffold to 




that although the shorter protein isoform of SUV39H2 was detected in both control and knockdown 
cells, there is no statistically significant change in either isoform (Figure 26). Although a change in 
SUV39H2 protein isoform levels could not be detected, the methylation pattern changes measured 







2.5.1 Multiple bioinformatics prediction tools are required for a comprehensive analysis of 
RNAseq data 
To further understand the role of Tra2 proteins in breast cancer cells, a key priority was to identify 
the full scope of genes whose alternative splicing was directly regulated by Tra2 proteins. To do so 
we used MISO and MAJIQ, two improved bioinformatics pipelines compared to DexSeq, to analyse 
the original RNAseq data obtained from the Tra2α/β double knockdown in MDA-MB-231 triple 
negative breast cancer cells. The increased capacity to detect alternative events by MISO and MAJIQ 
expanded the pool of alternatively spliced genes tenfold (from 54 to 556). Moreover, both MISO and 
MAJIQ were restricted to search for splice changes with a minimum of 20% dPSI, something that was 
not implemented in the DexSeq analysis. The large number of identified splice changes by MISO and 
MAJIQ suggest that the DexSeq pipeline has major limitations at identifying the full set of genes 
affected by the knockdown experiment. Although the newly expanded list of potentially Tra2-
regulated genes is substantially larger, a noticeable drawback is the small number of overlapping 
exons identified by all three pipelines. Despite this, the experimental validation success rate of the 
newly identified targets indicates that the predicted splice changes are indeed occurring upon Tra2 
double knockdown. A crucial conclusion to be drawn here is the fact that each bioinformatics 
package has its weaknesses and therefore must be used in conjunction with other packages in order 
to robustly identify the full range of alternative events. This was also highlighted by work published 
recently with collaborators in the recent publication of the newly developed SUPPA2 bioinformatics 
package used to analyse alternative splicing results (J. L. Trincado et al., 2018). Although SUPPA2 was 
able to achieve higher accuracy compared to other methods, especially at low sequencing depth and 
short read length, the investigation of Tra2-regulated targets identified several novel hits, suggesting 
MAJIQ, MISO and DexSeq had still not identified all alternative events from our RNAseq data. 
The presence of iCLIP tags on alternatively spliced targets indicates direct binding and regulation by 
Tra2 protein. The alternative splice changes identified by MISO and MAJIQ do not directly depend on 
the presence of Tra2β iCLIP tags. The analysis of the MAJIQ data (by Matthew Gazzara at the 
University of Pennsylvania) indeed shows that Tra2β binding is significantly associated with a change 
in alternative splicing. However, there were a number of alternative events identified by both MISO 
and MAJIQ that do not contain any Tra2β iCLIP tags associated with them. A potential explanation 
for this could be the effect of Tra2 proteins on the regulation of splicing of other splice factors such 




be due to stress induced changes in the cells by the absence of Tra2 proteins. Moreover, absence of 
Tra2β iCLIP binding tags is not direct evidence that Tra2α does not bind to these exons. Although 
previous work clearly indicates that Tra2 proteins share similarities in structure and target binding, it 
is possible that some of these targets are preferentially bound and regulated by Tra2α. Therefore, it 
would be unwise to exclude from the analysis any target genes showing strong splice changes based 
purely on the absence of Tra2β iCLIP tags. 
2.5.2 Tra2 proteins regulate a range of mechanistically different alternative events 
A strong advantage of using MISO and MAJIQ in the analysis of Tra2-regulated alternative events is 
their capability to detect complex alternative splice changes (as opposed to just cassette exons by 
DexSeq). Amongst the 502 novel alternative events, 334 alternative events were classified as 
complex. These include alternative 3’ and 5’ splice sites, intron retention events and mutually 
exclusive exons. However, overall analysis shows that 70% of Tra2-regulated events are alternative 
cassette exons, and a further 19% are constitutive cassette exons. This finding supports the concept 
that Tra2 proteins act by binding to and promoting the inclusion of exons via direct interactions 
through the exonic splicing enhancer sequences (Desmet et al., 2009; Tacke et al., 1998). However, 
the bioinformatics analysis also identified 35 repressed cassette exons. The analysis of iCLIP tag 
distribution shows a significant correlation between the flanking exons bound by Tra2β and 
repressed target exons, suggesting a potential mechanism of action for Tra2 proteins similar to that 
previously reported in the regulation of exon 11 of Ron by SRSF1 (Ghigna et al., 2005). Moreover, 
previous reports in the fruitfly Drosophila melanogaster have shown the tra2 protein can directly 
repress the splicing of its own M1 intron, which ultimately limits its expression (Chandler, Qi, & 
Mattox, 2003; Qi, Su, & Mattox, 2007). However, to the best of my knowledge there is no evidence 
of human Tra2 proteins acting to repress the splicing of exons. An interesting example showcasing 
exon repression by Tra2 proteins is clear in the DROSHA gene (Figure 27). Exon 6 of DROSHA has no 
associated iCLIP tags, but both flanking exons do. Furthermore, the largest cluster of Tra2β iCLIP tags 
is present in the downstream exon 7 of DROSHA, further backing up the notion of Tra2 proteins 





Figure 27 Alternative splicing of DROSHA exon 7. Tra2β iCLIP tags cluster on the downstream exon 8 but Tra2α/β 
knockdown shows exon 7 skipping indicating a potential mechanism where Tra2 proteins repress splicing of an upstream 
exon 
2.5.3 Tra2 proteins indirectly regulate expression of the TTC14 gene 
Previous reports have clearly demonstrated the capability of Tra2β regulating the expression of itself 
and that of Tra2α via the alternative splicing of poison cassette exons (Andrew Best et al., 2014; 
Stoilov, Daoud, Nayler, & Stamm, 2004). Our data highlights an interesting example where Tra2 
proteins can indirectly influence the expression of a gene via splicing of a key isoform. The 
alternative cassette exon 11 of TTC14 detected from DexSeq as alternatively spliced in cells treated 
with siRNA against TRA2A and TRA2B shows a clear relative drop in inclusion (Figure 28). The 
calculated PSI reduction is over 90% and this result was also confirmed by PCR in Dr. Best’s thesis. 
The Tra2β iCLIP data in MDA-MB-231 cells indicates a bundle of iCLIP tags (more than 100) on the 
alternative cassette exon 11 of TTC14 showing strong evidence of binding by Tra2β. Interestingly, 
the expression of the TTC14 gene was markedly increased in cells treated with TRA2A/B siRNAs. Dr. 
Best confirmed the increased gene expression by quantitative PCR during his PhD together with a 
range of other genes that also showed differential gene expression. Since there are no known 
associations of Tra2 proteins with regulation of transcription, the changes in expression measured 
upon Tra2 proteins knockdown were generally accredited to downstream effects such as cell growth 
or the cell cycle. However, in the case of TTC14, the increase in expression may be directly due to 
aberrant splicing in the absence of Tra2 proteins. On closer inspection of the RNAseq data the 
relative abundance of the isoform including exon 11 of TTC14 is clearly lower in the knockdown cells. 
However, the total expression of the isoform containing exon 11, as indicated by the RNAseq read 
peaks, remains the same. While this effect may be an attempt from the cell to maintain the 
expression of this specific isoform of TTC14, it is clearly the absence of Tra2 proteins and the 
subsequent missplicing of TTC14 that causes such an increase in the transcription of the gene. There 
is very little known about the function of TTC14. To date there is only one study that eludes to the 




of plasma autoantibodies (AAb) in patients with lung cancer vs smokers/patients with benign 
pulmonary nodules (J. Wang et al., 2016). Their results showed that two panels of 5 autoantibodies 
each could be used to differentiate between patients with lung adenocarcinoma vs smoker control 
participants and patients with lung adenocarcinoma vs patients with benign pulmonary nodules. 
Interestingly, TTC14 and the well-known proto-oncogene BRAF were in both five-AAb panels. The 
paper also highlights the results from The Cancer Genome Atlas database on lung adenocarcinomas 
(LUAD), showing a significant increase in the protein expression of TTC14 in LUAD patients. However, 
there is no indication as to which isoform of TTC14 the study refers to. Future investigations into the 
specific function of each isoform could highlight the importance of Tra2 proteins in the regulation of 






Figure 28 Exon 11 of TTC14 is alternatively spliced upon Tra2 double knockdown. However, total expression of the long isoform is not substantially different as shown by max peak reads (red 





2.5.4 Histone methylation pattern changes are too minor to explain the severe structural 
changes in the nucleus of Tra2-knockdown cells 
The Gene Ontology enrichment analysis highlighted a panel of GO terms associated with 
chromosome biology. Furthermore, previous investigations into the effect of Tra2 double 
knockdown in MDA-MB-231 cells show abnormal nuclear morphology (Andrew Best et al., 2014), 
suggesting absence of Tra2 proteins leads to aberrant splicing of key proteins involved in nuclear 
conformation and chromatin packaging. However, our results indicate that the RNA splice changes 
incurred by the Tra2 double knockdown are not reflected at the protein level for some of the tested 
genes (CENPQ, MAPKAP1, SUV39H2 and ZCCHC11). While we cannot measure a direct influence on 
the protein isoforms of the genes in enriched GO terms it does not mean that these changes are not 
representative of Tra2-regulated splice patterns in the cells. Tra2 proteins are ubiquitously 
expressed but the level of expression, particularly of Tra2β, can differ depending on cell type and 
developmental stage (A. Best et al., 2013). Therefore, the detrimental effects that Tra2 double 
knockdown has on cell survival may not be a good representation of the long-term effects of minor 
splice changes induced by Tra2 overexpression in cancer cells.  
Furthermore, GO enrichment analysis relies on a well annotated and updated database. On several 
occasions during the course of this PhD we have analysed the same gene set and obtained different 
GO enrichment results, suggesting that GO enrichment analysis should not be used alone as a 
guiding tool to highlight important cellular pathways. As a concrete example, the GO term “cellular 
response to vitamins” was identified as a significantly enriched term although only five genes were 
highlighted in this pathway. This is of course due to the small number of genes annotated in the 
“cellular response to vitamins” GO term database (only seven). Nonetheless, this GO term does not 
represent a large enough group of genes (out of the 556) to confidently conclude that one of the 
main roles of Tra2 proteins is to regulate cellular response to vitamins. 
The analysis of Histone H3 methylation patterns in Tra2 double knockdown cells indicates changes in 
alternative splicing are having some effect on histone methylation. However, it is difficult to explain 
such changes in methylation if none of the tested genes involved in chromosome biology show 
altered protein expression. One possible explanation could be the interaction between chromatin 
readers and modifiers is affected by the alternative splice changes induced by the Tra2 knockdown 
(Torres & Fujimori, 2015). This suggests that the methyltransferases, such as SUV39H2, could have 
their function impaired if the protein domains required for protein-protein interaction is spliced out, 




after Tra2 double knockdown would potentially bring to light affected chromatin remodelling 






2.6 Chapter summary 
In this chapter, I have utilised a range of recently developed bioinformatics tools to identify a large 
number of alternatively spliced targets in MDA-MB-231 cells regulated by the homologous splicing 
regulators Tra2α and Tra2β. Tra2 proteins were found to regulate predominantly alternative 
cassette exons, but intriguingly also repress cassette exons and regulate intron retention. I validated 
a substantial number of alternative events, some of which did not contain Tra2β iCLIP binding tags, 
suggesting some of these genes could be regulated indirectly by Tra2 proteins. Gene Ontology 
enrichment analysis directed us to test the methylation patterns of Histone H3. Western 
immunoblotting of proteins encoded by candidate genes that were alternatively spliced did not 
show any significant changes, suggesting that other cellular pathways and target genes may be 





Chapter 3: Induction of specific splice isoforms in breast cancer cells 
3.1 Introduction 
In chapter 2, MISO and MAJIQ helped identify many alternatively spliced target genes regulated by 
Tra2 proteins in MDA-MB-231 cells. The expanded list of target genes reveals a more realistic picture 
of the true scale of influence of Tra2 proteins in alternative splicing. Gene Ontology enrichment 
analysis is often a useful tool to highlight biological and cellular pathways from a large pool of genes. 
However, the data from chapter 2 suggests that enriched pathways of genes alternatively spliced 
upon Tra2 double knockdown are not necessarily affected at the protein level. This means that we 
cannot confidently suggest that these genes are affecting the cells’ function and viability in the 72 
hours of Tra2 double knockdown. While the role of these alternative splice changes in the long term 
may be important, in the short-term other genes could be playing a more essential role in cell 
survival. In order to identify such essential target genes a different approach would have to be 
employed. Firstly, GO enrichment analysis of differential gene expression previously reported in Dr 
Best’s thesis can be used to indicate the effect of the Tra2 double depletion in gene expression and 
in turn highlight pathways activated as a consequence of alternative splicing. Secondly, investigating 
splice targets with the strongest dPSI changes that have a clear and detrimental effect on the 
predicted protein could be a better way of identifying essential target genes. Finally, Dr Best’s 
previous investigation into DNA damage suggests Tra2 double knockdown has a clear and marked 
effect on DNA damage accumulation. The key role of CHEK1 in DNA damage response has been 
reported previously (Chen & Sanchez, 2004; Patil, Pabla, & Dong, 2013) and the drastic decrease of 
CHK1 protein levels upon Tra2 double knockdown suggest that DNA damage is accumulating. 
Therefore, it is possible that DNA repair genes other than CHEK1 are also affected by the Tra2 
depletion, which could explain why CHEK1 overexpression alone did not rescue the cells in the 
previous experiments (Andrew Best et al., 2014).  
In this chapter we investigate the impact of individual splice changes in MDA-MB-231 cells caused by 
Tra2α and Tra2β protein depletion. The effects of alternative events that introduce a premature stop 
codon in the reading frame, such as in the case of CHEK1, can be easily tested by knocking down the 
expression of the gene. However, alternative events that affect protein sequence and therefore 
induce the expression of a different protein isoform may be difficult to investigate by siRNA 
experiments. In order to recapitulate the alternative splice changes that occur upon Tra2 double 
depletion for individual genes we employ the use of modified antisense oligonucleotides. Various 




(PMO) and 2’O methyl phosphorothioate (2’OMePS) have been previously used to induce exon 
skipping (Shimizu-Motohashi, Murakami, Kimura, Komaki, & Watanabe, 2018; van Putten, 
Tanganyika-de Winter, Bosgra, & Aartsma-Rus, 2019). Morpholino oligomers introduce a neutrally 
charged backbone and are often used in clinical trials due to their reduced reactivity and adverse 
side effects. However, negatively charged oligonucleotides such as phosphorothioate modified 
oligos are more readily taken up by the cells making them ideal for transfection in vitro (Pitout, 
Flynn, Wilton, & Fletcher, 2019). The last part of this chapter will focus on the potential of 2’OMePS 
antisense oligonucleotides (AO) as a method of inducing gene specific alternative splice changes 
(Figure 29). Experimental evidence shifted the focus of the investigation towards genes involved in 
DNA repair, a largely regulated cellular pathway by Tra2 proteins that was not immediately 
highlighted by the Gene Ontology enrichment analysis. Phosphorylation of Histone H2AX (known as 
γH2AX) is a primary cellular response to DNA double strand breaks (DSB) which helps direct DNA 
repair mechanisms at damage foci (Pilch et al., 2003). γH2AX is a well-established marker of DNA 
damage accumulation and as such was used as the primary test to interrogate the function of 
individual isoforms.  
 







3.2 Chapter aims and objectives 
The main objective of this chapter is to investigate the function of alternative isoforms regulated by 
Tra2 proteins in breast cancer cells. The specific aims are: 
To identify a cellular pathway regulated by Tra2 proteins that is indicative of their role in breast 
cancer cells 
To investigate the effect of alternative splicing on the structure and function of DNA repair genes 
regulated by Tra2 proteins 
To induce the expression of individual isoforms regulated by Tra2 proteins 






3.3 Materials and methods 
3.3.1 Cell culture 
MDA-MB-231 cells were maintained in DMEM (no phenol red) plus 10% fetal bovine serum and 1% 
Penicillin Streptomycin. Human embryonic kidney fibroblast (HEK293T) cells were maintained in 
DMEM with phenol red plus 10% fetal bovine serum and 1% Penicillin Streptomycin. Human bone 
osteosarcoma (Saos2) cells were maintained in RPMI media plus 10% fetal bovine serum and 1% 
Penicillin Streptomycin. All cell lines were incubated at 37°C with 5% CO2 and stored in 75cm2 and 
25cm2 (Saos2) tissue flasks. These cell lines were provided to me by Dr Andrew Best but were 
originally purchased from the American Type Culture Collection and LGC Standards, Europe. 
3.3.2 siRNA and 2’O Methyl Phosphorothioate transfections 
siRNA transfections were performed as described in chapter 2. Antisense oligonucleotides were 
designed to target the appropriate 3’ splice site sequence of the target exons of BRIP1, CHEK1 and 
XPA (listed in the table below). Scramble sequence derived from IDT own negative control siRNA 
sequence was used to design negative control antisense oligonucleotide with modified nucleotides. 
MDA-MB-231 cells were seeded on 6-well plates for 24 hours prior to transfection at a confluence of 
1x106 in 1.5mL DMEM. The transfection mixture was made similarly to that described for siRNA: 
300µl Opti-MEM, 9µl RNAiMAX (ThermoFisher) and 4µl of 100µM BRIP1 AO or 10µl of 100µl XPA or 
CHEK1 AO to reach final concentrations of 200nM and 500nM, respectively. The combined mixture 























3.3.3 Western immunoblotting 
Standard Western blotting was performed as described previously in chapter 2. Antibodies used in 




Antibody target Cat. number Dilution 
BRIP1 #4578 (Cell signalling) 1/1000 
MBD4 Abcam, ab12187 1/2000 
UIMC1 (RAP80) Bethyl Labs, A300-763A 1/2000 
XPA Proteintech, 16462-1-AP 1/2000 
RBMX Sigma-Aldrich, HPA057707 1/100 
GFP Clontech, 632381 1/4000 
FLAG Sigma-Aldrich, F3040 1/2000 
β-Actin Sigma-Aldrich, A5441 1/2000 
α-Tubulin Sigma-Aldrich, T5168 1/2000 
GFP Abcam, ab1218 1/2000 
H2AX Santa Cruz Biotech, sc54-606 1/500 
γH2AX Santa Cruz Biotech, sc517348 1/1000 
2° Fluorescent Antibody     
Anti-mouse Alexa594 Abcam, ab150120 1/200 
Anti-rabbit Alexa488  Abcam, ab150077 1/200 
 
3.3.4 Nuclear fractionation 
MDA-MB-231 cells harvested after 72 hours of transfection with anti-Tra2 siRNAs were fractionated 
to separate the nucleus from the cytoplasmic components. The cells were trypsinised and 
transferred into Eppendorf tubes. Following PBS washing, cells were re-suspended in 1ml 
cytoskeletal (CSK) buffer (composed of 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2 and 10 mM 
PIPES (pH 6.8)). The buffer was removed after centrifugation at 3000 RCF for 2minutes. Cells were 
then re-suspended in 50µl of CSK buffer and 2µl of 5% Triton X-100 and incubated in ice for 3 
minutes. Samples were then spun at 3000 RCF at 4°C for 2 minutes. The resulting supernatant 
containing the cytoplasmic proteins is transferred into a fresh Eppendorf containing 50µl of 2x 
Protein Loading buffer. The pellet that remains is washed with 50µl of CSK buffer three times before 
being suspended in 50µl of 2x Protein Loading buffer.  
3.3.5 Immunocytochemistry  
Cells were fixed onto coverslips in 24-well plates overnight before treatment with siRNA for 72 hours 
as described above. At the end of treatment cells were fixed with 4% Paraformaldehyde (PFA 
dissolved in Phosphate Buffered Saline) for 15 minutes at room temperature. The fixed cells were 
then permeabilised with 0.1% Triton X-100 in PBS and incubated at room temperature for 15 
minutes. Coverslips were then blocked with 10% horse serum in PBS for 15 minutes at room 
temperature. Primary antibody was diluted in blocking solution at 1:200 ratio and was then 
incubated with the cover-slips for 1hour. Coverslips were washed three times with PBS and then 




PBS while minimising light exposure. Coverslips were again washed three times with PBS and then 
were mounted onto slides using Vectashield Mounting Medium with DAPI (Vector Labs, H-1200) for 
nuclear detection. Images were collected using a ZEISS Axioplan2 fluorescent microscope with 
Axiovision software. 
3.3.6 MBD4 Plasmid Cloning for MBD4 
3.3.6.1 Cloning 
Transformation of ligated plasmids was done in α-Select Chemically Competent Cells (Bioline) using 
the manufacturer’s heat shock protocol. Ampicillin-resistant transformed cells were plated onto LB 
agar plates containing ampicillin and incubated at 37°C for 16 hours. Colonies were screened by PCR 
using primers respective to the vectors. All PCR reactions during the cloning steps are performed 
using the Phusion High-Fidelity DNA polymerase kit (Thermo Scientific). Following screening, 
plasmids were sent for sequencing at Source BioScience. Purified plasmid DNA samples were diluted 
to 100ng/μl and analysed using the splice junction primers for the MBD4 alternative event or the 
pXJRTF forward primer and pXJB1 reverse primers (10μM). Resulting sequences were manually 
mapped onto the genome (UCSC genome browser) and visually inspected.  
Phusion PCR reaction  
5X HF Reaction Buffer 2µl 
Template (insert, vector, 20ng/µl 0.5µl 
Forward Primer (10µM) 1µl 
Reverse Primer (10µM) 1µl 
dNTPs (10µM) 0.2µl 
dH2O 5.2µl 
Phusion DNA Polymerase 0.1µl 
TOTAL 10µl 
Thermocycler programme   
1 Heat Activation  95°C 5 min 
2 Denaturation 95°C 20 sec 
3 Annealing 58°C 30 sec 
4 Extension 72°C 60 sec (Cycle to step 2 x29) 
5 Final Extension 72°C 10 min 
6 Cooling 4°C ∞ 
 
3.3.6.2 GFP- and Flag-tagged MBD4 
Short (Sh) and full length (FL) MBD4 inserts were prepared using cDNA extracted from knockdown 
cells. PCR amplified products were separated by gel electrophoresis and subsequently extracted 




added EcoRI and XhoI restriction sites, whereas MBD4-FLAG inserts contained added NotI and XbaI 
flanking restriction sites. Utilising these restriction sites, the inserts were ligated with pGFP3 and 
p3xFLAG vectors (N-Terminal) using T4 DNA ligase (New England Biolabs) following manufacturer’s 
procedure.  
3.3.6.3 MBD4 Minigene 
Minigene inserts were designed to cover the genomic DNA region that encompasses exons 2 and 3 
of MBD4, parts of the flanking introns and intron 2 (chr3:129155088-129156987; hg19, UCSC 
genome browser). The inserts were synthesised by IDT UK as two g-block fragments (IDT UK) 
overlapping exons 2 and 3 of MBD4, and flanking intronic sequences that may potentially affect 
Tra2β binding (Figure 30). These fragments are then joined with the common downstream fragment 
to form the minigene inserts. The wt minigene insert was digested with EcoRI restriction enzyme. 
The empty pXJ41 vector was digested with MfeI restriction enzyme and the linearised vector was 
treated with Antarctic Phosphatase (New England Biolabs) following manufacturer’s procedure. The 
wt minigene insert and pXJ41 vector were ligated with T4 DNA ligase (NEB). 
 
Figure 30 G-block fragments designed to reconstitute the alternatively spliced site in exon 2 of MBD4 in a pXJ41 plasmid. 
3.3.6.4 Plasmid transfection – for immunocytochemistry 
HEK293T and Saos2 cells were used for MBD4-GFP and MBD4-FLAG transfection (Dr Best performed 
transfection of Saos2 cells with MBD4-FLAG). HEK293T cells were seeded onto 24-well plates with 
cover-slips and incubated for 24 hours at 37°C. Transfection mixes containing 500ng of plasmid, 
100µl of Opti-MEM and 3µl of GeneJammer (incubated at room temperature for 30-40 min) were 
prepared for each of the following plasmids: FL MBD4-GFP, Sh MBD4-GFP, empty pGFP3, FL MBD4-
FLAG, Sh MBD4-FLAG and empty p3xFLAG. Each mix was split into 4 wells. Cells were incubated for a 
further 24-hour following transfection after which they were fixed using 4% PFA.  
3.3.6.5 Plasmid transfection – for fractionation  
The experimental procedure is like plasmid transfection for immunocytochemistry with the 




biological replicates were prepared for each plasmid. Cells harvested were fractionated as described 
above. 
3.3.6.6 Minigene transfection 
HEK-293 cells were seeded into 6-well plates (no cover-slips) for 24 hours at 37°C. Three biological 
replicates in each case were prepared with 200ng of the MBD4 minigene and 500ng of Tra2β-GFP 
plasmid (or pGFP3 plasmid as control). The plasmids were mixed with 100µl of Opti-MEM and 3µl of 
GeneJammer and incubated at room temperature for 30-40 min. Following transfection cells were 
incubated for 24 hours and harvested for RNA extraction.  
3.3.6.7 One-step RT-PCR 
HEK-293 cells transfected with minigene plasmids were harvested and the RNA was extracted using 
standard Trizol RNA extraction (Life Technologies) following manufacturer’s instructions. Reverse 
transcription and PCR were done in a single reaction, using One-step RT-PCR kit (Qiagen). The 
reaction mix contained pXJRTF and pXJB1, which are primers targeting the two flanking primer sites 
in the pXJ41 vector, and an internal screening primer mapping on exon 3 of MBD4. The standard 5µl 
reaction is outlined below: 
One-step RT-PCR  
5x reaction buffer 1µl 
Q-solution 1µl 
pXJRTF primer (10µM) 0.3µl 
pXJB1 primer (10µM) 0.3µl 
Internal primer (10µM) 0.3µl 
dNTPs (10µM) 0.2µl 
Enzyme mix 0.2µl 
RNA (50ng/µl) 1.7µl 
TOTAL 5µl 
Thermocycler programme   
1 Reverse Transcription 50°C 30 min 
2 Initial PCR step 95°C 15 min 
3 Denaturation 94°C 30 sec 
4 Annealing 58°C 30 sec 
5 Extension 72°C 60 sec (Cycle to step 2 x29) 
6 Final Extension 72°C 10 min 
7 Cooling 4°C ∞ 
 
2.3.7 Microsatellite instability assay 
Microsatellite instability assay using the Promega MSI analysis kit was performed by Dr Ghanim 




Tra2α/β siRNAs for 72 hours as per protocol. Genomic DNA was extracted using standard Phenol-
chloroform extraction protocol and diluted to 1 ng/ul for the MSI test. Samples were run on a 3130 
Genetic Analyzer.  
3.3.4 WST-1 cell survivability assay 
To quantify the cytotoxicity of 2’OMePS antisense oligonucleotides targeting BRIP1, CHEK1 and XPA, 
a WST-1 colorimetric assay was used. Cells were seeded onto a 96-well plate for 24 hours prior to 
transfection at 4x103 cells/well. Transfection mixture volume was adjusted accordingly maintaining 
the same ratios as in section 3.3.2 of this chapter. Every 24 hours after transfection 10µl WST-1 was 
added to each well containing cells and: a) negative control AO, b) targeting AO, c) DMEM media and 
d) DMEM media only (no cells). The absorbance of each well was measured at 450nm wavelength 








3.4.1 Differential gene expression changes and enrichment of DAVID terms indicate a role 
of Tra2 proteins in the regulation of DNA damage response genes 
Differential gene expression analysis using DeSeq identified a large number of genes showing up- or 
down-regulation. The function of these genes was investigated using GO enrichment analysis (Figure 
31 - data from Dr Best’s thesis).  Because Tra2 proteins are mainly implicated in controlling splicing 
rather than regulation of transcription, the gene expression changes were attributed to secondary 
effects of the Tra2-double knockdown. However, looking at the results of GO enrichment analysis of 
the differentially expressed genes we identified a large subset of genes involved in two major 
cellular processes: Cell cycle regulation and DNA damage response/repair. These data suggest the 
effect of the knockdown on the cells elicits a DNA damage response and also interferes with the cell 
cycle. Such response may be a consequence of the splice changes in genes that are involved in DNA 
maintenance and repair. CHEK1 is one example of a DNA repair gene being directly regulated by 
Tra2-proteins that has a clear role in managing DNA damage accumulation. Therefore, we searched 
the new and expanded Tra2-dependent differentially spliced gene list for genes involved in DNA 
damage repair/response. Interestingly, the most recent GO enrichment analysis highlighted nearly 
10% (47/556) of the genes are involved in ‘Cellular response to DNA damage stimulus’, but after the 
Benjamini-Hochberg adjustment the term is no longer significantly enriched. This does not however 
change the fact that a relatively large number of alternatively spliced genes are involved in DNA 





Figure 31 Differentially expressed genes upon Tra2 double knockdown in MDA-MB-231 cells. Data from Dr. Best’s thesis 
3.4.2 Important components of different DNA repair pathways are alternatively spliced in 
Tra2α/β knockdown MDA-MB-231 cells 
DNA damage can occur at an increased rate in fast replicating cancer cells. Mutations that occur in 
non-cancer cells can give rise to oncogenes or alter the expression/function of tumour suppressors 
which can lead to the formation of cancer cells. However, in cells that are already cancerous that do 
not depend on extracellular signals for growth, further mutations can be detrimental to cell 
survivability. In response to DNA damage cells can activate several DNA repair pathways to prevent 
them undergoing cell cycle arrest or apoptosis. Tra2 proteins may therefore have a role in 
preventing cell cycle arrest or apoptosis by regulating alternative splicing. This idea was put forward 
by Dr Best upon discovering that Tra2 proteins are essential to maintain the correct splicing of 
CHEK1, an important checkpoint kinase that is involved in DNA repair and cell cycle checkpoint 
control. The use of MISO and MAJIQ has helped us identify a substantial number of additional 
alternatively spliced genes in the Tra2 depleted MDA-MB-231 cells involved in different DNA repair 
pathways (Figure 32). The splice changes affect genes involved in several pathways such as excision 
repair, mismatch repair and DNA single/double strand break repair. We hence investigated splice 
changes in some of the most important genes involved in these different repair pathways. In each 




measured and crucially the predicted outcome of the splice switch on the function and structure of 
the protein. 
 
Figure 32 A subset of the DNA damage repair genes that are alternatively spliced in the Tra2 double knockdown cells. 
Diagram produced by STRING database of protein-protein interactions 
3.4.2.1 Tra2 proteins control several genes in the DNA Strand Break Repair pathways 
DNA double and single strand breaks can occur due to a range of endogenous and exogenous 
factors. The Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR) pathways are 
mechanisms used by the cells to repair DNA strand breaks. The CHK1 protein is an important kinase 
that regulates cell cycle progression in response to DNA damage via the ATR-CHK1 pathway. This 
pathway is essential for the survival of many cell types (Smith, Tho, Xu, & Gillespie, 2010), however 
the role of CHK1 is mainly as an effector to DNA damage. Among the alternatively spliced targets 
regulated by Tra2 proteins in MDA-MB-231 cells are many other genes involved in the NHEJ and 
HDR, such as MTA1 and PARPBP (Figure 33). Initially identified through a screen of genes in 
metastatic cancer cells, MTA1 (Metastasis Associated 1) encodes a transcription factor that acts as a 
transcriptional corepressor and coactivator, but also plays a role in p53-dependent and -
independent DNA repair following genotoxic stress (D.-Q. Li et al., 2010). The alternatively spliced 
exon 4 in MTA1 is one of the few repressed exon cases in our dataset. In the Tra2 double knockdown 
cells exon 4 of MTA1 is included 21% more than in the control cells. The additional 51 nucleotides 
are predicted to include an extra 17 amino acids within the Bromo-Adjacent Homology (BAH) 
domain - a domain that is well conserved across different MTA genes and their isoforms (Sen, Gui, & 




important to notice that it affects the sequence of the BAH domain and can potentially affect the 
role of MTA1. 
PARP1 Binding Protein (PARPBP) gene encodes a protein required to suppress inappropriate 
homologous recombination. There are two alternatively spliced exons in PARPBP that refer to the 
same isoform switch. Exon 3 and exon 5 of PARPBP (NM_017915.4) are found to be skipped upon 
Tra2 double knockdown at -31% and -35% dPSI respectively. The resulting predicted transcript is 
anticipated to utilise a different start codon downstream within exon 7 that expresses a shorter 
protein of 294 amino acids. Interestingly, there are no predicted protein domains or motifs in either 
of the PARPBP protein isoforms, making it very difficult to predict the effect of the splice change on 
the function of the protein. 
 
Figure 33 Alternative events in MTA1 and PARPBP genes. MTA1 exon 4 (red box) is included at a higher percentage in 
Tra2α/β siRNA treated MDA-MB-231 cells as shown by the RNAseq data (UCSC browser) and RT-PCR validation. PARPBP 
shows a complex set of potential isoforms, one of which was validated by RT-PCR (Primers indicated by black arrows and 
capillary gel electrophoresis shown). dPSI calculation was based on data from three biological repeats. ** represents 
p<0.01, *** p<0.001.  Student’s t-test. 
3.4.2.1.1 Skipping of three consecutive exons in the UIMC1 gene leads to a shift in the reading 
frame 
One of the genes involved in DNA strand break repair and alternatively spliced upon Tra2 double 




encodes for the RAP80 protein which is required for the recognition and recruitment of BRCA1 to 
DNA damage sites (J. Wu et al., 2009). The RAP80 protein contains a C-terminal zinc finger domain 
and an N-terminal UIM (ubiquitin terminating motif), the latter being important for the DNA 
damage-induced focus formation. The MAJIQ analysis was able to detect three consecutive exons 
being skipped in the UIMC1 gene. The dPSI calculated by MAJIQ varies depending on the local 
splicing variation (LSV) used and ranges from -54% to -21%. We tested the alternative splice junction 
using primers on the flanking exons and measured an average dPSI change of -61% in the Tra2 
double knockdown MDA-MB-231 cells (Figure 35a). The alternatively spliced exons in this event 
include 968 coding nucleotides, which is not divisible by 3 and causes a shift in the reading frame. As 
a result, the alternative UIMC1 mRNA expressed in the Tra2 depleted cells contains a premature 
stop codon and is anticipated to be targeted by nonsense mediated decay.  
 
Figure 34 Alternative splicing of UIMC1. RNAseq data for UIMC1 shown on UCSC browser does not evidently indicate a 
splice event (red box), however MAJIQ predicts skipping of 3 consecutive exons from two ‘viewpoints’: first by looking at 
junction read changes downstream of exon “14” and by comparing exon junctions connected upstream of exon “9”. Note: 
“#” for exon numbers on MAJIQ/Voila are used as these are not necessarily the same as coding exons for the gene mRNA 




3.4.2.1.2 Tra2 protein depletion causes reduced expression of the full-length UIMC1 (RAP80) 
protein 
To test the effect of the alternative splice switch in the UIMC1 gene we investigated changes in the 
levels of RAP80 protein (Figure 35). Western immunoblotting was performed on protein samples 
from control and Tra2α/β siRNA treated MDA-MB-231 cells extracted after 72 hours. The antibody 
against RAP80 detected a band just above 100kDa which significantly drops in intensity in the 
knockdown samples (p-value 0.001, -61%). Absence of Tra2 proteins is clearly having a direct effect 
on the expression of RAP80 via alternative splicing. The result measured by Western blotting show 
that a strong switch in dPSI is important in order to detect a significant change at the protein level. In 
the case of UIMC1 the alternative splice change is clear and has a definitive effect on the stability of 
the mRNA isoform. 
 
Figure 35 Validation of UIMC1 splice switch and protein expression change. Alternative splicing verified by a) RT-PCR and 
an apparent reduction in protein expression by b) Western Immunoblotting. Data shown is representative of three 
biological repeats. Student’s t-test, **p<0.01 
3.4.2.2 Components of the Fanconi anaemia group involved in Interstrand Crosslink Repair are 
alternatively spliced upon Tra2 depletion 
Interstrand crosslinks (ICL) are by-products of endogenous metabolic reactions or exogenous 
chemotherapeutic reagents that result in the covalent bonding of DNA strands and obstruct DNA 
replication (Muniandy, Liu, Majumdar, Liu, & Seidman, 2010). ICLs are categorised as cytotoxic 
lesions and it is estimated that 20-40 unrepaired ICLs can kill a mammalian cell (Dronkert and 
Kanaar, 2001; McHugh et al., 2001; Lawley and Phillips, 1996). The Fanconi Anaemia (FA) proteins 




Interestingly, Tra2 protein knockdown causes a difference in the splicing of two FA genes: FANCG 
and BRIP1 (aka. FANCJ). The penultimate exon of FANCG is skipped in the Tra2 double knockdown 
cells with a dPSI of -23%. This leads to a frameshift in the shorter isoform of FANCG which causes a 
premature stop codon. However, since this stop codon would still be within the last exon of the gene 
it is unlikely that the mRNA will be degraded by NMD. The alternative event in BRIP1 is also a 
cassette exon (exon 5/20) not divisible by 3 (Figure 36). The frameshift causes a premature stop 
codon very early in the mRNA sequence. Interestingly, the Fanconi Anaemia proteins do not share 
sequence similarity, but instead are related by their assembly into a common nuclear complex. This 
is evident when investigating the protein domains of the two affected genes: FANCG has no known 
protein domains in its sequence whereas BRIP1 contains two important motifs, DEAD-2 and Helicase 
C-terminal domain. However, the importance of each component of the FA complexes cannot be 
underestimated since the repair of inter-strand crosslinks involves the recruitment of other 
pathways such as Nucleotide Excision Repair (NER) and Homologous Recombination (HR) 
(Andreassen & Ren, 2009). This means that genes such as FANCG with no enzymatic motifs can be 
crucial for interaction with other proteins from different repair pathways. 
 
Figure 36 Alternative splicing of BRIP1 (aka. FANCJ). UCSC browser view of the RNAseq data showing reduction in the reads 
covering exon 5 of BRIP1 associated with Tra2β iCLIP tags. Exon 5 is a constitutive exon and when spliced out causes a shift 
in the ORF 
3.4.2.2.1 Tra2α/β knockdown strongly influences the splicing of BRIP1 and reduces protein 
expression 
Although the alternative event in BRIP1 changes splicing with high amplitude after Tra2α/β 
depletion, it was only MAJIQ that was able to identify this splice change. The dPSI change measured 
by MAJIQ was -43% but the RT-PCR results show a stronger splice switch of -65%. This is possibly due 
to a different knockdown efficiency and amplicon bias, or may be a difference between in silico 
prediction and experimental confirmation. A large number of iCLIP tags mapped to the target 




double knockdown and the predicted mRNA degradation of the shorter isoform we tested the levels 
of BRIP1 protein. Western immunoblotting showed that there was a decrease in the expression of 
the full length BRIP1 protein in MDA-MB-231 cells treated with Tra2α/β siRNA compared to cells 
treated with control siRNAs (Figure 37).  
 
Figure 37 Regulation of BRIP1 gene at RNA and protein level. a) Capillary gel electrophoresis of the splice junction 
surrounding exon 5 of BRIP1. b) Western immunoblotting of the BRIP1 protein in MDA-MB-231 cells treated with control 
and Tra2α/β siRNA. Statistical significance measured across three biological replicates using Student’s t-test. **, p<0.01 
3.4.2.3 MSH2 and POLD3 are genes involved in the DNA Mismatch Repair pathway that are 
alternatively spliced upon Tra2 double knockdown 
The Mismatch Repair (MMR) pathway is a post-transcriptional repair mechanism that recognises 
mismatched nucleotides in the newly formed DNA double strand and differentiates between the 
parental and daughter strand in order to excise and replace misincorporation errors. At least two 
important genes involved in MMR were identified as alternatively spliced targets of Tra2 proteins: 
MSH2 and POLD3.  
DNA Polymerase Delta 3 (POLD3) codes for a key component of the trimeric DNA polymerase delta 
complex involved predominantly in lagging strand synthesis and repair. Pol-delta3 interacts with 
PCNA and RFC1-replication factor C complex in order to recruit POLD1, the catalytic subunit of DNA 
polymerase delta complex, to the DNA damage sites and carry out nucleotide base excision (Ogi et 
al., 2010). The alternative event that occurs in the Tra2 knockdown cells implicates the use of an 
alternate last exon of POLD3 with a dPSI of -20%, which was confirmed by RT-PCR. The new shorter 
isoform has a considerably shorter 3’UTR and the amino acid sequence clearly affects the CDC27 




MSH2 is a primary member of the MutSα (MSH2/MSH6) and MutSβ (MSH2/MSH3) complexes that 
recognise mismatched nucleotides in the DNA double strand. The alternative event in MSH2 is one 
of the 25 cases of intron retention identified by MAJIQ (Figure 38). Several Tra2β iCLIP tags 
associated with the final exon of MSH2, suggesting binding of Tra2β is required for the definition of 
the 3’ splice site of the last exon. In the absence of Tra2 proteins the intron is potentially not well 
defined leading to intron retention in this case. RT-PCR using primers binding on the flanking exons 
and an internal primer targeting the intron confirm the RNAseq analysis results. The intron 
introduces a ‘premature’ stop codon into the mRNA, but since there are no other exon-exon 
junctions downstream it is unlikely that this mRNA isoform will be targeted by nonsense mediated 
decay (Nagy & Maquat, 1998; J. Zhang et al., 1998). The alternative isoform is likely to express a 
protein isoform with few different amino acids in the C-terminal of the protein that are not 
predicted to affect any of the protein domains on Pfam.  
 
Figure 38 Alternative splicing of MSH2. The last intron of MSH2 is retained in the Tra2α/β kd cells as indicated by the 
RNAseq and validated by RT-PCR. CGE image representative of three biological replicates. Student’s t-test, *p<0.05 
3.4.2.3.1 Tra2 depleted cells do not show sign of microsatellite instability 
Defects in the mismatch repair activity of the cell are known to cause microsatellite instability, a 
phenomena affecting more than 15% of colorectal cancers (Boland & Goel, 2010). Considering the 
key importance of MSH2 and POLD3 in MMR we predicted that the Tra2 double knockdown may 
have an effect in microsatellite instability. We assayed the microsatellite instability of MDA-MB-231 
cells treated with control and Tra2α/β siRNAs for 72 hours. Extracted genomic DNA was tested using 
the Promega MSI analysis kit which assesses the length of 5 mononucleotide repeats 
(microsatellites) commonly affected in breast cancer tissues. The analysis was performed by Dr 
Ghanim Alhilal (Newcastle University). The electrophoretically separated PCR products did not show 




in MMR genes induced by the Tra2 knockdown are not inducing microsatellite instability, at least not 
in the timeframe of the experiment (Figure 39). 
 
Figure 39 Microsatellite instability assay. Genomic DNA from control (bottom) and Tra2 double knockdown (top) was 
tested for microsatellite instability, however no change was visible as indicated by the presence of only one peak at 150 bp. 
Assay detects variations in the length of five mononucleotide repeats: NR-21, BAT26, BAT25, NR-24 and MONO27. 
3.4.2.4 Tra2 proteins regulate alternative splicing of crucial Base Excision Repair genes 
In our gene list we also identified two important genes involved in base excision repair (BER): MBD4 
(Methyl-CpG Binding Domain 4) and TDG (Thymine DNA Glycosylase). Interestingly, these genes are 
known to interact with each other and compensate for each other’s role to some extent in the repair 
of mismatched DNA (Sjolund, Senejani, & Sweasy, 2013). The Methyl Binding Domain 4 (MBD4) gene 
which was identified by MISO and MAJIQ, but not by the DexSeq analysis, shows a very strong 
change in PSI upon Tra2 depletion (dPSI, -74%) (Figure 40). The MBD4 gene encodes a methyl-CpG 
binding protein that has glycosylase activity. The commonly expressed isoform of MBD4 encodes a 
66kDa protein that is known to specifically recognise G:T mismatches in DNA and is able to remove 
the mismatched thymine via BER. The RNAseq data clearly shows a dramatic change in the splicing 
of MBD4 that involves the use of an alternative 5’ splice site within exon 2. The alternative 5’ splice 
site use in exon 2 correlates with skipping of the downstream exon 3, producing an mRNA isoform 




splice event does not create a frameshift. The shorter mRNA isoform has been previously identified 
by Owen et al. 2007 in HeLa cells and is predicted to produce a 30kDa protein (Owen, Baker, Bader, 
Dunlop, & Nicholl, 2007). The Pfam protein domain prediction online tool clearly indicates that the 
shorter protein isoform of MBD4 does not contain the crucial Methyl-CpG binding domain to 
recognise the DNA. Importantly, the shorter isoform also is missing the ‘intervening region’, the 
amino acid sequence following the MBD motif. The intervening region was shown to be necessary 
for the interaction of MBD4 and UHRF1 complex and the subsequent localisation to chromocenters 
in heterochromatin replication and formation.  
Upon Tra2 double knockdown exon 2 or exon 2 and 3 together of TDG are spliced out at -29% and -
27% dPSI, respectively. The alternative mRNA isoform in both cases is predicted to utilise a 
methionine start codon in exon 4 and anticipated to express a protein 143 amino acids shorter than 
the control expressed protein. Although the splice switch substantially reduces the size of the 
protein, the UDG (Uracil DNA glycosylase) motif is predicted to remain intact.  
 
 
Figure 40 Alternative 5' splice site of exon 2 in MBD4 causes skipping of exon 3 also. UCSC browser view of RNAseq 
indicating alternative splice site selection (arrow) and subsequent skipping of exon 3. Pfam domain track (bottom of image) 
indicates the MBD-domain is encoded by the spliced sequence. This sequence is also highly conserved across species – 
green track of conservation across 100 vertebrates. 
3.4.2.4.1 MBD4 expresses a shorter protein isoform that is exclusively localised in the 
cytoplasm 
To assess if the alternative splice change induced by the Tra2 double knockdown is affecting the 
MBD4 protein we analysed the control vs Tra2α/β siRNA treated samples using Western blotting 




the shorter isoform expressed in the knockdown samples but not in the control. Interestingly, the 
intensity of the band corresponding to the full-length isoform does not appear to be reduced upon 
Tra2 knockdown. Considering the role of MBD4 in DNA binding and repair we tested the localisation 
of the two protein isoforms. We then used nuclear fractionation on control and Tra2 double 
knockdown MDA-MB-231 cells. Western immunoblotting of the separated nuclear and cytoplasmic 
compartments shows exclusive expression of the full-length isoform in the nucleus and exclusive 
expression of the short isoform in the cytoplasm, suggesting the shorter isoform of MBD4 has lost 
the nuclear localisation signalling motif (Figure 42). We then attempted to visualise the localisation 
of the endogenous short and full-length protein isoforms of MBD4 using immunofluorescence 
microscopy. MDA-MB-231 cells were seeded onto coverslips and treated with control and Tra2α/β 
siRNA for 72 hours. However, the antibody appeared to stain all the cells uniformly and we were 
unable to see any differences in the Tra2 double knockdown cells. 
 
Figure 41 MBD4 alternative splicing is validated by a) capillary gel electrophoresis and the short protein isoform detected 
by b) Western Immunoblotting. CGE image representative of three biological replicates. Student’s t-test, **p<0.01 
 
Figure 42 Nuclear fractionation experiment. Separated nuclear extract and cytoplasmic extracts show distinct expression of 




3.4.2.4.2 GFP- and Flag-tagged MBD4 short protein isoforms show predominantly cytoplasmic 
localisation 
Although nuclear fractionation shows the two protein isoforms are clearly localised into different 
compartments, it is possible that the short MBD4 isoform is simply ‘leaking’ into the cytoplasm 
during the nuclear fractionation experiment. To validate the cytoplasmic localisation results 
obtained above we constructed a set of DNA plasmids to overexpress the short and full length MBD4 
isoform with associated GFP and Flag tags. The GFP tagged plasmids were transfected into HEK293T 
cells, whereas the Flag tagged plasmids were transfected into HEK293T and Saos2 cells seeded onto 
coverslips. Immunocytochemistry clearly demonstrate that the Flag-tagged short isoform is localised 
in the cytoplasm and the full-length isoform of MBD4 is localised predominantly in the nucleus 
(Figure 43). The exclusive localisation was clearly visible in the transfected Saos2 cells as well (Figure 
44). The GFP-tagged isoforms show a similar pattern but there is some overspill from the 
fluorescence indicating the GFP tag may be affecting the localisation of the protein, or the plasmid is 
expressed at a high rate.  
 
Figure 43 Fluorescence immunocytochemistry in HEK293T cells. Flag-tagged and GFP-tagged MBD4 expression plasmids 
transfected into HEK293T cells show the different localisation pattern for the short and full-length isoforms. DAPI is a blue 
fluorescent DNA stain used to highlight the nucleus. Here, the hollowed appearance of cells expressing the short MBD4 





Figure 44 FLAG-MBD4 plasmid expression in Saos2 cells. Immunocytochemistry of Saos2 cells shows a clear differentiation 
in the localisation of the two MBD4 isoforms. This is highlighted by the abundantly bright overlay of the DAPI stain 
(nucleus) in the short MBD4 plasmid, but not in the full-length plasmid. Merged image. Scale bars: 25µm 
To try to replicate the results by Western immunoblotting the DNA plasmids were transfected into 
HEK293T cells seeded onto 6-well plates. After 72 hours cells were harvested, and the nuclear and 
cytoplasmic compartments were separated using nuclear fractionation. Western blots of the Flag 
tagged short isoform of MBD4 demonstrated exclusive cytoplasmic localisation (Figure 45). 
However, both GFP- and Flag-tagged full-length plasmids demonstrate expression in the nucleus and 
in the cytoplasm, indicating that the added peptide sequences may have some effect on the 
localisation of MBD4. 
 
Figure 45 Nuclear fractionation of HEK293T cells transfected with a) Flag- and b) GFP-tagged MBD4. 
3.4.2.4.3 Analysis of MBD4 splicing control in vitro using a minigene 
The mechanism of alternative splicing of MBD4 is likely to be dependent on Tra2 proteins binding 




designed minigene plasmids using the pXJ41 vector which harbours a human CMV promoter 
allowing the expression of the minigene in human cell lines. The MBD4 insert was cloned into the 
vector within intron 2 of the rabbit β-globin gene flanked by constitutive exons. The introduction of 
the MBD4 exons between these two constitutive exons was designed to test the strength of the 
splice sites and their response to Tra2β. This minigene construct was transfected into HEK293T cells 
alongside expression vectors encoding either Tra2β-GFP or GFP alone. Cells were harvested for RNA 
purification after 24 hours.  One-Step RT-PCR analysis detected two amplification products from the 
HEK293T cells co-transfected with the GFP-only plasmid and the minigene. The shorter PCR 
amplification product (representing the short MBD4 isoform) is not detected in the Tra2β-GFP 
plasmid transfected cells (Figure 46). 
 
Figure 46 MBD4 minigene plasmid A and B in HEK293T cells. The introduction of the Tra2β overexpressing plasmid 
eliminates the expression of the shorter isoform (blue arrow) as detected by capillary electrophoresis.  
3.4.2.5 Tra2 proteins regulate the splicing of XPA and other Nucleotide Excision Repair genes 
Nucleotide Excision Repair (NER) is one of the most important DNA repair pathways that targets 
non-specific DNA lesions induced by UV light, environmental mutagens or chemotherapeutic drugs 
(Schärer, 2013). Deficiencies in NER are linked to xeroderma pigmentosum which predisposes 
sufferers to developing UV-induced skin cancer in their lifetime (Dworaczek & Xiao, 2007). In our 
panel of genes alternatively spliced upon Tra2 depletion there are at least three genes known to be 
involved in the NER pathway: CHD1L, HMGN1 and XPA. The alternative cassette exon in CHD1L is 
skipped 27% more in the Tra2 double knockdown cells compared to control siRNA depletion. The 
presence of a few Tra2β iCLIP tags on the target exon are consistent with regulation by Tra2 
proteins. The alternative shorter isoform of CHD1L is predicted to express a protein 28 amino acids 
shorter than the control isoform, and the Pfam database suggests that this shorter isoform disrupts 




HMGN1 includes a switch in the splicing of two mutually exclusive exons at -41% dPSI (Figure 47). 
However, both exons are only included in less than 5% of the total transcripts of the HMGN1 gene 
making it difficult to suggest a role for these isoforms.  
 
Figure 47 Alternative splicing of two cassette exons of HMGN1. UCSC genome browser view of RNAseq shows the isoforms 
including the two cassette exons are expressed far less than the main isoform of the gene (red arrows highlighting the 
different RNAseq depth coverage of the region viewed) 
An interesting target gene that changes splicing upon Tra2 double knockdown is the Xeroderma 
Pigementosa group A (XPA) gene. The XPA gene codes for an essential component of the NER 
pathway that is required for the recognition of DNA damage lesions and nucleotide excision. MDA-
MB-231 cells treated with siRNA against Tra2α/β express a short isoform of XPA that excludes three 
consecutive and constitutive exons of the gene (dPSI, -63%) (Figure 48). Interestingly, skipping of all 
three exons does not affect the reading frame of XPA, and a shorter protein isoform of 143 amino 
acids (273aa full length) is anticipated to be expressed. The Pfam domain prediction tool shows that 
the shorter isoform is missing both domains in the gene: the XPA_N and XPA_C domain. Moreover, 
previous reports have shown that the region between amino acid 74-114 is essential for the 
interaction of XPA and ERCC1, important for the nucleotide excision step (L. Li, Peterson, Lu, & 
Legerski, 1995), and the short isoform is missing a significant part of this sequence. This suggests 





Figure 48 Capillary gel electrophoresis of XPA, showing all three exons are simultaneously skipped in the Tra2α/β 
knockdown cells. CGE image representative of three biological replicates. Student’s t-test, **p<0.01 
3.4.2.5.1 Tra2 double knockdown cells express the short protein isoform of XPA 
The alternative switch in the XPA gene is a complex event and was only identified by MAJIQ. To 
validate the splice change observed in the RNAseq data we designed PCR primers to amplify 
between exon 2 and 6 of the XPA mRNA. RT-PCR from Tra2 double knockdown mRNA samples 
detected the expression of the shorter isoform at the expected size, while the control samples only 
express the full-length isoform. Considering that skipping these exons is not predicted to cause a 
frameshift in the XPA mRNA, we tested the XPA protein expression using a polyclonal antibody 
raised against the full length XPA protein. As predicted, the Tra2 double knockdown cells expressed 
the 16kDa short isoform of XPA but the control treated cells did not (Figure 49). Interestingly, the 
intensity of the band corresponding to the full-length isoform of XPA does not go down upon 
Tra2α/β knockdown.  
 
Figure 49 Western immunoblotting of XPA. Short isoform appears only in the TRA2 double knockdown cells. Quantification 
of the upper band detected by the anti-XPA antibody shows no significant reduction(p=0.08) relative to α-Tubulin. 




3.4.2.5.2 The endogenous short isoform of XPA is exclusively localised in the cytoplasm 
Like the alternative event in the MBD4 gene we were able to detect a shorter protein isoform of XPA 
in the Tra2 double knockdown cells, which prompted us to test the localisation of this isoform. 
Nuclear fractionation of MDA-MB-231 cell extracts (2x control vs Tra2 double knockdown) were used 
for western immunoblotting. The shorter protein isoform of XPA was detected only in the 
cytoplasmic compartment of the knockdown samples. Interestingly, the full length isoform of XPA 
was detected in the nuclear and cytoplasmic compartment of both the control and knockdown 
samples (Figure 50). The loading controls (tubulin and the nuclear H2AX) clearly show the separation 
of the compartments was adequate, indicating full length XPA is predominantly localised in the 
cytoplasm. 
 
Figure 50 Nuclear fractionation of MDA-MB-231 cells. Short protein isoform of XPA is exclusively detected in the 
cytoplasmic extract by western immunoblotting. 
3.4.3 Using modified oligonucleotides to induce Tra2-specific splice changes 
3.4.3.1 Antisense oligonucleotides targeting the alternative events in BRIP1, CHEK1 and XPA induce 
the same splice changes as those observed in the Tra2 knockdown 
Knocking down both Tra2 proteins in the MDA-MB-231 cells influences the splicing of many genes 
involved in a range of cellular processes. The impact of the Tra2 double knockdown on the cell 
viability, DNA damage and nuclear structure is detrimental (Best, 2014). However, it is difficult to 
associate a specific splice change with the global effects of the Tra2 knockdown on the cell since 
these splice changes are occurring all at the same time. Therefore, we tried to induce specific splice 
changes observed in the Tra2 knockdown cells individually by introducing antisense oligonucleotides 
(AO) to the cells. 2’O Methyl Phosphorothioate (2’OMePS) AOs are a commonly used form of 




influence the splice pattern of a certain gene (Yoo, Bochkareva, Bochkarev, Mou, & Gray, 2004). 
Therefore, we designed 2’OMePS AOs against some of the Tra2 responding targets from our panel of 
DNA repair genes. To select the best candidate genes, we considered the strength of dPSI, evidence 
of an effect on the protein and importantly the complexity of the splice change. Using these 
parameters, we designed AO targeting exon 5 of BRIP1, exon 3 of CHEK1, and exon 5 of XPA, at the 
5’ end of the exon in each case. MDA-MB-231 cells were transfected with a control AO and the gene 
specific AOs and were incubated for 72 hours. The splicing profile changes were measured using the 
same primer sets that were previously used to validate the endogenous splice changes upon Tra2 
double knockdown. RT-PCR and capillary gel electrophoresis shows strong target exon skipping in 
the case of BRIP1 and CHEK1. To our surprise, the AO against exon 5 of XPA induced skipping of all 
three exons (exon 3, 4 and 5) simultaneously, albeit at a much lower dPSI than the other two genes 
(Figure 51). This suggests that exon 5 inclusion/definition may be essential for the inclusion of the 
other two exons. 
 
Figure 51 Capillary electrophoresis of 2'OMePS treated MDA-MB-231 cells after 72 hours. CGE image show two biological 
replicates. Student’s t-test performed for all three experiments showed p<0.05 
3.4.3.2 2’OMePS AOs affect the CHEK1 and XPA proteins but not BRIP1 
The results from 2’OMePS treated cells were promising at recapitulating the splice changes occurring 
in the Tra2 double knockdown cells. To test if the splice changes induced by 2’OMePS AOs affect the 
proteins of these genes we treated the MDA-MB-231 cells over the course of 72 hours and 
harvested the protein extracts. Western immunoblotting of the CHK1 protein shows a significant 
decrease in expression after 72 hours (p-value 0.02) in MDA-MB-231 cells treated with the 2’OMePS 
against exon 3 of CHEK1 (Figure 52). Although the AOs against exon 5 of BRIP1 can successfully 
induce a splice change at the mRNA, Western blotting of the protein could not conclusively 
determine a change in the protein level. Finally, we assayed the protein expression of XPA. Western 
blotting was able to detect the previously identified shorter protein isoform of XPA confirming that 






Figure 52 Western immunoblotting of 2'OMePS treated MDA-MB-231 cells. Figure shows antisense oligos targeting CHEK1 
and XPA successfully induce changes at the protein level. The western blot of BRIP1 proved to be difficult to conduct due to 
the abnormally large size of the target protein, but also the non-specific binding of the antibody. Bottom, right corner 
shows quantification of the visible bands relative to tubulin expression (quantified using ImageJ). * Represents p<0.05. 
3.4.3.3 WST-1 cell viability assay of 2’OMePS treated cells 
Tra2 double knockdown has a detrimental effect on the survivability of the cells. Therefore, we 
tested the effect of the individual 2’OMePS antisense oligos on the viability of the transfected cells. 
Cells were seeded onto 96 well plates for 24 hours and then treated with control AO or one of the 
gene specific AOs (BRIP1, CHEK1 or XPA) initially and then again (half the dose) after 72 hours. The 
WST-1 based colorimetric assay was used to measure the cell confluency every 24 hours after the 
initial transfection with AOs. The results show the cells treated with CHEK1 and BRIP1 AOs are more 
viable than those treated with the control and XPA AOs. After day 4 cells treated with the antisense 





Figure 53 WST1 assay used to assess the viability of the cells after transfection with 2'OMePS. An increase in absorption at 
550nm wavelength indicates cell proliferation. Bars represent Standard error, calculated based on three biological 
replicates at each time point.  
3.4.3.4 Phosphorylated Histone H2AX levels increase in the cells treated with 2’OMePS against exon 5 
of XPA 
Phosphorylated histone H2AX (γH2AX) is a well-established marker of DNA damage and was shown 
to accumulate in Tra2 double knockdown cells (Best, 2014). The critical role of BRIP1, CHK1 and XPA 
in DNA repair lead us to investigate the accumulation of γH2AX in cells treated with 2’OMePS AOs. 
We considered that the accumulation of γH2AX would require more time therefore we treated the 
MDA-MB-231 cells over a course of 5 days with 2’OMePS AOs (control and gene specific). Western 
immunoblotting of protein extracted from the 2’OMePS treated cells using an antibody against 
γH2AX detects a significant increase in the total accumulation of phosphorylated Histone H2AX for 
BRIP1 and XPA targeting AOs, indicating the induced expression of the shorter mRNA isoforms of 










 3.5 Discussion 
3.5.1 Tra2 proteins regulate the alternative splicing of DNA repair genes important to 
cancer cell survival  
In chapter 2 we attempted to validate protein isoform changes of genes from enriched GO terms 
connected with chromatin, but western immunoblotting did not identify a significant change for any 
of the proteins tested. In order to infer a role for the transcriptomic changes identified by the 
bioinformatics pipelines, protein changes must be detected in the MDA-MB-231 cells by following 72 
hours of siRNA transfection. The gene ontology results from the differential gene expression changes 
are an indicator of the necessity of the cells to adapt to the Tra2 double knockdown.  The 
enrichment of ‘DNA repair’ and ‘Response to radiation’ GO terms for differentially expressed genes 
directed our attention to alternative splice changes in genes involved in DNA damage repair. 47 
components of the DNA damage repair pathway were identified as potential targets of Tra2 
proteins, showing strong dPSI changes that in most cases directly affect the ORF (including the 
CHEK1 gene) and sometimes protein domains. Interestingly, components of different DNA repair 
pathways are differentially spliced upon Tra2 double knockdown, suggesting potential compensatory 
roles of these pathways may be prevented in the case of Tra2 double knockdown (Figure 55). The 
implication of Tra2 proteins in regulating DNA repair genes in breast cancer cells indicates a 
potential role of Tra2 proteins in cancer progression. While the double Tra2 knockdown experiment 
has a detrimental effect on the breast cancer cell survivability, the overexpression of Tra2 proteins 
reported in various cancer types (Fischer et al., 2004b; Watermann et al., 2006) would suggest the 
two homologs act to protect the cells from further DNA damage accumulation in vivo, allowing them 









3.5.2 Tra2 proteins regulate the expression of protein isoforms of DNA repair genes 
Among the 47 alternatively spliced genes of the DNA damage repair pathways we investigated 
protein expression in four genes (BRIP1, MBD4, UIMC1 and XPA) and detected changes in protein 
isoforms in all of them. Together with changes in the protein level of CHEK1, previously reported by 
our lab (Andrew Best et al., 2014), our data suggests that Tra2 proteins indeed regulate the protein 
expression of genes involved in DNA repair via splicing control. GO enrichment analysis of 
alternatively spliced genes did not highlight ‘DNA repair/damage response’ as an enriched term, 
suggesting such analyses must be used in conjunction with other methods to identify regulated 
pathways. Importantly, the tested genes were carefully selected based on strong dPSI changes and 
predicted effect on the protein structure or translation, factors that must be considered when 
investigating protein expression.  
3.5.2.1 Protein expression of BRIP1 and its implication in cancer biology 
Alternative splicing of BRIP1 exon 5 in Tra2 double knockdown cells results in the expression of an 
mRNA isoform predicted to contain a premature stop codon and likely to be targeted by NMD. The 
strong dPSI change and abundant cluster of Tra2β iCLIP tags indicate a direct role of Tra2 proteins 
regulating expression of this gene via alternative splicing. Several population and case studies 
suggest pathogenic germline variants in BRIP1 are associated with increased susceptibility of breast 
cancer (Couch et al., 2015; Kuusisto, Bebel, Vihinen, Schleutker, & Sallinen, 2011) and triple negative 
breast cancer (Buys et al., 2017). However, a meta-analysis of 41 studies and over 90 000 patients 
specifically concludes that truncating mutations in BRIP1 are not associated with a substantial 
increase in breast cancer risk (Easton et al., 2016), suggesting only deleterious mutations - on par 
with the alternative splicing of exon 5 - may contribute to the risk factor. Previous reports indicate 
BRIP1 overexpression in breast cancer, including triple negative breast cancer, is associated with 
poor survival rate (Gupta et al., 2018). Furthermore, BRIP1 is shown to be overexpressed in MDA-
MB-231 and MCF7 cells compared to benign breast tissue, but is downregulated in HeLa cells 
compared to cervical tissue (Gupta et al., 2018; Zou et al., 2016). In vitro studies in HeLa cells 
followed by in vivo mouse xenograft experiments show induced overexpression of BRIP1 enhances 
the antitumour activity of cisplatin by inhibiting Rac1 GTPase activity (Y. Liu et al., 2016).This falls in 
line with the principle mechanism of action of cisplatin whereby DNA repair pathways unable to 
cope with the increased DNA damage causes cell cycle arrest and apoptosis, suggesting patients with 
overexpressed BRIP1 would show better response to cisplatin treatment. Our data suggests Tra2 
proteins promote the inclusion of BRIP1 exon 5 in MDA-MB-231 cells and  targeting BRIP1 exon 5 




protein expression affected by the knockdown of Tra2α/β and by the AO targeting BRIP1 exon 5 is 
necessary to conclude this isoform switch directly interferes with DNA damage repair or affects the 
cells’ susceptibility to antitumour drugs such as cisplatin, a hypothesis worth testing in the future. 
3.5.2.2 A cytoplasmic location of the short MBD4 isoform suggests loss of the nuclear localisation 
motif 
The alternative event of MBD4 revolves around the expression of a previously identified alternative 
isoform that expresses a truncated MBD4 protein maintaining its uracil DNA glycosylase activity 
(Owen et al., 2007). The selection of an alternative 5’ splice site within exon 2 of MBD4 consequently 
causes the skipping of exon 3 in Tra2 double knockdown cells. Expression of the shorter protein 
isoform was confirmed by Western blotting. Immunocytochemistry and nuclear fractionation 
showed the short MBD4 isoform is exclusively localised in the cytoplasm. Previous reports have 
identified at least four putative nuclear localisation signals located within or near the Methyl-CpG 
Binding Domain (abbreviated MBD) (Bellacosa et al., 1999; Owen et al., 2007), indicating the short 
MBD4 protein isoform expressed in Tra2 double knockdown cells lacks these localisation signals and 
is therefore unable to enter the nucleus post-translation. Furthermore, reports from colorectal 
cancer cells show nuclear localisation of a truncated MBD4 protein that is missing the C-terminal 
glycosylase domain but retains the nuclear localisation signals near the MBD (Suzuki et al., 2016). 
MBD4 was originally identified and classified due to the presence of the “Methyl-CpG Binding 
Domain”, which is conserved across all four members of the MBD family and MeCP2 (Brian Hendrich 
& Bird, 1998). This suggests a role for MBD4 in transcription repression by binding to methylated 
CpG islands in promoter regions. Several studies have indeed identified transcriptional regulation of 
genes such as CDKN1A, CDKN2A, MLH1 and MSH4 through binding of MBD4 to their methylated 
promoters (Kondo, Gu, Horii, & Fukushige, 2005; Laget et al., 2014). However, it is worth noting that 
these reports aim to reinforce the idea that all MBD family members are solely involved in gene 
transcription while disregarding substantial evidence that MBD4 plays a key role in DNA mismatch 
repair (Cortellino et al., 2003; B. Hendrich, Hardeland, Ng, Jiricny, & Bird, 1999; Millar et al., 2002; 
Petronzelli et al., 2000). While it is likely that MBD4 has a role in transcription control, there is strong 
evidence to suggest the methyl-CpG binding domain is important to guide the activity of the 
glycosylase. A study investigating the affinity of MBD4 to mismatched DNA substrate identified 
increased affinity for methylated m5CpG-TpG and suggested that truncated MBD4 lacking the MBD, 
retains the glycosylase activity in vitro but loses the m5CpG-TpG specificity (B. Hendrich et al., 1999). 
The study further suggests the function of MBD4 is to counteract the mutability of m5C due to 




through base excision (Figure 56). An accurate distinction of the role of MBD4 is important to 
understand the significance of our finding of the alternative splice switch in breast cancer cells. The 
shorter isoform expressed in the Tra2 double knockdown cells lacks the MBD and therefore is likely 
to have reduced affinity for methylated CpG-TpG mismatches. In addition, the cytoplasmic 
localisation of the short MBD4 isoform suggests it will be unable to interact with nuclear DNA. 
Therefore, it is difficult to assign a role to this isoform whether that is as a transcription regulator or 
as base excision repair protein since both require direct interaction with DNA.  
The MBD4 minigene assay used in this chapter showed a decrease in the short isoform of MBD4 
expressed in HEK293T cells overexpressing Tra2β, providing further evidence of regulation of the 
splice event by Tra2 proteins. However, in order to conclusively determine direct binding and 
regulation by Tra2 proteins, in vitro examination of minigenes designed by site directed mutagenesis 
to specifically target and interrogate the regulatory sequence elements within exon 2 of MBD4 could 
be used in future experiments. 
 
Figure 56 Proposed mechanism of action for MBD4 in repairing G-T mismatches due to deamination. Image adapted from 
Hendrich et al. 1999  
3.5.2.3 Tra2 proteins indirectly regulate splicing of two upstream exons in the XPA gene 
The data in this chapter indicates that double knockdown of Tra2 proteins in MDA-MB-231 cells 
cause three consecutive and constitutive exons of XPA to be spliced out of the mRNA. The resulting 
in-frame mRNA isoform was shown to express a corresponding truncated protein that is exclusively 
located in the cytoplasmic compartment of the cells as demonstrated by nuclear fractionation 
experiments. The XPA gene codes for an essential protein of DNA damage recognition and repair. 
Germline mutations in the XPA gene are a known cause for Xeroderma Pigmentosum, a rare 
autosomal recessive disorder with characteristic UV hypersensitivity and a 1000-fold increased 
frequency of cancer on sun-exposed skin (Cleaver, 1968; Kraemer et al., 1990). The XPA protein is 
primarily involved in the nucleotide excision repair (NER) pathway where it interacts with a range of 
proteins to perform nucleotide excision and replacement in DNA adducts (mainly cyclobutane 
pyrimidine dimers (CPD)) caused by UV irradiation of DNA (Cleaver, Lam, & Revet, 2009). Processing 




protein kinase Ataxia telangiectasia and Rad3-related (ATR). ATR phosphorylates Checkpoint kinase 
1, another splice target of Tra2 proteins, and other kinases in order to arrest cell cycle progression 
and allow DNA repair (Zhao & Piwnica-Worms, 2001). Hela cells deficient in XPA and XPA-depleted 
Xenopus egg extracts exhibit defects in CHK1 phosphorylation during S phase (Bomgarden et al., 
2006), indicating a direct relationship between XPA-directed NER and CHK1-dependent cell cycle 
arrest. Investigations into direct protein-protein interactions of XPA with Cep164, a chromosomal 
protein involved in ATR-mediated checkpoint activation upon UV damage, show amino-acids 4-97 of 
XPA are essential for direct binding and colocalisation at DNA damage sites (Y. R. Pan & Lee, 2009). 
Furthermore, UV-induced CHK1 phosphorylation was deficient in fibroblasts expressing an XPA 
(delta 10-88) mutant. However, these amino acid residues (4-97) are not spliced out in the 
alternative isoform we observe in MDA-MB-231 cells treated with Tra2α/β siRNAs, suggesting the 
short XPA isoform may still be recruited to CPD sites via interactions with Cep164. The nuclear 
fractionation experiment in this chapter indicates high abundance of the full length XPA protein in 
the cytoplasm of both control and Tra2 knockdown cells. This is in line with previous reports showing 
XPA (full length) is localised in the cytoplasm of synchronised G1 and S phase Hela cells, but is only 
imported into the nucleus of S phase cells upon exposure to UV irradiation (Z. Li, Musich, Cartwright, 
Wang, & Zou, 2013; Zhengke Li, Musich, Serrano, Dong, & Zou, 2011). The nuclear import of XPA 
upon UV-induced DNA damage is regulated by ATR and p53 (X. Wu, Shell, Liu, & Zou, 2007), but not 
by affected by expression of CHK1 or MAPKAPK2, both of which are downstream targets of ATR 
(Zhengke Li et al., 2011). ATR binds to XPA via the Lys188 and Ser196 residues (of XPA) in its helix-
turn-helix (HTH) motif, important for the efficient repair of CPD adducts (Musich, Li, & Zou, 2017). 
These residues and the HTH motif are spliced out of the short XPA protein isoform expressed in Tra2 
double knockdown MDA-MB-231 cells, indicating that the short XPA protein isoform is missing key 
interaction motifs that would allow its nuclear import by ATR. This suggests that any possible NER 
functions of the short XPA isoform may not be active, however, possible non-NER roles of XPA in the 
cytoplasm may still take place (Musich et al., 2017). 
In order to investigate the individual impact of the short XPA isoform on cell viability and DNA 
damage in this chapter we used antisense oligonucleotides to interfere with the splicing of XPA in 
MDA-MB-231 cells. The 2’OMePS AO targeting the 3’ splice site of intron 4 and exon 5 of XPA 
induced the expression of an mRNA product (detected by PCR) of the same size as the one observed 
in Tra2 double knockdown cells. Consequent Western blots of XPA and gammaH2AX indicate 
expression of the short XPA protein isoform correlated with an increase in DNA damage 
accumulation. However, there are certain aspects of the AO based experiments that must be 




XPA gene in the AO treated cells shows a far weaker band than Tra2α/β siRNA treated cells, yet the 
Western blots show a prominent band corresponding to the short isoform as well as new 
intermediary bands not previously detected (Figure 57). While it is possible that these intermediary 
bands correspond to other possible isoforms of XPA induced by the AO, no other PCR bands that 
could explain such isoforms are detected. Secondly, the cytotoxicity induced by control AOs is too 
high to be neglected. Both gammaH2AX levels as well as WST1 data show evidence of cytotoxicity in 
the control AO, suggesting that any effects on cell viability or DNA damage by the splice switch in 
XPA may be masked by the side effect of AOs. Although the data demonstrating an effect of the XPA 
protein isoform on DNA damage may not be conclusive, the splice change induced at the mRNA level 
is strongly suggestive of a regulatory mechanism where Tra2 proteins act transversely to regulate 
the splicing of exons 3 and 4 (Figure 58). A future potential genetic modification using a CRISPR Cas9 
system to either abolish Tra2β binding sites or delete exon 5 altogether would directly answer the 
question of transverse regulation of splicing of exons 3 and 4 by Tra2 proteins. However, creating a 
stable cell line harbouring a deletion of an exon of an important DNA repair gene such as XPA may 
prove challenging. In chapter 2 we discussed other cases such as DROSHA where Tra2 proteins act to 
repress the inclusion of upstream exons. Although the exact mechanism of repression or definition 
for upstream exons by Tra2 proteins may not be clear, further cases confirming such regulatory 
junctions could change the portrayed role of Tra2 proteins in alternative splicing. 
 
Figure 57 Detection of the short protein and mRNA isoform of XPA. Comparison of Tra2 double knockdown cells against 




isoform. Quantification of the upper bands of full length XPA protein relative to loading control are shown in figures 49 and 






Figure 58 Alternative splicing of XPA. RNAseq data viewed on the UCSC browser clearly indicating skipping of three consecutive exons in the XPA gene upon Tra2 double knockdown (bottom 




3.5.3 Alternatively spliced Mismatch Repair genes and their potential role in microsatellite 
instability 
The alternative splicing events in POLD3 and MSH2, two crucial genes involved in MMR (Edelbrock, 
Kaliyaperumal, & Williams, 2013; Nicolas, Golemis, & Arora, 2016), are located near the end of the 
genes. A large body of evidence, particularly in colorectal cancer, show germline mutations in MMR 
components such as POLD3 and MSH2 lead to microsatellite instability in early stage cancer 
development, which results in progressive late stage cancers harbouring mutations in many other 
tumour suppressor genes (Bubb et al., 1996; Vilar & Gruber, 2010; Zhou et al., 2018). However, our 
data shows no detectable microsatellite instability in the Tra2 double knockdown cells. The absence 
of microsatellite instability in our results could be due to the limited timeframe of the knockdown 
experiment which does not allow enough time for the cells to undergo multiple cell division cycles 
and show microsatellite instability. The alternative isoform of POLD3 expressed at a higher level in 
the Tra2 knockdown cells is predicted to code for a protein with a disrupted CDC27 motif. Yeast two-
hybrid experiments show the final ten residues of the C-terminal comprise the DNA sliding clamp, 
suggesting this isoform of POLD3 may potentially have altered affinity for DNA (F. C. Gray, Pohler, 
Warbrick, & MacNeill, 2004). Moreover, the alternative final exon of POLD3 also contains a different 
3’ UTR sequence. The intron retention detected in MSH2 after Tra2 double knockdown is not 
predicted to affect the functional motifs in the final protein. However, it would introduce a different 
3’ UTR sequence, like the case of POLD3 (Figure 59). A study investigating the mechanism by which 
Helicobacter pylori induces gastric cancer identified increased expression of miRNA-150-5p and 
miRNA-155-5p that bind to POLD3 and MSH2 mRNAs, respectively (binding confirmed by luciferase 
reporter assay)(Santos et al., 2017). The consequential reduced expression of POLD3 and MSH2 in 
gastric cells suggests that their 3’UTRs are essential for the endogenous regulation of expression via 
miRNAs. Therefore, it is possible the alternative events regulated by Tra2 proteins may cause small 
but important changes in the expression of POLD3 and MSH2. Such splice changes in vivo may prove 
essential to the early stages of cancer development via microsatellite instability, pointing to Tra2 





Figure 59 Alternative splicing of POLD3. UCSC browser view of RNAseq and iCLIP data over the alternatively selected last 
exon of POLD3. Isoform A, which is predominantly expressed in the control MDA-MB-231 cells, is predicted to produce the 





3.6 Chapter summary 
In this chapter, I utilised RNAseq differential gene expression data from Tra2 double knockdown cells 
which directed the attention towards a set of DNA repair genes that were not previously highlighted 
by GO enrichment analysis. Key components of different DNA repair pathways show strong dPSIs in 
Tra2 double knockdown cells and corresponding reductions in protein expression (BRIP1 and UIMC1) 
or expression of a shorter protein isoform (MBD4 and XPA). Nuclear fractionation experiments and 
immunocytochemistry show exclusive cytoplasmic localisation for the short protein isoforms of 
MBD4 and XPA. Antisense oligonucleotides targeting splice junctions of regulated by Tra2 proteins in 
BRIP1, CHEK1 and XPA induce the same splice changes. In XPA, a single AO causes skipping of all 
three consecutive exons, followed by expression of the short protein isoform and apparent 





Chapter 4: Alternative splicing regulation by RBMX in breast cancer 
cells and the overlap with Tra2 proteins 
4.1 Introduction 
Regulation of alternative splicing is a complex process that involves a range of proteins and RNPs 
interacting with the pre-mRNA. While the role of Tra2 proteins in breast cancer cells’ alternative 
splicing is the focus of the previous chapters, here we will investigate the potential function of the 
known co-regulator RBMX (also known as hnRNP G). RBMX is an hnRNP encoded by the gene RBMX 
which is located in the X chromosome and ubiquitously expresses a 43kDa protein with an N-
terminal RNA recognition motif (RRM) (Figure 60) (David J. Elliott, Caroline Dalgliesh, Gerald Hysenaj, 
& Ingrid Ehrmann, 2019). RBMX has a homolog on the Y chromosome, RBMXY. Two other family 
members RBMXL1 and RBMXL2 are thought to have evolved via retrotransposition of RBMX early in 
mammalian evolution. Gene expression network analyses have identified RBMX as a key switch 
associated with cancer drivers (Climente-González, Porta-Pardo, Godzik, & Eyras, 2017). 
Interestingly, one study found RBMX is accumulated at DNA lesions through multiple domains in a 
PARP1-dependent manner thereby promoting DNA double-strand break repair though homologous 
recombination (Adamson, Smogorzewska, Sigoillot, King, & Elledge, 2012). Several previous reports 
have demonstrated association between expression of RBMX and several cancers (breast cancer 
(Martínez-Arribas et al., 2006), lung cancer (D. Zhang et al., 2018), endometrial cancer (Ouyang et 
al., 2011)).  
 
Figure 60 Protein structure RBMX highlighting the RRM and interacting motif of the protein. Image adapted from (David J. 
Elliott et al., 2019) 
Crucially, RBMX has been known to interact with other RNA binding proteins, such as Tra2β, through 
the C-terminal motif (S. Grellscheid et al., 2011; Kanhoush et al., 2010). RBMX and Tra2β 




muscular atrophy patients (Cléry et al., 2011; Moursy et al., 2014). However, they have been shown 
to antagonistically regulate the skeletal muscle-specific exon of TPM3 (Nasim et al., 2003). While the 
model for the synergistic regulation of SMN2 exon 7 relies on protein-protein interaction between 
RBMX and Tra2β (Hofmann & Wirth, 2002), the antagonistic regulation of TPM3 suggests they may 
also function as competitors (Nasim et al., 2003). Therefore, we hypothesised that some of the Tra2-
regulated targets in breast cancer may also be regulated by RBMX. Furthermore, RBMX may function 
independently of Tra2 proteins in regulating splicing of other genes. 
This chapter describes work that was chronologically performed alongside some of the Tra2 project, 
and therefore is at times difficult to justify the flow of experiments considering conclusions and 
observations made in the previous chapters. We initially identified by chance several Tra2-regulated 
genes to be under the control of RBMX too, particularly genes that were found to be repressed by 
Tra2 proteins. Following this discovery, we were prompted to replicate the strategy used for the 
investigation of Tra2 alternative splice regulation using a variety of packages to interrogate RNA 






4.2 Chapter aims and objectives 
The main objective of this chapter is to identify novel alternative splicing events regulated by RBMX 
in breast cancer cells, and any potentially co-regulated genes with Tra2 proteins. Specifically, we aim 
to: 
• Identify alternatively spliced genes under the regulation of both RBMX and Tra2 proteins in 
the MDA-MB-231 cells 
• Analyse RNAseq data from RBMX knockdown cells to search for alternative events under the 
regulation of RBMX independently of Tra2 proteins 
• Investigate any potential autoregulatory mechanisms of RBMX expression 




4.3 Materials and Methods 
4.3.1 Cell culture and cell lines  
MDA-MB-231 cells were maintained in DMEM (no phenol red) plus 10% fetal bovine serum and 1% 
Penicillin Streptomycin. HEK293T cells were maintained in DMEM with phenol red plus 10% fetal 
bovine serum.  
4.3.2 siRNA knockdown 
RBMX transient knockdown was established using two different siRNAs targeting RBMX mRNA 
transcripts (hs.Ri.RBMX.13.1 and hs.Ri.RBMX.13.2, from Integrated DNA Technologies). Negative 
control cells were transfected with scramble siRNA (IDT). Cells were seeded onto 6-well plates at a 
confluence of approximately 1x106 and incubated for 24hours. After the incubation period, 6µl of 
10µM siRNA was diluted in 150µl of Opti-MEM which was then mixed with 6µl of Lipofectamine 
RNAiMAX also diluted in 150µl. The combined reaction mix was incubated at room for 5 min and 
then added dropwise onto the seeded cells. Transfected cells were then incubated for 72h at 37°C 
before harvesting. RNA was extracted using standard Trizol extraction protocol and DNAse treated 
using DNA-free kit (Invitrogen). 2x Protein Loading buffer was used for protein extraction. 
4.3.3 Tetracycline-controlled transcriptional activation of RBMX and RBMXL2 
HEK293T tetracycline-inducible RBMX- and RBMXL2-overexpressing cells were established by Dr 
Mahsa Kheirollahi-Kouhestani. Cells were thawed and seeded for 24hr in standard DMEM with 
phenol red. Cells containing pcDNA empty vector, RBMX- and RBMXL2-overexpressing vectors were 
treated with Tetracycline at a final concentration of 1µg/ml alongside corresponding control 
untreated cells, which were then incubated for 24hours at 37°C. RNA was extracted using standard 
Trizol extraction protocol and DNAse treated using DNA-free kit (Invitrogen). 
4.3.4 cDNA and PCR quantification 
The RNA from siRNA-treated cells was extracted using standard Trizol RNA extraction (Life 
Technologies) following manufacturer’s instructions. cDNA was synthesized from 500ng total RNA in 
10µl reactions using Superscript VILO cDNA synthesis kit (Invitrogen) following manufacturer’s 
instructions. To analyse the splicing profiles of the alternative events primers were designed using 
Primer 3 Plus and the predicted PCR products were confirmed using the UCSC In-Silico PCR tool. 
Primers were designed to have a melting temperature of 60°C (+/-1°C) often including an internal 
screening primer. All PCR reactions were performed using GoTaq G2 DNA polymerase kit from 




(Qiagen). Primers used for this chapter and corresponding coordinates of alternative events 
regulated by RBMX are listed in Appendix. 
4.3.5 RNA sequencing 
For the purpose of RNA sequencing, RNA was extracted from cells using RNeasy Plus Mini Kit 
(Qiagen) following manufacturer’s instructions and re-suspended in nuclease-free water. RNA 
samples were DNase treated using DNA-free kit (Invitrogen). Pair-end sequencing was done initially 
for two samples, one of negative control siRNA treated MDA-MB-231 cells and one of RBMX siRNA 
treated cells, using Illumina HiSeq 2000. We then sequenced three biological repeats of negative 
control and RBMX siRNA treated MDA-MB-231 and mouse 3T3 fibroblasts using the same 
sequencing method. 
4.3.6 RNAseq analysis 
The base quality of raw sequencing reads was checked with FastQC. RNAseq reads were mapped to 
the human genome hg19 reference with Tophat2 (D. Kim et al., 2013). RNAseq mapping was 
performed by the bioinformatics unit at the Institute of Genetic Medicine, Newcastle University. 
Differential splicing analysis was determined using MAJIQ, performed by Matthew Gazzara, 
University of Pennsylvania (Vaquero-Garcia, Barrera, Gazzara, Gonzalez-Vallinas, et al., 2016).  
4.3.7 WST-1 cell survivability assay 
To test cell viability after RBMX knockdown we utilised the WST-1 colorimetric assay. After 
treatment with siRNA cells were incubated in solution for 3 hours at days 2, 3, 4 and 5 following 
manufacturer’s protocol. Cells were seeded onto a 96-well plate for 24 hours prior to transfection at 
4x103 cells/well. Transfection mixture volume was adjusted accordingly maintaining the same ratios 
as in section 3.3.2 of this chapter. Every 24 hours after transfection 10µl WST-1 was added to each 
well containing cells and: a) negative control AO, b) targeting AO, c) DMEM media and d) DMEM 
media only (no cells). The absorbance of each well was measured at 450nm wavelength using 







4.4.1 Tra2 proteins and RBMX have antagonistic effects on splicing of SMN2 exon 7 in MDA-
MB-231 cells 
The splicing regulator RBMX coded by the RBMX gene has been previously identified as a co-
regulator of alternative splicing working together with Tra2β. A classic example of their interaction is 
the co-regulation of exon 7 of the SMN2 gene. Correct splicing of exon 7 is crucial for the production 
of active SMN protein in patients suffering from Spinal Muscular Atrophy (SMA) (Moursy et al., 
2014). The alternative splicing of exon 7 is reliant on Tra2β binding an ESE within the exon. Clery et 
al. 2011 suggest that RBMX interacts with Tra2β to promote the inclusion of exon 7 of the SMN2 
gene (Cléry et al., 2011). Furthermore, they show that RBMX binds to CAA motifs and mutations in 
the binding motif of exon 7 minigenes greatly affected the binding affinity of RBMX, and 
subsequently influenced inclusion of the exon in vitro. To test if endogenous RBMX and Tra2 
proteins have the same effect on SMN2 exon 7 splicing we knocked down the expression of RBMX in 
MDA-MB-231 cells using two different siRNAs. After 72 hours of siRNA treatment cells were 
harvested for RNA and protein extraction. Firstly, we tested the efficiency of the RBMX knockdown 
using western immunoblotting (Figure 61). The results show a marked decrease in RBMX expression 
from both siRNAs. We then tested the inclusion of SMN2 exon 7 in control, RBMX and TRA2A/B 
siRNA treated cells using RT-PCR. Contrary to the suggestions from Clery et al, 2011 we find that 
endogenous RBMX represses the inclusion of SMN2 exon 7, whereas Tra2 proteins promote the 
inclusion of the exon (Figure 62). Our results suggest that RBMX and Tra2 proteins have antagonistic 
roles over the splicing inclusion of exon 7 of the SMN2 gene. 
 
Figure 61 Western immunoblotting of MDA-MB-231 cells treated with two different siRNAs against RBMX. Western blot 





Figure 62 Alternative splicing control of SMN2 exon 7. a) Capillary gel electrophoresis of siRNA treated MDA-MB-231 cells, 
blue arrow indicates exon 7 inclusion band, red arrow exon 7 skipping. b) Quantification of SMN2 exon 7 splicing in MDA-
MB-231 cells. c) Indirect validation of Tra2α/β knockdown by quantification of CHEK1 alternative splicing of exon 3. d) 
Western blot of Tra2α/β siRNA treated cells using anti-Tra2β antibody and corresponding quantification using ImageJ 
indicates clear reduction in Tra2β. All p-values are calculated from three biological replicates. * Represents p<0.05; ** 
represents p<0.01; and *** represents p<0.001. 
4.4.2 Tra2-repressed exons are more likely to be regulated by RBMX 
In line with the idea that Tra2β and RBMX interact to regulate alternative splicing we tested the 
splicing profiles of 19 genes from our Tra2 target panel in the RBMX knockdown cells by RT-PCR. 




double knockdown MDA-MB-231 cells. Of the targets selected for testing, 10 exons were repressed 
by Tra2 proteins. Interestingly, five of the Tra2-repressed exons also respond to the RBMX 
knockdown in the same direction of change (Figure 63). Of the nine exons that are activated by Tra2 
proteins only FAM35A exon 3 responds to the RBMX knockdown. Contrary to our findings in the 
regulation of SMN2 exon 7 and previous reports suggesting antagonising roles of RBMX and Tra2β in 
alternative splicing (Nasim et al., 2003; Yan Wang, Wang, Gao, Stamm, & Andreadis, 2011), our 
results suggest the alternatively spliced targets regulated by RBMX and Tra2 proteins mainly change 
in the same direction. Moreover, repressed exons are more likely to be commonly regulated by 
RBMX and Tra2 proteins than promoted exons. 
Interestingly, these results also indicated a clear correlation between RBMX knockdown efficiency 
and dPSI. We notice this in some examples such as SS18 exon 8 and HMGXB4 exon 2, where the 
splice change is stronger in the more efficient knockdowns. The two isoforms of SS18 have both 
been previously described to interact with RBM14 and function as nuclear receptors and 
transcriptional activators (Iwasaki, Koibuchi, & Chin, 2005). However, the SS18 gene is often 
associated with synovial sarcoma due to it being commonly translocated and fused with other genes 
(particularly SSX1 and SSX2)(Przybyl, van de Rijn, & Rutkowski, 2019), therefore the role of this 
alternative isoform in carcinogenesis may be difficult to determine. The HMGXB4 gene on the other 
hand is associated with transcriptional regulation in primary myelofibrosis patients. Specifically the 
silencing of HMGXB4 was noted to induce megakaryocyte differentiation and inhibit erythroid 
development in human stem cells (Salati et al., 2016). Upon RBMX knockdown exon 2 of HMGXB4 is 
included 11% more. The exon 2-containing isoform codes for a protein 111 amino acids longer than 
the control expressed isoform (utilises a different start codon), however the two predicted domains 





Figure 63 Delta PSI of previously identified Tra2 targets. RBMX knockdown MDA-MB-231 cells show significant changes in 
splicing of genes that are repressed by Tra2 proteins. All changes shown are statistically significant (p<0.05) and are 




4.4.3 RNA sequencing of RBMX knockdown MDA-MB-231 cells and analysis using MAJIQ 
Our preliminary results comparing regulated alternative events by RBMX and Tra2 proteins 
prompted us to continue searching for targets regulated by RBMX. To be able to globally compare 
our results from the RBMX knockdown with those from the Tra2 experiments we continued using 
the same cell line, as we had already mapped Tra2 target exons in MDA-MB-231 cells. Therefore, we 
knocked down RBMX expression in MDA-MB-231 cells as previously described using siRNA and 
harvested the RNA after 72 hours. The RNA was DNAse treated and prepared for RNA sequencing. 
We initially sequenced the total RNA from only 1 control and 1 RBMX knockdown sample using 
paired-end sequencing on the Illumina HiSeq 2000 platform. In our previous analysis of the RNAseq 
data from the Tra2 double knockdown cells it was evident that the MAJIQ pipeline can efficiently 
identify most alternatively spliced events in the dataset. Therefore, we also analysed the RNAseq 
data from the RBMX knockdown samples using the MAJIQ pipeline. The bioinformatics analysis was 
performed by Matthew Gazzara at the University of Pennsylvania comparing 1 control sample vs 1 
knockdown sample. The analysis identified 596 unique local splicing variations (LSV) at a 20% dPSI 
minimum cut off from 505 different genes regulated by RBMX.  
Given the success of MAJIQ at identifying a large subset of potential alternative splice targets 
regulated by RBMX in a 1-to-1 comparison, we decided to perform the RNA sequencing on three 
biological replicates (3 control vs 3 RBMX knockdown). The increased sample number made it 
increasingly easier to confidently determine if alternative events identified by MAJIQ are indeed 
being affected by the RBMX knockdown and are not RNAseq artefacts.  
4.4.4 RBMX auto-regulates its expression via alternative splicing of the 3’ UTR 
4.4.4.1 RBMX knockdown causes a switch in alternative splicing of the RBMX isoforms 
Tra2β has been reported to overlook the expression of itself and Tra2α by directly binding to poison 
exons within TRA2A/B that introduce premature termination codons (S. Grellscheid et al., 2011). 
Therefore, we reasoned that a similar autoregulatory mechanism may be in place in the RBMX gene. 
Unlike TRA2A or TRA2B, RBMX does not have a known poison exon that is alternatively spliced. 
However, there are at least 4 known alternative isoforms of the RBMX gene, one of which contains a 
splice junction within the 3’UTR. The presence of a splice junction means that an exon-exon junction 
complex (EJC) will be present in the mRNA downstream of the termination codon, potentially 
subjecting this isoform to nonsense mediated decay. To test this hypothesis, we examined our 




the RBMX gene created using the IGV browser clearly shows the splice junction reads mapping to 
the spliced 3’UTR isoform was present only in the control samples (Figure 65). The total gene 
expression of RBMX has decreased more than 4-fold in the siRNA treated cells. The alternative 
isoform containing the splice junction within the 3’UTR is absent from the knockdown samples. This 
result suggests that in an attempt to sustain the expression of the functional RBMX isoform, the 
alternative splicing of RBMX has switched to the production of the more stable protein coding mRNA 
isoform to compensate for the knockdown. To validate these results by PCR we designed primer 
combinations that interrogate the expression of each known RBMX isoform. RNA extracted from 
RBMX knockdown MDA-MB-231 cells and control cells was tested by RT-PCR to compare the relative 
expression of four potential RBMX isoforms. Capillary gel electrophoresis shows the expression of 
the T1 isoform (corresponding to the isoform containing a splice junction within the 3’UTR) was 
reduced drastically with respect to all other three isoforms (Figure 64). This data confirms the results 
from RNAseq, that splicing switches to reduce levels of the potentially NMD degraded mRNA after 
RBMX depletion. These data are thus consistent with the existence of a concentration dependent 
RBMX autoregulatory feedback pathway. 
 
Figure 64 Autoregulation of RBMX expression. UCSC transcripts (top) tested using different primer combinations to assess 





Figure 65 Sashimi plot of RBMX 3'UTR region. Sashimi plot of RNAseq data using IGV clearly indicates a drastic drop in 
expression of 'T1' isoform of RBMX. Splice junction reads mapping to the T1 isoform pointed out by blue arrows. 
4.4.4.2 UPF1 knockdown allows accumulation of the NMD-targeted RBMX isoform 
The above data suggest that the human RBMX gene can switch its own splice pattern in order to 
maximise the expression of the functional isoform if necessary. Under this hypothesis the RBMX 
isoform containing an exon junction within the 3’UTR is degraded by nonsense mediated decay 
(NMD). To test this, we knocked down the expression of UPF1, a crucial RNA helicase required for 
NMD, in HEK293T cells for 24 hours (knockdown experiment performed by Dr Ingrid Ehrmann, 
Newcastle University). We extracted the RNA and performed RT-PCR using the same primer 
combinations as previously interrogating the 3’UTR isoforms of RBMX. Capillary gel electrophoresis 
showed the relative abundance of isoform T1 significantly increases with respect to all three other 
isoforms in the absence of Upf1 (Figure 66). The increased stability of the T1 isoform after UPF1 





Figure 666 UPF1 knockdown HEK293T cells show increased expression of the T1 isoform of RBMX relative to the other 
isoforms. No significant difference was measured in the relative expression of T2 vs T3 isoforms. Capillary gel 
electrophoresis (left) and corresponding quantification. * indicates p<0.05 
4.4.4.3 Autoregulation of the mouse Rbmx may be conserved 
To see if the autoregulation of RBMX is conserved in mice we tested the alternative splicing of Rbmx 
(the mouse RBMX homologue) in 3T3 mouse fibroblasts. Cells were treated for 72 hours with two 
different siRNAs against Rbmx and one control. RNA was extracted, DNAse treated and analysed by 
RT-PCR to evaluate the splice changes in the Rbmx gene, using specific primers that were able to 
detect the respective isoforms. Capillary gel electrophoresis showed a significant drop in the relative 
expression of the T1 isoform (containing the splice junction) compared to the other isoforms. 
However, the presence of non-specific PCR bands and detection of just a small dPSI prompted us to 
continue the investigation. We determined the efficiency of the knockdown using quantitative-PCR 
and used the samples with the most efficient knockdown for RNA sequencing. However, the RNAseq 
data and Sashimi plots of the Rbmx gene show no visible change to the alternative splicing of the 
gene. Moreover, the expression of Rbmx is reduced only by approximately 0.5-fold by the siRNA 
treatment (low compared to the 4-fold expression change in the human breast cancer cells) (Figure 
67). This could be the reason why there is no clear difference in the splice pattern of Rbmx in 3T3 





Figure 677 Rbmx knockdown in mouse 3T3 fibroblast cells shows a switch in the expected T1-like isoform at 571 bp, but 
two intermediary bands that were not expected to amplify indicate a potentially more complex splice junction at the 3'UTR 
of the mouse Rbmx. Right panel shows qPCR quantification of the knockdown, * indicates p<0.05 
4.4.4.4 RBMX and RBMXL2 overexpression both repress the expression of endogenous functional 
isoform of RBMX 
To investigate further the implications of gene expression changes for RBMX in the regulation of its 
own splicing we used an RBMX overexpressing HEK293T cell line previously established by Dr Mahsa 
Kheirollahi-Kouhestani in the group. RBMX overexpression was induced using tetracycline alongside 
cells containing the empty vector pcDNA, and with and without tetracycline used as controls. 
Capillary gel electrophoresis showed a clear downregulation of the RBMX isoforms 2 and 4 relative 
to isoform 1 containing the 3’UTR splice junction. The RBMXL2 (RBMX-Like-2) gene codes for hnRNP-
GT, a member protein of the RBMX family thought to have arisen from retrotransposition of RBMX. 
As such the RBMXL2 gene contains no introns and shares 73% sequence homology with RBMX at the 
protein level. RBMXL2 is an autosomal gene expressed only during and immediately after meiosis, 
but not in the preceding spermatogonial cells of male mice (Ehrmann et al., 2008).  Interestingly, 
HEK293T cells overexpressing RBMXL2 show clear downregulation of the functional isoforms of 
RBMX through capillary gel electrophoresis, suggesting RBMXL2 can also regulate the alternative 





Figure 688 Tetracycline induced overexpression of RBMX and RBMXL2 in HEK293T cells shows an increase of the relative 
abundance of isoform ‘T1’ of RBMX. CGE image representative of three biological replicates. Student’s t-test, *p<0.05 
4.4.5 Investigating alternatively spliced targets in the RBMX knockdown MDA-MB-231 cells 
4.4.5.1 Only 51% of targets selected through MAJIQ are validated by RT-PCR 
The 1-to-1 comparison of RBMX knockdown to control RNAseq data using MAJIQ identified 596 
unique LSVs above the minimum 20% dPSI. However, the results obtained from the 1-to-1 analysis 
may contain false positive splice changes. Such false positives would be difficult to spot due to the 
absence of biological repeats. Therefore, many LSVs were manually inspected using the RNAseq data 
from the 3-to-3 knockdown experiment visualised on the UCSC browser. Subsequently, 70 
alternative events were selected to be tested by RT-PCR as the most likely true positive candidate 
targets in the panel. Primers designed to differentiate between each isoform were used to test the 
splicing profiles of all 70 target genes by RT-PCR and capillary gel electrophoresis. 36 of the tested 
genes (51%) show alternative splice changes upon RBMX knockdown in MDA-MB-231 cells 
(Appendix table 3). The validation rate of RBMX regulated genes is considerably lower than the Tra2 
protein-regulated genes in Chapter 2, clearly indicating the need of a 3-to-3 comparison in the 
bioinformatics analysis. 
4.4.5.2 Majority of RBMX regulated targets are cassette exons but also include a substantial 
proportion of alternative polyadenylation sites 
Heterogeneous nuclear ribonucleoproteins such as RBMX generally bind to intronic splicing silencer 
(ISS) sequences and mask the splice sites of downstream exons causing skipping of such exons. 
However, this is a general rule for hnRNPs and in our dataset we observed a variety of alternative 




cassette exons comprising nearly 60% of the total events. Interestingly, more than 20% of the target 
events regulated by RBMX are alternative polyadenylation (11 genes) sites or alternative 
promoter/start exons (four genes). While alternative polyadenylation often only affects the length of 
the 3’UTR, a few target genes lose a substantial number of coding exons upon RBMX knockdown. In 
the cases of ASPH and KLHL7 the shorter mRNA isoforms are predicted to code for much shorter 
protein isoforms that are missing important protein domains in their C-terminal (Figure 69). The 
short isoform of ASPH is missing the TPR_16 domain, a tetratricopeptide repeat predominantly 
found in transglutaminase enzymes, and Aspartyl/Asparaginyl β-hydroxylase domain which is crucial 
for the catalysis of oxidative reactions in a range of metabolic processes. Interestingly, the functions 
of both isoforms of ASPH have been previously investigated and it was shown the shorter isoform 
plays a role in Ca2+ sensing (Srikanth et al., 2012) while the full length isoform is involved in 
hydroxylation of Asp and Asn residues of epidermal growth factor-like proteins (Dinchuk et al., 
2002). KLHL7 encodes a gene recognised to be involved in ubiquitination. The short isoform of KLHL7 
is missing four Kelch motifs which form a β-propeller tertiary structure that is often required for 
interaction with Cullin 3 ubiquitin ligases (Kigoshi, Tsuruta, & Chiba, 2011). The role of RBMX in 
alternative promoter selection or transcription has not been previously described. The alternative 
promoter of TCEA2 leads to the expression of a longer mRNA isoform upon RBMX knockdown. 
Interestingly, the longer isoform introduces a second Med26 protein domain at the N-terminus 
which is often found in transcription initiation or elongation factors (Soutourina, 2018). The MAJIQ 
analysis of RNAseq data from the Tra2-double knockdown in MDA-MB-231 cells showed 
approximately 6% of the target exons were repressed by Tra2 proteins. The role of RBMX in exon 
repression is more persistent as data shows RBMX represses the splicing of more than 13 of its 






Figure 699 Alternative polyadenylation events in KLHL7 and ASPH. UCSC genome browser views show clear isoform switch which results in the likely expression of two truncated proteins 





Figure 7070 Pie chart of alternative events regulated by RBMX. Unsurprisingly, RBMX acts as a repressor relatively more 
often than Tra2 proteins. The diagram represents proportions of different alternative event types from the 36 validated 
splice events identified by the 1-to-1 comparison. 
 
4.4.6 Reciprocal splice changes in six target genes indicate direct regulation by RBMX 
Unlike Tra2 proteins, RBMX has not been reported to be overexpressed in cancers relative to normal 
tissue. Therefore, we tested the effect of RBMX overexpression on the splice variations identified by 
RNAseq. During her PhD, Dr Mahsa Kheirollahi-Kouhestani established a stable HEK293T cell line 
overexpressing RBMX which we used to test the splicing profiles of 16 target genes. Of these, 6 
alternative events show statistically significant changes in PSI in the RBMX overexpressing cells vs 
pcDNA empty vector/control cells. ETAA1 codes for a protein kinase that binds to ATR and is 
accumulated at DNA damage sites (Figure 71). Upon RBMX knockdown exon 5 of ETAA1 uses an 
alternative 3’ splice site which leads to the expression of an mRNA isoform encoding for a shorter 
protein (724aa shorter) that is missing a large portion of the Pfam predicted Ewing’s tumour-
associated antigen motif. Only exon 10 of STX3 gene showed a PSI change in the RBMX-
overexpressing cells that is in the same direction as in the RBMX knockdown cells. In the ATRX gene 
the knockdown of RBMX causes the formation of an exitron – a sequence within the exon is spliced 
out as an intron – however there was no measurable change to the exitron splicing in overexpressing 
cells. Although we do not have iCLIP data for the binding sites of RBMX, the reciprocal splice changes 





Figure 7171 The role of RBMX in regulating splicing of ETAA1 and ATRX. Capillary gel electrophoresis of knockdown and overexpressing cells showing reciprocal switch in ETAA1, but not ATRX. 




4.4.7 WST-1 assay indicates the RBMX knockdown does not have detrimental effects on cell 
viability 
To assess the role of RBMX in the viability of the cells we used WST-1 based colorimetric assay. We 
measured the confluency of the cells every 24 hours after 2 days of siRNA transfection. The RBMX 
knockdown efficiency was estimated based on the strength of splice switch within the 3’UTR of 
RBMX. Unlike Tra2 protein double knockdown, the RBMX knockdown does not dramatically affect 
the viability of the cells. However, the confluency of the cells is initially reduced but the cells 
continue to grow after day 2 (Figure 72). This indicates that RBMX is not an essential gene for cell 
survivability and that the overall changes in alternative splicing are not detrimental to the cell. 
 
 
Figure 72 WST1 assay assessing MDA-MB-231 cell survivability upon RBMX knockdown. Relative expression of RBMX was 
measured from RNA of corresponding wells using 3'UTR splice junction primers. Bars show standard error calculated from 






4.5.1 RNAseq analysis of single RBMX knockdown data identifies too many false positive 
splice events 
We initially sequenced a single biological replicate of the RBMX knockdown in MDA-MB-231 cells 
against negative control siRNA treated cells. Analysis of the RNAseq data using MAJIQ identified 596 
local splicing variations indicating the RBMX knockdown has a strong impact on alternative splicing. 
However, the validation rate of the splice events (51%) was considerably lower than that of Tra2-
regulated genes (over 88%). The primary reason for the low validation rate is the use of a single 
biological replicate for RNAseq. Previous reports investigating differential gene expression changes 
detectable from a simple control vs treated experiment show that three biological replicates can 
detect between 20-40% of differentially expressed changes without setting a minimum threshold for 
fold-change (Schurch et al., 2016). Recently developed and improved bioinformatics packages such 
as SUPPA2 exploit the variability between biological replicates to determine the uncertainty in the 
PSI values (Juan L. Trincado et al., 2018). Although we repeated the RNAseq experiment for the 
RBMX knockdown in triplicates, the data was not subsequently analysed for differential splicing 
during this project. Following our conclusions from chapter 2, the RNAseq data from the triplicate 
RBMX knockdown should be analysed using at least three bioinformatics pipelines. Therefore, the 
identified and validated RBMX-regulated alternative events in this chapter do not represent the full 
spectrum of genes regulated by RBMX. Hence, Gene Ontology enrichment analysis of this data set 
would be biased and misleading but robust analysis of the RNAseq data from three biological repeats 
is essential for the continuation of this project. 
4.5.2 Joint regulation of alternative events by RBMX and Tra2 proteins show predominantly 
synergistic regulation 
Previous reports into the regulation of alternative splicing by RBMX have suggested an interaction 
between RBMX and Tra2β is vital to the inclusion of SMN2 exon 7, rather than the non-specific 
interaction of RBMX with the pre-mRNA (Hofmann & Wirth, 2002). Contrary to this conclusion, here 
we find that exon 7 inclusion of SMN2 is repressed by RBMX but activated by Tra2 proteins. 
However, of 13 alternative splice events regulated by both RBMX and Tra2 proteins, 11 show 
differential splice changes in the same directions suggesting RBMX and Tra2 proteins work 
synergistically to regulate splicing. This supports previous findings showing protein-protein 
interactions of RBMX and Tra2β  and co-localisation in human spermatocytes (J. P. Venables et al., 




alternative event has been previously confirmed by several different reports (Cléry et al., 2011; 
Hofmann & Wirth, 2002; Moursy et al., 2014). Interestingly, analysis by MAJIQ (although in the 1-to-
1 comparison) of the RBMX knockdown did not identify exon 7 of SMN2 as differentially spliced, nor 
was the event identified in the Tra2 double knockdown cells. This is likely due to the low dPSI of the 
alternative event. The reason why an antagonistic regulation is observed in the splicing of SMN2 
could be due to the low dPSI and potentially to the diversity of other RNA binding proteins expressed 
in the MDA-MB-231 cells that might affect the interactions of RBMX and Tra2 proteins with RNA. 
While the splicing of exon 7 in SMN2 is clinically important in relation to SMA patients, the role of 
RBMX and Tra2 proteins in alternative splicing of other genes is significantly stronger. 
4.5.3 RBMX regulates alternative splicing independently of Tra2 proteins 
Due to previous evidence of RBMX interaction with Tra2β, regulation of alternative splicing by RBMX 
has often been studied in conjunction with other splice regulators. However, in this chapter we 
validated a total of 47 alternative events, 36 of which are only regulated by RBMX suggesting 
interaction with Tra2 proteins is not necessary for alternative splice regulation. The other validated 
11 target events are co-regulated by RBMX and Tra2β, six of these were tested prior to RNAseq 
analysis and shown in Figure 63.  Mechanisms of alternative events regulated by RBMX involve some 
unique splice junctions such as the exitron in ATRX and 13 alternative polyadenylation events. By 
contrast, Tra2-regulated alternative splice events are mainly alternative cassette exons. The classical 
model of alternative splicing regulation by hnRNPs suggests binding to exonic or intronic splicing 
silencer cis-acting elements to suppress nearby exon recognition by the spliceosome (Busch & 
Hertel, 2012). The high number of alternative polyadenylation/last exon events suggest RBMX is 
potentially acting by masking the recognition of some of these exons which are only spliced when 
RBMX is knocked down. The same principle may also apply for the exitron in ATRX. Spanning only 87 
nucleotides (29aa) within exon 9 of ATRX, the splice junctions flanking the exitron are only utilised in 
the RBMX knockdown cells, suggesting RBMX represses the recognition of these splice sites. A major 
drawback of the current study is the absence of a clear indication of RBMX binding. iCLIP data for 
RBMX in MDA-MB-231 cells would provide clear evidence of regulation by RBMX and help identify 
binding sites within the regulated genes. 
 4.5.4 Autoregulatory feedback mechanism of RBMX relies on an alternative polyadenylation 
signal 
In this chapter we discuss the effect of RBMX knockdown on the expression of its own alternative 




potential autoregulatory mechanism, like that between Tra2β and Tra2α (S. Grellscheid et al., 2011), 
might be in place. Similarly, previous reports have shown RBM10 negatively regulates its own mRNA 
and protein expression via alternative skipping of exon 6 creating an out of frame isoform targeted 
by NMD (Sun et al., 2017). Furthermore, RBM10 was shown to promote skipping of exon 6 or 16 of 
its paralog RBM5. The known isoform of RBMX (UCSC Id: NM_001164803) that contains a splice 
junction within the 3’ UTR is a potential target for NMD. Primers testing the expression of four 
different mRNA isoforms of RBMX different at the 3’ end showed a significant decrease in the 
relative expression of the NMD-targeted isoform (T1) (Figure 64). Furthermore, the same relative 
decrease was detected using two different siRNAs against RBMX, suggesting this effect is not due to 
biased isoform targeting by the siRNA. To strengthen the argument that the T1 isoform is regulated 
by and dependent on RBMX expression levels, we showed that RBMX overexpressing HEK293T cells 
also influence the relative expression of T1. Capillary gel electrophoresis indicates that induced 
RBMX overexpression causes a reduction in the relative expression of the endogenous isoforms T2, 
T3 and T4 rather than increase the expression of T1. Interestingly, we find the same results 
replicated when overexpressing the paralog RBMXL2, suggesting expression of RBMX may be under 
the regulation of hnRNP-GT (RBMXL2). Ideally, we would test the effect of RBMXL2 knockdown on 
RBMX splice pattern changes, but the germline/meiosis specific expression of RBMXL2 restrict us 
from doing so. UPF1 knockdown in HEK293T cells shows a relative increase in the expression of the 
T1 isoform suggesting this isoform is targeted by NMD. When comparing the relative expression 
changes between T2 and T3, no significant difference was measured suggesting these isoforms are 
not affected by UPF1 knockdown. Furthermore, I searched through online publicly available 
differential gene expression data from a previous report of UPF1/XRN1 knockdown in HEK293T cells 
(Lykke-Andersen et al., 2014) and found that the expression of the corresponding T1 isoform 
increases 3-fold, although this increase was marginally non-significant (p=0.08). In line with our 
observations above into the alternative events regulated by RBMX, the autoregulatory mechanism 
within RBMX is another example of alternative poly(A) site selection. However, we must note that 
the T1 isoform is not predicted to be targeted by NMD according to the UCSC or NCBI gene 
predictions. In fact, the splice junction within the 3’UTR is only 27 nucleotides downstream from the 
predicted stop codon, which does not conform with the general rule suggesting splice junctions must 
be more than 55 nucleotides downstream in order for NMD to be triggered (Nagy & Maquat, 1998; J. 
Zhang et al., 1998). Therefore, the isoform changes measured in this chapter should be considered 
with caution and must be backed with further evidence. Although the data from mouse Rbmx 
knockdown 3T3 fibroblasts is not definitive, improvements in knockdown efficiency and a better 









4.6 Chapter summary 
In this chapter, I investigated the effects of RBMX knockdown in regulating alternative splicing in 
MDA-MB-231 cells. I tested the splice changes in several genes previously identified as Tra2-
regulated targets and detected several alternative events differentially regulated in the same 
direction in the RBMX knockdown cells. Interestingly, RBMX regulates a proportionally large number 
of alternative polyadenylation events suggestive of an inhibitory mechanism in splicing regulation. 
Similarly, an alternative polyadenylation event at the 3’ end of RBMX’s own mRNA is under the 
regulation of RBMX and RBMXL2. The alternative isoform of RBMX is potentially targeted by 









Chapter 5: Concluding remarks and future work 
The vast majority of human protein-coding multiexon genes are under the regulation of alternative 
splicing which greatly increases the coding capacity of the human genome. Classically, gene 
expression changes and somatic mutations have been the primary identifier of cancer hallmarks 
(Hanahan & Weinberg, 2011). However, alternative splicing has a much stronger impact on 
proteome diversification and as such has been increasingly linked to the central cancer hallmarks 
(Oltean & Bates, 2014). More recently RNA binding proteins involved in regulation of alternative 
splicing have emerged as a new class of oncoproteins and tumour suppressors (Urbanski, Leclair, & 
Anczukow, 2018). Exploring the orchestration of alternative splicing by various RNA binding proteins 
(RBPs) can help understand their role in cancer hallmarks. This thesis largely focuses on the specific 
splice changes regulated by Tra2α and Tra2β, but also includes the first global analysis of alternative 
splicing events regulated by RBMX. 
In this thesis, I present results from three different bioinformatics pipelines analysing the same 
RNAseq data from Tra2α/β double knockdown breast cancer cells previously reported by Best et al. 
2014 (Andrew Best et al., 2014). The results clearly indicate the necessity of using more than one 
bioinformatics pipeline to analyse alternative splice changes. Out of a total of 556 target genes 
identified to be alternatively spliced in Tra2 double knockdown cells, only 5 alternative events are 
detected by all three bioinformatics analyses (DexSeq, MISO and MAJIQ). This is particularly 
concerning when considering the relatively strong splice changes that are measured in many target 
genes (72 alternative events show dPSI greater than 40%). However, the high validation rates of 
differentially spliced events identified by both MISO and MAJIQ is indicative that these packages use 
very strict selection criteria in order to eliminate false positives. The added benefit of the new 
analysis methods revealed a range of alternative events that suggest Tra2 proteins regulate complex 
splicing events other than cassette exons. Unexpectedly, Tra2 proteins act by repressing splicing in 
important genes such as DROSHA and regulate intron retention in the mRNAs of genes such as 
POLR3C. These complex alternative events suggest different mechanistic regulation of splicing by 
Tra2 proteins compared to the classical model of ESE binding that leads to exon activation. Several 
bioinformatics packages, other than the ones used in this study, are available for the analysis of 
alternative splicing, such as SUPPA2 (J. L. Trincado et al., 2018), Psichomics (Saraiva-Agostinho & 
Barbosa-Morais, 2019), rMATS (Shen et al., 2014), LeafCutter (Y. I. Li et al., 2018). Future studies 





Consequently, I investigated the protein expression of several Tra2-regulated genes from GO 
enriched pathways showing splice changes that were expected to impact protein structure or 
expression. However, protein expression of GO-enriched genes did not appear to change. 
Specifically, the protein expression of CENPQ, MAPKAP1 (Sin1) and SUV39H2 did not show 
significant isoform changes or reductions in line with the mRNA differential splicing measured. A 
potential explanation for this could be that these proteins may have long protein turnover rates. 
Turnover studies in mice found the average half-lives of proteins in the brain and blood to be 
between 3.5 and 9 days (Price, Guan, Burlingame, Prusiner, & Ghaemmaghami, 2010), whereas 
dividing mammalian cells show protein turnover rates up to a maximum of 35hr (Cambridge et al., 
2011). Although different cell conditions affect the metabolic rate and overall protein turnover, 
some proteins will inevitably have shorter half-lives that closely relate to their individual role in the 
cell. In line with this idea, CHK1 is known to have a central role in cell cycle regulation. While 
phosphorylation and dephosphorylation of CHK1 is the main mean of regulation of cell cycle, the 
importance of rapid protein turnover is paramount when considering the impact of expression 
fluctuations on cell cycle and survivability (Andrew Best et al., 2014). Consequently, I identified 
protein expression changes in several genes involved in DNA repair pathways. Using cellular 
fractionation and immunocytochemistry I detected the short protein isoforms of MBD4 and XPA 
localised in the cytoplasm of MDA-MB-231 cells treated with Tra2α/β siRNAs. These shorter protein 
isoforms have either lost their nuclear localisation motifs (MBD4 (Bellacosa et al., 1999; Owen et al., 
2007)) or are unable to interact with other proteins that regulate their nuclear import (XPA (X. Wu et 
al., 2007)). Although the iCLIP data clearly indicates Tra2β binds these target mRNAs, an additional 
experiment to verify direct binding and regulation of the MBD4 and XPA alternative mRNAs by Tra2 
proteins could be set up in the future. Such experiments could involve minigene constructs 
harbouring point mutations that interfere with Tra2α/β binding, or RNA electrophoretic mobility 
shift assay (RNA EMSA) to assess binding of Tra2α/β on specific target RNA sequences. 
Tra2 double knockdown by siRNA causes MDA-MB-231 cells to die. The broad range of differentially 
spliced events orchestrated by Tra2 proteins present in the knockdown cells poses a problem in 
determining the role of each individual isoform. Therefore, I utilised 2’O methyl phosphorothioate-
modified antisense oligonucleotides to target specific mRNA splice junctions and induce the 
expression of Tra2-regulated isoforms in BRIP1, CHEK1 and XPA. Surprisingly, an AO targeting exon 5 
of XPA caused skipping of three consecutive exons, like the splice event in Tra2 double knockdown 
cells, suggesting Tra2 proteins may play a key role in the definition and recognition of exon 5 by the 
spliceosome and inclusion of exon 5 is essential for the inclusion of the upstream exons 3 and 4. 




CHEK1. Although very promising, the data presented here relating to the induction of DNA damage 
by AOs targeting DNA damage repair genes must be considered with caution, primarily due to the 
strong cytotoxic effect of the negative control antisense oligonucleotide. An alternative option to the 
use of AOs is genome editing using the CRISPR/Cas9 system. During my PhD, I attempted to establish 
a cell line harbouring a mutation in the MBD4 gene that would potentially interfere with Tra2 
protein binding (data not shown). Although I could induce the mutations at the specified site, I was 
unable to successfully grow single cell colonies with the genetic modification. It is possible that a cell 
line with mutated splice sites in the target genes may not be viable due to the importance of these 
isoforms to the cell.  
In the final part of this thesis, I describe the first global analysis of differentially spliced genes under 
the regulation of RBMX. Tra2β and RBMX have been described to synergistically regulate the splicing 
control of SMN2 exon 7 (Cléry et al., 2011; Hofmann & Wirth, 2002; Moursy et al., 2014). 
Unexpectedly, the endogenous splicing of SMN2 was found to contradict previous reports, showing 
opposite changes in the inclusion of exon 7 from RBMX and Tra2α/β siRNA treated MDA-MB-231 
cells. However, both conditions induce only a small change in PSI which could indicate weak overall 
effects of either RBMX or Tra2 proteins on exon 7 splicing. A future interesting experiment might 
involve knocking down RBMX and Tra2 proteins at the same time to assess the effect on the SMN2 
gene, but this may prove technically difficult. The RNAseq data from the RBMX knockdown 
experiment was analysed using MAJIQ only, but in concordance with my previous conclusion, a 
second analysis should be conducted. Interestingly, the data showed a range of alternative 
polyadenylation sites in RBMX-siRNA treated cells suggesting RBMX acts as a splicing silencer. RBMX 
was also found to regulate the alternative splice pattern of its own mRNA via an alternative event 
involving a potentially NMD-targeted isoform switch. This is a novel autoregulatory mechanism 
suggested for RBMX, but other RNA binding proteins such as Tra2β and RBM10 have been shown to 
self-regulate splicing of NMD-targeted isoforms confirming it as a common theme among RBPs (S. 
Grellscheid et al., 2011; Sun et al., 2017).  
Global analysis of differential splicing generates a large number of potential target genes. A standard 
method of clustering important and related genes is by doing Gene Ontology enrichment analysis. 
GO is best tailored to identify enriched biological and cellular pathways where all the gene entries 
are known to be affected by the condition tested. However, alternative splicing events do not always 
infer a difference in the coding sequence of the final mRNA. Therefore, such gene entries may skew 
or dilute the data. In the GO enrichment analysis of Tra2-regulated genes, we identify several 
enriched pathways involved in chromosome biology. Although experimentally the GO enriched 




induced by Tra2 proteins could play a key role in the cells’ fate in vivo, potentially initiating 
tumorigenesis. However, the data in this thesis suggests the role of Tra2 proteins is to regulate the 
alternative splicing of DNA repair pathways in order to maintain their functional isoforms in check 
and protect the cells from DNA damage-induced apoptosis or cell cycle arrest. Furthermore, 
alternative splice changes can influence the impact of drug responses, making them potential 
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Table 1. Tra2α/β regulated targets identified by MISO 
MISO identified alternative events regulated by Tra2 proteins: primers, genomic locations and PCR validation 
Gene HG19 Event coordiantes Forward primer Reverse primer Internal/alt primer 
Validated 
dPSI 
AKIP1 chr11:8934000:8934080:+ CGAACGGATAAGAGAAGAGGAG TCGACCATGGGCAGCATAG   -23 
AKT1S1 chr19:50376174:50376559:- TTACTGAGGAAGAAATTGTTGACC TTTGATATTCTCCATTGTTGGAA   -34 
AP1AR chr4:113184144:113184242:+ CCATGGTGGTCTTGCGGG GTCCGCCATTTCTTCTGCAT   -58 
APOPT1 chr14:104037960:104038157:+ AATCGGTACAAGATGGCGGA CTCGCCATGTAAAGCCTGTC   -37 
ATL2 chr2:38570410:38570654:- CTTTGCAGGAGTTAGCCGAC TCCTTGCGTCTGTCCTTCTT   -45 
BCLAF1 chr6:136588167:136588313:- CAGACTTGGCCCAGTGTTTC TAAACCCTGGAAGTGGTGCA   -30 
BIRC5 chr17:76212745:76212862:+ CAGATTCAGAAGCGTCAACAGT TGCTCTTGTTTTCGATGCCT TGGGAGAATCTGACTTGCCA -31 
CCPG1 chr15:55657386:55657507:- GACGAACCAGTGAGCTAAGC TGGAAGAGCACATAAACCGAG   -37 
CDKN3 chr14:54866612:54866694:+ GGACTCCCCTCACAAGTTCT GCTTGGGTCTTACTTGCTGG ATTGATGGAGTTGGCAGCAC -40 
COX10 chr17:13980052:13980373:+ CCTGCAACTTCGCCACTTAA TGACTTCTTCTAGGGATGGCA   -43 
DEPDC1 chr1:68960113:68960378:- TTGAGAGAGACACGACACGG ACTTCCCTCTCCAGTCATGC CAGACACAAGCTGGAAAGAGT -37 
FAM53C chr5:137677498:137677555:+ AGGACAAGACCATCGAGCTC CGGTAATAAAGTCCCGCTGC   -27 
FBXW11 chr5:171341347:171341409:- GGATTTCCTTTTGCCTTCGGT GAGTTTGAGACGAACCTGGG ATGAGGAGAAGAGCACAGGG -36 
HNRNPC chr14:21679565:21679722:- CCTGCAAAAGTGGAAGCGAA TCCTCAGTCTTCGTTTCCCC   -34 
IP6K2 chr3:48732127:48732257:- GGCCATTAAGAAGGAGCTGA AAGAGTCATCCTCGCCATTG   -45 
MAPKAP1 chr9:128434679:128434922:- CTTCTGGAGCCCTTTGTCCA ATCCTCCCAAAGTCTTCCCC CCAACAAAGACCCCACCATG -36 
MBD4 chr3:129155286:129156151:- CTCCCCTCAGGAACGTGT TTGCATTTGATCTGGTTTTGTC   -76 
MFF chr2:228193394:228193505:+ CAAGAACCCATCGCTTCTGC ATCTGTGTTCGTGGGATGGT AGTCACCTTTCCTTTGGGCT -32 
MPP5 chr14:67745735|67745967:67746254:+ CACGAACACTCTTCCGCTAC GAGAAGGAAATGCTGCCCTG   -36 
MRPS33 chr7:140710417|140710460:140710219:- ACCGGAGAAGAGAAACTAAAAGG CCTCTCTCCTACGCCTCATG   -33 
NUSAP1 chr15:41643186|41643231:41643327:+ GCAACCAGGAAGAAGCTGAG AGATCCTGGCTTTCCTGCTT   -22 
PARPBP chr12:102542013:102542241:+ GTGCAGACTCCATGCTCTTG ACGGTTGTATTTACTTGTTGGTG   -31 




PPP2R3C chr14:35585816:35585943:- GAACTTGTGGCAGCCTGAAG CCCCTGCTCACAACACATTT TTGTTCCTCCCTACTGCGAG -40 
RBBP4 chr1:33145241|33146127:33146254:+ GACGCCCAACACCTGTCC AACAGTTCTCTGCTTTTTCTTTG   -59 
RNPS1 chr16:2314574:2314761:- TGGTGGTCATACTGCCAAGA GCTTTGTTGAATCAAGCCCC ATGGAGAGTAACAGGCCTGC -26 
SGOL1 chr3:20215741:20216547:- TGAACTTCCAGGACAAGGAGA CTGCTGGGCTTGCTTTATTC   -38 
SNHG6 chr8:67834559:67834627:- CGAAGAGCCGTTAGTCATGC ATACATGCCGCGTGATCCTA AAGAACATTCATCTACAGCAACC -35 
SUV39H2 chr10:14938845:14938976|14939516:+ GAAGTGCCCGTTACTGCTTC ACTGTCCTCGTCTTTCAGCT   -44 
TCF19 chr6:31126674|31126920:31127484:+ TGCTTGAAGAGGAGGCTACT TGCAAACTCAGGAACACGTC   -24 










PTC/Frameshift Pfam predicted effect Type of event 
Validated 
dPSI 
AKIP1 Yes -  N/A Cassette exon -23 
AKT1S1 Yes -  N/A Alternative 5’ splice sites -34 
AP1AR Yes -  N/A Cassette exon -58 
APOPT1 Yes -  N/A Cassette exon -37 
ATL2 Yes - GBP Cassette exon -45 
BCLAF1 Yes -  N/A Cassette exon -30 
BIRC5 Yes Yes BIR Cassette exon -31 
CCPG1 Yes -  N/A Alternative 3’ splice sites -37 
CDKN3 Yes Yes CDKN3 Cassette exon -40 
COX10 Yes Yes UbiA Cassette exon -43 
DEPDC1 Yes Yes DEP Cassette exon -37 
FAM53C Yes -  N/A Mutually exclusive exons -27 
FBXW11 Yes -  N/A Cassette exon -36 
HNRNPC Yes -  N/A Cassette exon -34 
IP6K2 Yes -  N/A Cassette exon -45 
MAPKAP1 Yes - SIN1 Cassette exon -36 
MBD4 Yes - MBD Cassette exon -76 
MFF Yes - DUF800 Cassette exon -32 
MPP5 Yes -  N/A Alternative 3’ splice sites -36 
MRPS33 Yes -  N/A Alternative 3’ splice sites -33 
NUSAP1 - -  N/A Alternative 3’ splice sites -22 
PARPBP Yes -  N/A Cassette exon -31 
PCNP - -  N/A Alternative 3’ splice sites -31 
PPP2R3C Yes -  N/A Cassette exon -40 
RBBP4 Yes -  N/A Alternative 3’ splice sites -59 




SGOL1 -   N/A Cassette exon -38 
SNHG6 Yes   N/A Mutually exclusive exons -35 
SUV39H2 Yes - SET Alternative 5’ splice sites -44 
TCF19 -   N/A Alternative 3’ splice sites -24 




Table 3. Tra2α/β regulated targets identified by MAJIQ 
Gene 
HG19 Event 































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. List of targets previously identified by DexSeq and validated by Dr Best. 




by MISO Event type 
PTC/ 
Frameshift Domain affected 
ANKRD1 chr10:92678888-92679025  -73 Yes - Cassette exon   N/A 
CDCA7L chr7:21951235-21951372  -26 - Yes Cassette exon   N/A 
CHEK1 chr11:125497502-125497725  -55 Yes Yes Cassette exon Yes Tyrosine Kinase  
CSDE1 chr1:115292442-115292828  -5 Yes - Cassette exon   N/A 
GLYR1 chr16:4881980-4882222  -41 Yes Yes Cassette exon   N/A 
HDLBP chr2:242194789-242194995  -27 Yes Yes Cassette exon - KH_1  
KIAA0586 chr14:58926561-58926788  -37 Yes - Cassette exon   N/A 
MSL3 chrX:11779619-11779701  -41 Yes - Cassette exon - MRG  
NAP1L1 chr12:76462689-76462774  -11 Yes Yes Cassette exon   N/A 
NUB1 chr7:151046159-151046326  -41 Yes - Cassette exon   N/A 
PDCD6IP chr3:33895371-33895505  -4 Yes - Cassette exon   N/A 
PPP1R7 chr2:242092891-242093019  -23 Yes - Cassette exon   N/A 
SMC4 chr3:160137146-160137331  -66 Yes - Cassette exon - SMC_N  
TBC1D12 chr10:96256812-96256929  -39 Yes - Cassette exon   N/A 
ZCCHC7 chr9:37126309-37126939  -72 Yes - Cassette exon   N/A 





Table 5. List of RBMX regulated genes in MDA-MB-231 cells. List of target genes and respective alternative events regulated by RBMX 







































































































































































































































































































































































































































Other RBMX related sequences 
3' UTR primers (human) 
RBMX 3'UTR F CCAAGTGGAGGTTCCTACAGAG Product size (F + xR) 
RBMX 3'UTR 1R AGATCCACAGGAACCCCTGA 236 
RBMX 3'UTR 2R TGAAAAGCAATGCGAAAGTCA 558 
RBMX 3'UTR 3R TAAAAGCAAGCACCACACAGC 130 
RBMX 3'UTR 4R TTCTTTGAACTGGGATTTTGGTC 391 
3'UTR primers (mouse)  
Rbmx 3'UTR Fm GATGGCTATGGTCGGGATCG Product size (F + xR) 
Rbmx 3'UTR 1Rm AGGAATCACGTGGAGGAGGG 301 (968) 
Rbmx 3'UTR 2Rm TGCCAGGGGTTGAATGCTAG 571 
qPCR primers for mouse rbmx (from UCSC - primer pair name: 
Rbmx_uc009thh.2_4_1_1) 
Rbmx qPCR Fm CAAGAGGATTCGCTTTTGTCA Product size 
Rbmx qPCR Rm CCTTGATGGCTTTCCCATCT 99 
qPCR Human RBMX (from UCSC - primer pair name: RBMX_uc004fae.2_4_1_1 
RBMX qPCR F CCTCCAAGAAGTAGAGGCCC Product size 







Figure Apx.1. Representative RT-PCR capillary gel electrophoresis images of MISO identified Tra2α/β regulated targets. All changes shown are statistically 






Figure Apx.2. Representative RT-PCR capillary gel electrophoresis images of MAJIQ identified Tra2α/β regulated targets. All changes shown are statistically 
significant, calculated from three biological replicates. Student’s t-test, for all events shown p<0.05 
 
